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Inducing broadly neutralizing antibodies targeting the HIV-1 envelope is thought to be crucial for 
developing an effective vaccine. The Membrane Proximal External Region (MPER) within the HIV-
1 gp41 envelope is a promising vaccine target. The MPER is highly conserved, functionally 
constrained, facilitates virus fusion and is targeted by broadly neutralizing monoclonal antibodies. 
The objectives of this research were 1) To evaluate the neutralization breadth of antibodies induced 
by epitopes within the MPER compared to the PG9/16-site in chronically HIV-1-infected 
individuals, 2) to identify neutralization resistant HIV-1 isolates (using plasma samples infected with 
the same subtype) and to characterize their sensitivity to anti-MPER antibodies and 3) to determine 
the accessibility of the MPER to HIV-1 induced polyclonal anti-MPER antibodies in a highly 
neutralization resistant virus (253-11; CRF02_AG subtype).  
Results: 
Epitopes within the MPER and the PG9/16-site are two targets of broadly neutralizing monoclonal 
antibodies. Chapter two of this thesis describes the neutralization activity directed against the MPER 
and the PG9/16-site from serum samples of ARV-naïve chronically HIV-1 infected individuals 
(n=177) from South Africa. The neutralization breadth of the sera was measured on a diverse (n=24 
viruses representing five different subtypes) and neutralization-resistant (tier 2 and tier 3) HIV-1 
pseudovirus panel. Anti-MPER antibodies were measured using three HIV-2/HIV-1 MPER chimeric 
viruses and PG9/16 epitope mutants were used for detecting PG9/16-site specific neutralization. A 
substantial proportion of the sera had anti-MPER (19%, 33/177) and anti-PG9/16-site specific (34%; 
37/108) neutralization activity. Twenty percent (35/177) of the cohort were identified as broad 
neutralizers (geometric mean ID50>200 against the panel viruses). The neutralization breadth of the 
MPER recognizing sera was significantly higher than that of the non-MPER recognizing samples 
(median 102 vs 53, p<0.0001, Wilcoxon rank sum test). In contrast, samples with dominant anti-
PG9/16 site antibodies did not elicit higher neutralization breadth than samples which lacked anti-
PG9/16-site antibodies (median 114 vs 105, p=0.64, Wilcoxon rank sum test), and were less likely to 
be broadly neutralizing (p=0.04). The epitope variability of the MPER was substantially lower than 
that of the PG9/16-site and other antibody targets, measured by analyzing 3829 envelope sequences. 
In chapter three, highly neutralization resistant CRF02_AG viruses were identified and their 
vulnerability to anti-MPER monoclonal antibodies was tested. The neutralization activities of ARV-
naïve CRF02_AG subtype infected plasma samples from Cameroon were used to identify highly 
iv 
 
neutralization resistant CRF02_AG viruses. The neutralization capacity of the CRF02_AG plasma 
samples was tested by assembling a virus panel (n=27) including several CRF02_AG viruses. 
CRF02_AG viruses have been previously reported to be highly neutralization resistant even to 
plasma pool infected with the same subtype. However, in contrast to previous reports, CRF02_AG 
plasma samples neutralized CRF02_AG panel viruses better than viruses from other subtypes. This 
included six of the eight CRF02_AG viruses previously designated as resistant (tier 2/3 or 3). Only 
two CRF02_AG viruses (253-11 and 278-50) remained highly resistant. Even the resistant 
CRF02_AG viruses were sensitive to MPER-specific monoclonal antibodies (2F5 and 4E10), 
revealing vulnerable neutralization targets. 
Finally, (chapter four) we analyzed the sensitivity of the highly resistant CRF02_AG virus (253-11) 
to a set of polyclonal anti-MPER antibodies. An HIV-1 infected polyclonal serum panel (n=217) 
from the South Africa cohort rarely neutralized 253-11, even by recognition through the MPER. 
However, 19 other sera (9%) recognized 253-11’s MPER in an HIV-2 chimeric construct despite 
being unable to recognize the same MPER in the original 253-11 virus (ID50<100). A similar 
resistant pattern was observed in a second virus (Du422.1, subtype C). Importantly, at least 13/19 of 
the 253 MPER recognizing sera neutralized other HIV-1isolates via the MPER, indicating that these 
anti-MPER antibodies are not defective for neutralizing HIV-1 isolates. The MPER recognizing sera 
which failed to neutralize 253-11, targeted several distinct epitopes within the MPER as revealed by 
alanine scan mapping.   
 
Conclusions: 
For effective protection from a vaccine, antibodies induced by an immunogen targeting the HIV-1 
surface envelope should be broadly neutralizing. Antibodies induced by MPER epitopes were 
broadly neutralizing in contrast to antibodies targeting the anti-PG9/16-site, suggesting that the 
conserved MPER might be more amenable to vaccine design than the more variable PG9/16-site. 
The anti-MPER monoclonal antibodies also neutralized highly resistant CRF02_AG isolates (253-11 
and 278-50) suggesting that the MPER can be targeted to effectively neutralize CRF02_AG isolates.   
However, the CRF02_AG isolate, 253-11 which we identified as highly resistant was rarely 
neutralized by anti-MPER antibodies from a polyclonal serum panel. We then directly tested for 
recognition of the 253-11 MPER in an HIV-2 chimeric construct. The anti-MPER neutralized HIV-1 
isolates and recognized several distinct epitopes within the MPER suggesting that conformational 
differences of the MPER between the native 253-11 virus and the HIV-2/253-11 MPER chimera 
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seems unlikely to explain the inability of so many independent antibodies (with distinct epitopes) to 
neutralize 253-11. Several possible explanations for our observations are discussed; but, we propose 
that the most parsimonious explanation for the rare anti-MPER-neutralization of 253-11 is 
obstruction of access of antibody to the MPER. Analysis of the natural immune response to the 
MPER by a virus such as 253-11 which is resistant to most anti-MPER antibodies will aid in the 
understanding needed to develop a vaccine that induces broadly neutralizing antibodies directed 
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Acquired immunodeficiency syndrome, caused by the Human Immunodeficiency Virus (HIV), 
remains a global infectious disease threat with 2.5 million new infections and 34 million existing 
infections world-wide according to the UNAIDS 2011 report (www.unaids.org). Since the 
identification of HIV-1 three decades ago (Barre-Sinoussi et al., 1983), considerable progress has 
been made to understand HIV-1 pathogenesis (Swanstrom and Coffin, 2012), anti-HIV-1 drug 
development (Arts and Hazuda, 2012; Flexner, 2007) and vaccine design (Burton et al., 2012a). 
However, a cure for HIV-1 is very difficult (Yukl et al., 2013) and reported rarely (Persaud et al., 
2013) . Designing an effective vaccine which prevents the establishment of new viral infections is a 
high global priority. 
 
Advances made in HIV therapeutics over the past years have made great progresses through multiple 
approaches to contain the virus. Highly Active Anti-Retroviral Therapy (HAART) have drastically 
reduced morbidity and mortality of HIV/AIDS (Coovadia, 2004; May et al., 2011; Moore et al., 
1991) and have extended the survival of HIV-1 infected individuals (2008; May et al., 2011; Moore 
et al., 1991) by suppressing HIV-1 replication (to almost undetectable viral loads) and preventing 
disease progression (Graham et al., 1992). More importantly, at a population level, HAART can 
reduce new HIV-1 transmissions (Cohen, 2013; Montaner et al., 2010; Tanser et al., 2013). Most 
current HAART regimens consist of a combination of nucleoside reverse transcriptase inhibitors 
(NRTIs), protease inhibitors (PI) and/or non-nucleoside reverse transcriptase inhibitor (NNRTI).  
 
In South Africa, around 6.1 million people are estimated to be living with HIV-1 (UNAIDS, 2013b). 
As at 2012, an estimated 2.5 million HIV-1 infected people in South Africa were receiving primary 
health care (SANAC, 2012).  Extensive antiretroviral drug programmes have substantially reduced 
AIDS related deaths and vertical transmission of HIV-1 from mother to child, with1.6 million (out of 
8.6 million people having access to antiretroviral therapy in low- and middle-income countries 
globally) received antiretroviral treatment as at the end of 2011(SANAC, 2012; UNAIDS, 2013a). 
The initial HAART regimen uses fairly efficacious "first-line" drugs with low side-effect profiles. 
However, the high cost of HIV-1 drug management (approx. 13 billion South African Rand was 
spent on HIV/AIDS and TB for the financial year 2009-2010), need for lifelong treatment (with a 
lifelong need for clinical management and laboratory testing and risk of drug-associated toxicity) and 
the emergence of drug resistant virus mutants makes dependence on HAART alone difficult (Arts 




Latent virus reservoirs established early in acute HIV-1 infection pose an important challenge in 
eradicating the virus from the host (Finzi et al., 1999). They form a major barrier to curing HIV-1 
infection; as the proviral DNA is integrated into the host genome, establishing a reservoir of virus 
variants within the host that is not susceptible to antiretroviral drugs (Noe et al., 2005 ) or immune 
surveillance (Richman et al., 2009). Upon receiving appropriate activation signals, replication 
competent viruses are generated from the latent reservoir. This makes cure difficult, if not impossible 
in most HIV-infected individuals. 
 
A prophylactic vaccine which could prevent virus establishment within the host is highly essential to 
control the pandemic. One of the major vaccine approaches against HIV-1 (Walker and Burton, 
2008) would be to generate a neutralizing antibody response which would prevent virus 
establishment within the host. The other major approach is to induce an effective T cell response 
which can attenuate HIV-1 replication soon after the initial infection event. The viral envelope, a 
trimer of hetero-dimers of gp120 and gp41 is the sole HIV-1 derived antigenic protein on the surface 
of HIV-1 (Corti and Lanzavecchia, 2013; Wyatt and Sodroski, 1998), and is thus an attractive target 
for antibody based vaccine design, while other HIV-1 proteins like Gag and Nef are targets for cell-
mediated immune response (Barouch, 2008). 
 
A critical component of most antibody-based vaccine approaches is neutralizing antibodies, which in 
some cases could prevent the establishment of infection or would at least limit the initial explosion of 
virus replication (Plotkin, 2008; Plotkin, 2013). There is convincing evidence for sterilizing 
protection provided by passively immunized neutralizing antibodies against viral infection in 
nonhuman primate animal models (Hessell et al., 2009; Mascola et al., 1999; Mascola et al., 2000; 
Moldt et al., 2012; Shibata et al., 1999). Once infection is established, neutralizing antibodies may 
contribute lesser towards disease progression (Doria-Rose, 2010; Euler et al., 2010; Piantadosi et al., 
2009); largely due to the emerging escape variants (Moore et al., 2009; Rong et al., 2009) resulting 
from the humoral immune pressure (Frost et al., 2005; Richman et al., 2003), although this does not 
necessarily mean that antibodies cannot play a protective role (Huang et al., 2010).  
 
In approximately 80% of heterosexual HIV-1 transmissions (Abrahams et al., 2009; Keele et al., 
2008; Shaw and Hunter, 2012), 68% of mother to child transmissions (Russell et al., 2011) and 60% 
of homosexual transmissions (Li et al., 2010), virus dissemination results from a single virus variant 
referred to as the transmitted/founder (T/F) virus (Shaw and Hunter, 2012). If broadly neutralizing 
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antibodies targeting this T/F virus is pre-existing before establishment of infection (i.e. induced by a 
vaccine), they presumably can provide sterilizing protection (Haigwood and Hirsch, 2009). 
Designing an immunogen towards achieving this goal is a global health priority (Barouch, 2008; 
Walker and Burton, 2008).  
 
1.2. HIV-1 transmission: 
1.2.1. Introduction:  
Around 2.5 million new HIV-1 transmissions were reported in 2011 by UNAIDS 
(http://www.unaids.org). The major routes of HIV-1 transmission can be attributed to three different 
means; transmission via genital mucosa (heterosexual transmission, transmission in men who have 
sex with men), mother to child transmission and transmission in injection drug users. However, HIV-
1 is not very efficiently transmitted; for a productive clinical infection in heterosexual transmissions, 
approximately 200 or more coital acts are required (Powers et al., 2008). Various factors determine 
the probability of virus transmission; socioeconomic factors (Ajoge et al., 2013), higher viral loads 
(Shaw and Hunter, 2012) or sexually transmitted diseases in the partner (Galvin and Cohen, 2004) 
and type of sexual contact (Abrahams et al., 2009; Bar et al., 2010). 
 
A rapid virus evolution occurs after transmission by multiple mechanisms; resulting in a quasi-
species of virus variants in HIV-1 infected individuals (Taylor et al., 2008). Despite high degrees of 
viral diversity in the transmitting partner, there exists a “transmission bias” i.e. Some virus variants 
are preferentially transmitted from the transmitting partner to the recipient (Derdeyn et al., 2004; 
Wolinsky et al., 1992; Zhu et al., 1993). This “transmission bottleneck” would allow the carry-over 
of only a limited number of variants to the infecting partner while establishing a new infection. This 
bottleneck could be largely attributed to the selection of particular characteristics of the virus 
immediately following transmission. For example, the CCR5 co-receptor engaging virus variants are 
preferentially transmitted over the CXCR4 variants (Keele, 2010; Keele et al., 2008; Shaw and 
Hunter, 2012). 
 
1.2.2. Multiplicity of infection of Transmitted/Founder variants: 
A single genetic variant of virus (called the founder virus) is responsible for the establishment of 
most HIV-1 infections (Figure 1.1). The most convincing early evidence for this came from Derdeyn 
et al, who studied the envelope genotype and phenotype of viruses from eight heterosexual 
transmission pairs (Derdeyn et al., 2004). Full length envelope sequences from each of the donor and 
recipient were amplified and sequenced; Phylogenetic trees were constructed to understand the 
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similarities/differences between the viruses for each transmission pair. Viruses from the recipient 
were monophyletic with limited divergence after transmission in comparison to the viruses from the 
transmitting partner. Surprisingly, viruses within the recipient were sensitive to the antibodies from 
the transmitting partner indicating that even low titers of antibodies induced by a vaccine might be 
helpful in preventing transmission (Derdeyn et al., 2004).  
 
A single genome amplification (SGA) technique was used later to precisely identify the transmitted 
virus and track their evolution in the recipient (Abrahams et al., 2009; Keele et al., 2008; Salazar-
Gonzalez et al., 2008; Salazar-Gonzalez et al., 2011). SGA has several advantages (Keele, 2010) 
over the conventional PCR amplification techniques which were used widely before, because SGA 
eliminates errors induced by the PCR polymerase and viral genome recombination. Additionally any 
cloning bias for particular sequences over others is avoided as sequencing is performed on the PCR 
product before cloning. SGA was performed to amplify hundreds of HIV-1 envelope sequences from 
subtype B (n=102) and subtype C (n=69) HIV-1 infected individuals in the three studies (Abrahams 
et al., 2009; Keele et al., 2008; Salazar-Gonzalez et al., 2008). The studies concluded that 
approximately 75% of the heterosexual transmissions were by a single virus variant. The other 
infections were established by multiple variants; however these were generally limited to less than 
five virus variants. These studies established that there is severe reduction in viral diversity soon 
after heterosexual transmission of HIV-1. A later study on three acutely HIV-1 infected individuals 
with 454 sequence data on thousands of sequences also came to the conclusion that a single virus 
initiates acute HIV-1 infection (Fischer et al., 2010). The probability of single variant transmission in 
mother-to-child transmissions (Russell et al., 2011), men who have sex with men (Li et al., 2010), 
and injection drug users (Bar et al., 2010) is however lower than heterosexual transmissions (68%, 
60% and 40% respectively in comparison to the 75% in heterosexual transmissions). Thus, most 
variants fail to make productive infections (considered defective or less fit) while other viruses have 




   
 
Figure 1.1: HIV-1 transmission (Shaw and Hunter, 2012): 
In this model for HIV-1 transmission, the transmitting partner has a viral quasi-species as shown in 
the inoculums; however, only the most fit variant (T/F virus variant, coloured red) establishes 
infection in the recipient. The virus in the recipient eventually diversifies.   
 
 
1.3. HIV-1 diversity: 
The present day distinct HIV lineages (HIV-1 groups M, N, O, P and HIV-2 ) in humans are 
presumed to have resulted from independent zoonotic transmission events of Simian 
Immunodeficiency Virus (SIV) from non-human primates (Hemelaar, 2012; Hemelaar, 2013; Vallari 
et al., 2011). It have been estimated that SIV, which was previously thought to have evolved over 
millions of years, may have infected its natural hosts for only hundreds of years before giving rise to 
HIV in the twentieth century (Sharp and Hahn, 2011). This would make SIV and HIV the youngest 
and fastest evolving lentiviruses (Hemelaar, 2012; Wertheim and Worobey, 2009).  
 
The worldwide spread of HIV is accompanied by its enormous genetic variability (Figure 1.2) and 
rapid evolution, which makes the virus highly adaptable to new hosts and selection pressures 
(Abecasis et al., 2009; Hemelaar et al., 2006; Kwong et al., 2012; Lynch et al., 2009). Consequently, 
within the HIV-1 group M alone, nine subtypes are recognized and designated by the letters A–D, F–
H, J, and K (Aldrich and Hemelaar, 2012; Hemelaar, 2013).  The high rates of viral replication and 
lack of proofreading mechanism of HIV’s reverse transcriptase enzyme is responsible for the high 
mutation and recombination rates (Taylor et al., 2008). As a result of high mutation rates, HIV 
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sequence diversity can differ by up to 10%, 30% and 40% respectively within a single individual, 
within a subtype and between subtypes (Lynch et al., 2009). High recombination rates led to early 
formation of recombinant forms; a few of these were widely transmitted and apparently gave rise to 
new circulating recombinant forms (CRFs), while others did not and remained what are termed 
unique recombinant forms (URFs) (Hemelaar et al., 2006). Recombination events earlier in the 
epidemics in Central Africa led to formation of some CRFs like CRF01_AE and CRF02_AG, 
although the sequence of events and which is the actual original and actual recombinant form is a 
matter of debate (Abecasis et al., 2007). Recombination between subtypes and CRFs is still ongoing 




Figure 1.2: Phylogenetic tree of SIV and HIV-1 (Hemelaar, 2012):  Phylogenetic tree based on 
polymerase sequences of reference sequences of SIV and HIV-1.  
 
Two-thirds of global HIV infections occur in generalized epidemics and most of these epidemics 
occur in sub-Saharan Africa (Aldrich and Hemelaar, 2012).  Only a few of the recognized subtypes 
and CRFs, subtype A-D, G, CRF01_AE and CRF02_AG, are responsible for the 95% of the global 
HIV-1 infections. Subtype C alone is responsible for nearly half (48%) of the global burden. Subtype 
C is nearly the exclusively subtype found in Southern Africa, Ethiopia and India. CRF02_AG, which 
is presently the predominant HIV-1 subtype circulating in West Africa (94% of global CRF02_AG), 
is the highest prevalent CRF and the fourth most prevalent subtype globally (Hemelaar, 2013; 
Hemelaar et al., 2006; Hemelaar et al., 2011b). HIV diversity is the critical driver of the HIV-
1epidemics and has important implications for pathogenesis, transmission, the immune response and 
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clinical management (Hemelaar, 2012; Hemelaar et al., 2011a; McBurney and Ross, 2008). Since the 
diversification and evolution of HIV is ongoing, the development of a preventative HIV vaccine will 
be a herculean task. 
1.4. HIV-1 envelope: 
1.4.1. Introduction: 
HIV-1 like other primate lentiviruses has the common genomic structure LTR-gag-pol-vif-vpr-tat-
rev-env-nef-LTR (Barre-Sinoussi et al., 1983; Ratner et al., 1985). Infection of the host cell by HIV 
is initiated by interactions between the gene products of env (“envelope spike”) located on HIV-1’s 
envelope lipid bilayer (which is derived from the membrane of the host cell) and cell-surface CD4 
molecules (Julien et al., 2013a; Wyatt et al., 1998). Additional interactions with chemokine receptors 
trigger a conformational change that leads to fusion of the viral and cellular membranes (Blumenthal 
et al., 2012; Wyatt and Sodroski, 1998). This critical role of the envelope spike has made envelope 
the most important target for neutralizing antibody based vaccine development (Benjelloun et al., 
2012). 
The HIV-1 envelope spike is a heterodimeric trimer with three units of gp120 and three units of gp41 
associated via non-covalent interactions (Wyatt and Sodroski, 1998). Overall, HIV-1 envelope 
adopts a mushroom-shaped structure with an overall mass of approximately 160 kDa and is highly 
glycosylated (Figure 1.3). The gp120 and gp41 complex are involved in different functions 
(Pantophlet and Burton, 2006); (1) The gp120 mediates attachment of the virus to the target cell 
membrane by interaction with the CD4 receptor and the coreceptor, CCR5 and CXCR4 and (2) the 
“stalk” gp41 helps attach the envelope spike to the virus membrane and in fusion of the virus and 
target cell membranes. The greatest amount of genetic diversity in HIV-1 genome is found in the 
envelope, whose amino acid sequences can differ as much as 15% between isolates within a single 
subtype and more than 35% between envelopes from different subtypes (Lynch et al., 2009). This 
diversity poses challenges towards the development of antibody-inducing AIDS vaccines. However, 
recently considerable advance has been made in the isolation of broadly neutralizing mAbs against 
the viral envelope, despite the variability (Kwong et al., 2012; Overbaugh and Morris, 2012). These 
broad antibodies are models for what an effective antibody-based vaccine might induce (Burton et 
al., 2012a; Burton et al., 2012b). Furthermore, a huge improvement in our understanding of the HIV-
1 envelope architecture was possible at the atomic level by the recent cryo–electron microscopic 
study of a cleaved, soluble envelope trimer (BG505 SOSIP.664 gp140) in complex with two broadly 
neutralizing antibodies (Julien et al., 2013b; Lyumkis et al., 2013). The HIV-1 envelope structure 
which was visualized at 5-6 Å resolution gave us a glimpse on how each of the gp120 subunits hold 
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together in the trimer. Additionally, the studies elucidated the spatial arrangement of the envelope 




Figure 1.3: Schematic depiction of the HIV-1 gp120 (McBurney and Ross, 2008): 
The top panel depicts the linear sequence of regions of gp160 and the bottom panel represents a 
simplified model of the gp120 conformation. 
 
1.4.2. Structure and function of gp120: 
For HIV-1 to infect the host cell, the envelope gp120 have to sequentially interacts with the CD4 
molecule (present on CD4 T cells) followed by an interaction with the co-receptors, CCR5/CXCR4 
(Dalgleish et al., 1984; Feng et al., 1996; Klatzmann et al., 1984). The gp120 is highly glycosylated 
and contributes a “silent face”. The linear amino acid sequence of gp120 (Figure 1.3) comprises of 
five variable loops (V1-V5) and five constant regions (C1-C5) (Willey et al., 1986; Zolla-Pazner and 
Cardozo, 2010). The variable regions are generally more exposed and may occlude the conserved 
regions from Nabs (Krachmarov et al., 2005; Sagar et al., 2006; Wyatt et al., 1995).    
 
 CD4 binding site: Studies on the crystal structure of gp120:   
The first crystal structure of gp120 was deduced using a “gp120 core” bound to a two domain 
soluble CD4 (Kwong et al., 1998; Wyatt et al., 1998). The “gp120 core” used by Kwong et al was 
truncated (without V1, V2 and V3 variable loops) and highly de-glycosylated, still the gp120 core 
bound to CD4 and the CD4 binding site mAb, b12. Crystal structure revealed that the “gp120 core” 
comprised of an inner domain, an outer domain and a bridging sheet. Another study on the gp120 
crystal structure (Figure 1.4) (Zhou et al., 2007) using a stabilized gp120 (stabilized such that the 
Figure 2. Schematic of HIV-1 envelope
(A) shows the division of Envgp160 into Envgp120 and Envgp41, as well as the regions of
envelope and their location within Envgp120 and Envgp41. (B) A schematic of folded
Envgp120. The constant regions are shown in blue with the variable regions shown in purple.
Disulfide bonds are shown in green.
ICD: Intracytoplasmic domain.
McBurney and Ross Page 18



















































gp120 maintains the CD4 bound conformation even in the absence of CD4) and b12 confirmed the 
observations made by Kwong et al (Kwong et al., 1998) and also gave insights into the structure of 
CD4 binding site (Julien et al., 2013a). The stabilized gp120 construct was important since flexibility 
in gp120 complicates antibody recognition analysis. The crystal structure revealed that the outer 
domain comprised of two barrels, stacked by a barrel-barrel juncture. The distal barrel comprised 





Figure 1.4: Conformational state of gp120 (Zhou et al., 2007): 
The unliganded, b12- and CD4-bound conformations of gp120 are depicted. The polypeptides are in 
ribbon representation and disordered regions depicted as dashed lines. Inner domains are grey, outer 
domains are red and regions that are in the CD4-bound state correspond to the bridging sheet are 
blue. Comparison of these three gp120 conformations highlights not only the structural plasticity of 
the inner domain and bridging sheet, but also the conformational stability of the outer domain. 
 
 
The CD4 binding site in the gp120 is formed by a recess within the trimeric context of gp120. Many 
mAbs like b12, VRC-series, NIH45-46 and others target regions overlapping the CD4 binding site 
(Saphire et al., 2001; Scheid et al., 2011; Zhou et al., 2010; Zhou et al., 2007). There is also an 
overlap between the mAb binding sites and the CD4 binding site (Zhou et al., 2010; Zhou et al., 
2007).  
 
In principle, the CD4 binding surface forms an ideal vaccine target. The huge breadth and potency of 
CD4 binding site mAbs isolated to-date supports this (Scheid et al., 2011; Wu et al., 2010; Wu et al., 
2011; Zhou et al., 2010). Binding of recombinant soluble CD4 to the CD4 binding surface results in 
gp120 shedding from virions, mimicking HIV-1 neutralization (Moore et al., 1990). Sensitivity of 
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viruses to soluble CD4 is also correlated with the CD4 binding site exposure of HIV-1 (Pugach et al., 
2004). However, despite being constrained to bind CD4 to gain cell entry, the CD4 binding site 
within HIV-1 is differentially sensitive to soluble CD4, leading to the conclusion that the CD4 
binding site is inaccessible/flexible in some viruses (Blish et al., 2009; Blish et al., 2007; Daar et al., 
1990). Additionally, the CD4 binding site might be more flexible which might make them capable of 
evading even broadly neutralizing antibodies (Chen et al., 2009). 
 
 Chemokine receptor binding site in gp120: 
HIV requires the presence of co-receptor molecules on the surface of the target cells, in addition to 
CD4 receptors. HIV-1 uses either one of the two chemokine receptors CCR5 or CXCR4, for entry 
into the target cell after receptor activation (CD4 binding). Most transmitted/founder viruses use 
CCR5 as the coreceptor, but isolates arising later during infection may use CXCR4. This 
phenomenon is referred to as coreceptor switching and is more prominent in subtype B viruses. The 
chemokine binding surface in gp120 is formed by two separate components: the chemokine receptor 
surface within the bridging sheet (Pantophlet and Burton, 2006) and the V3 loop (Rizzuto et al., 
1998). CD4 binding induces conformational changes, bringing the bridging sheet and the V3 loop 
close together to form a contiguous binding site. After receptor activation by CD4, in the closed 
conformation, the V3 protrudes into the envelope spike facilitating the co-receptor binding (Huang et 
al., 2007; Rizzuto and Sodroski, 2000).  
1.4.3. Structure and function of gp41: 
Structure of gp41: 
HIV-1 gp41 catalyzes the fusion between the viral and target cell membrane. It is relatively more 
conserved in comparison to gp120. The membrane anchored gp41 comprises approximately 345 
amino acid residues and is mostly occluded within the envelope spike. Structurally, it could be 
divided into three major domains (Figure 1.5): the ectodomain, the transmembrane domain and the 





Figure 1.5: Schematic diagram of HIV-1 gp41 (Garg et al., 2011) 
NHR: N-terminal Heptad Repeat, CHR: C-terminal Heptad Repeat, MPER: Membrane Proximal 
Ectodomain Region, MSD: Membrane Spanning Domain, LLP1 and LLP2 (Lentiviral Lytic Peptide 
1 and 2). 
 
1. The ectodomain:  
The ectodomain (HXB2 numbering 512 to 683) mediates the major functions of gp41. It is further 
subdivided into four functionally distinct regions: 
a. Fusion Peptide:  
Fusion peptide (Bosch et al., 1989) comprises the N-terminal hydrophobic peptide of gp41 (Figure 
1.5) and is approximately 23 amino acids long. The fusion peptide is believed to insert itself into the 
host cell membrane, following receptor activation by host CD4 and the co receptors. Mutational 
studies confirm the role of the fusion peptide region in the fusion process (Freed et al., 1992).   
b. N-terminal heptad region and C-terminal heptad region (NHR and CHR):  
The NHR (also known as HR1) is adjacent to the fusion peptide and together with the CHR (also 
known as HR2) forms a 6 helix bundle (6HB).  Three NHR helices form a coiled-core loop which 
can be visualized as a trimer of hairpins (Buzon et al., 2010). The CHR helices bind into the 
hydrophobic NHR coiled-core loop. Thus each of the coiled-coil trimer associates together in an 
anti-parallel fashion to form the 6HB. The formation of the 6HB is thought to bring the viral and the 
host cell membrane together for fusion (Blumenthal et al., 2012). The NHR and the CHR are 
separated from each other by a loop (Figure 1.5).  
c. Membrane Proximal External Region (MPER):  
The MPER, a linear stretch of 24 amino acids located at the C terminus of the gp41 ectodomain, is 
detailed in section 1.7 . 
13 
 
2. The transmembrane domain/membrane spanning domain:  
As the name suggests, this region of approximately 25 amino acids, spans the virus membrane 
(Figure 1.5). The transmembrane domain anchors the envelope to the viral membrane. This region is 
highly hydrophobic and conserved in nature. Some studies point out that the transmembrane domain 
plays a role in virus fusion, as the substitution of the transmembrane domain by glycosyl-
phosphatidylinositol (GPI) attachment results in reduced fusion (Salzwedel et al., 1993). Another 
study by Miyauchi (Miyauchi et al., 2005) demonstrated that the transmembrane domain 
replacement mutants have impaired fusion activity and further supports its role in fusion (Lin et al., 
2003).  
 
3. Cytoplasmic tail: 
HIV-1 gp41 contains an unusually long cytoplasmic tail (Postler and Desrosiers, 2013) typical of 
lentiviruses. The cytoplasmic tail can be approximately 150 amino acids long. It is divided into 
distinct domains (Figure 1.5): The N terminus is a richly hydrophilic while the C terminus contains 
three highly conserved Lentivirus Lytic Peptide (LLP) domains. LLP domains are amphipathic 
alphahelical domains (Montero et al., 2008a). The cytoplasmic tail exerts multiple functions (Postler 
and Desrosiers, 2013) like viral replication and infection, clathrin mediated endocytosis of envelope 
(for maintaining a low but constant levels of envelope expression) and envelope incorporation into 
virions.    
 
Function of gp41 and the mechanism of viral fusion into the membrane: 
The genome of HIV-1 is wrapped with lipids, proteins and carbohydrates. Upon infection, the viral 
genome has to cross into the host cell membrane. In order to achieve this, penetrating a double 
barrier (viral membrane followed by the host membrane) is essential. This penetration is achieved by 
fusion, facilitated by the envelope gp41(Wyatt and Sodroski, 1998). Soon after host CD4-HIV-1 
gp160 CD4 binding site interaction and the co-receptor binding (Figure 1.6 upper panel), large 
conformational changes occur which leads to the fusion of virus and cell membrane, resulting in the 
transfer of the viral genome into the host (Blumenthal et al., 2012; Garg et al., 2011).  
 
The gp41 catalyzes the fusion process. Soon after CD4 binding (Kwong et al., 1998), the inner and 
outer domains of gp120 gets rearranged. The gp120 domain turns outward (Liu et al., 2008) and 
moves away from the gp41 stalk. This exposes the variable loops within gp120 for co-receptor 
binding, which in turn induces conformational changes within the gp41. The fusion peptide inserts 
into the target cell membrane and forms a highly stable intermediate known as the “pre-hairpin 
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intermediate” (Jacobs et al., 2007; Liu et al., 2008). The pre-hairpin then refolds into the 6 helix 




Figure 1.6: Simplified diagram depicting the process of HIV entry (Garg et al., 2011): 
 Top panel: gp120 associates with CD4 and causes a conformational change in gp120 which leads 
to co-receptor binding. Bottom panel: Binding of co-receptor induces further conformational 
changes, including formation of a gp41 extended intermediate, hemifusion and postfusion states. 
 
 
1.5. Neutralizing antibody response to HIV-1 infection:  
1.5.1. Introduction: 
A critical component of many vaccines is that they induce an effective neutralizing antibody 
response. Many diseases have been controlled using a neutralizing antibody (NAb) inducing vaccine. 
Smallpox, diphtheria, tetanus and many other examples exist for control of infections by NAbs 
(Plotkin, 2008; Plotkin, 2013). Antibodies exert their function by multiple methods such as 
neutralization, antigenic binding, opsonisation or antibody mediated cellular cytotoxicity (ADCC) 
(Overbaugh and Morris, 2012). Neutralizing antibodies act by blocking viral entry into target cells. 
Pre-existing neutralizing antibodies before infection provide sterilizing protection from acquisition of 
HIV-1 in primate models (Mascola et al., 1999; Mascola et al., 2000; Shibata et al., 1999). A major 
focus of HIV-1 vaccine field is to design immunogens which could induce broadly neutralizing 
antibodies. Vaccine induced antibodies if present before infection could diminish viral acquisition 
(Doria-Rose, 2010; Haigwood and Hirsch, 2009; Stamatatos et al., 2009) (Figure 1.7; lower panel) 
and may contribute towards the control of HIV-1 replication. Key to this proposed approach is the 
fact that only one or a few viruses have to be neutralized for the vaccine to prevent an infection from 
an exposure. This is likely to be true because most (approximately 80%) heterosexual infections 
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results from the dissemination of a single virus variant (Abrahams et al., 2009; Keele et al., 2008; 




Figure 1.7: Neutralizing antibodies before infection might be protective (Haigwood and Hirsch, 
2009):  
Neutralizing antibodies that are induced by a vaccine before infection (lower panel) may be effective 
as the antibodies have to tackle one or only a few virus variants (mainly the T/F virus). However, 
once infection is established NAbs may not contribute much towards disease progression as viral 
diversity is established (upper panel).  
 
 
1.5.2. HIV-1 envelope: Target of neutralizing antibodies: 
The HIV-1 envelope is the major target for neutralizing antibodies (Mascola and Montefiori, 2010; 
Pantophlet and Burton, 2006), though antibody responses to HIV-1 proteins other than envelope are 
induced in natural infection (Wieland et al., 1990). HIV-1 envelope protrudes from the viral 
membrane in the form of spikes. Most HIV-1 infections induce host neutralizing antibody responses 
against their own virus envelope (autologous response) within few months after infection (Bar et al., 
2012; Gray et al., 2007; Richman et al., 2003). Yet, only a small subset of HIV-1 infected 
individuals develop broadly neutralizing antibodies (capable of neutralizing diverse HIV-1 strains). 
Multiple factors govern the generation of broadly neutralizing antibodies including time since 
infection (Gray et al., 2011; Mikell et al., 2011; Sather et al., 2009), higher viral load (Piantadosi et 
al., 2009), HIV-1 envelope diversity (Piantadosi et al., 2009), lower set point CD4 T cell count 
(Euler et al., 2010; Gray et al., 2011), greater CD4 count decline upon infection (Gray et al., 2011) 
and characteristics of the initially transmitted HIV-1 variant (Gnanakaran et al., 2011). 
  
Antibodies produced 















1.5.3. Initial autologous NAb response in HIV-1 infection: 
Recently, there is a better understanding of the early immune response against the viral envelope. As 
early as a week after plasma virus detection, antigen-antibody complexes are detected followed by 
the development of envelope specific antibodies (Tomaras et al., 2008). This initial antibody 
response is directed against the transmembrane protein gp41 (Liao et al., 2011), conversely, the 
antibody response against gp120 appears later. The first antibody response is largely non-
neutralizing and may have very little impact on the dynamics of early virus replication (Keele et al., 
2008; Liao et al., 2011; Tomaras et al., 2008). However, a recent study appreciated even low titer 
neutralizing antibodies capable of exerting immune pressure on the virus as early as two weeks post 
sero-conversion (Bar et al., 2012).  
 
The autologous NAb response developed during the early months of infection (Aasa-Chapman et al., 
2004; Gray et al., 2007; Richman et al., 2003), are principally subtype specific (Moore et al., 2008; 
Moore et al., 2009). They may not confer wide protection against the virus quasi-species (Burton, 
1997; Wyatt et al., 1998). However, autologous neutralizing antibodies can exert immune pressure. 
This results in the rapid selection of HIV-1 escape variants. Escape happens by insertions, deletions, 
substitutions, evolving glycan shield and other mechanisms (Mascola, 2009; Moore et al., 2009; 
Rong et al., 2009). Thus autologous neutralizing antibodies usually do not generally neutralize the 
contemporaneous viral variants and lags behind the viral variants at most time points (Mascola, 
2009).  However, de-novo immune responses capable of targeting the escape variants are generated 
eventually (Bar et al., 2012; Euler et al., 2012; Gray et al., 2007; Lynch et al., 2011; Mahalanabis et 
al., 2009; Moore et al., 2009; Rong et al., 2009; Wibmer et al., 2013).  
 
The pressure exerted by the NAbs comes with a fitness cost on the escape variants (Bar et al., 2012; 
Huang et al., 2010; Moore et al., 2009), although some studies draw the opposite conclusion (van 
Gils et al., 2010a). Moore at al (Moore et al., 2009) demonstrated a seven fold drop in HIV-1 viral 
load in a study participant with autologous anti-C3 antibodies. Bar et al demonstrated that Nab 
escape variants had up to 24% low replication fitness (Bar et al., 2012). In summary, autologous 
neutralizing antibodies, though strain specific may contribute towards a partial containment of virus 






1.5.4. Broadly neutralizing antibodies and disease progression: 
A desirable HIV-1 vaccine would have to generate antibodies capable of neutralizing multiple 
heterologous HIV-1 variants (Stamatatos et al., 2009). There has been a search for BNABs within 
infected individuals over the past years (Doria-Rose, 2010; Doria-Rose et al., 2010b; Euler et al., 
2010; Gray et al., 2011; Mikell et al., 2011; Simek et al., 2009; Walker et al., 2010). The mechanism 
of neutralization and understanding the  immunological conditions required for antibody maturation 
would improve our understanding on how to induce them using a vaccine (Euler et al., 2010; Gray et 
al., 2011; Mikell et al., 2011; Piantadosi et al., 2009; Sather et al., 2009). Approximately 10-30% of 
the individuals develop broadly neutralizing antibodies, indicating such antibodies are not rare and 
their generation at least in natural infections is not an insurmountable task (Binley et al., 2008; 
Doria-Rose et al., 2010a; Euler et al., 2010; Gray et al., 2011; Mikell et al., 2011; Simek et al., 
2009). Broad neutralizing antibodies develop approximately after a year of infection and peaks at 
around three to four years post-infection (Euler et al., 2012; Gray et al., 2011; Mikell et al., 2011; 
Sather et al., 2009). 
 
Multiple factors contribute towards the development of neutralization breadth. First, broadly 
neutralizing antibodies tend to develop later during infection (Piantadosi et al., 2009; Sather et al., 
2009). In a longitudinal study, cross neutralizing antibodies developed at about an average of 2.5 
years post infection, but as earlier as one year post infection in rare cases (Mikell et al., 2011). 
Second, the development of breadth is associated with higher viral loads (Gray et al., 2011; 
Piantadosi et al., 2009; Sather et al., 2009; Simek et al., 2009) and early HIV-1 envelope sequence 
diversity (Piantadosi et al., 2009). This implies that constant antigenic stimulation of the immune 
system is a criterion for generating breadth. Thirdly, breadth has been shown to be associated with 
lower CD4 T cell count (before infection) and with a greater drop in CD4 cell count soon after 
infection (Euler et al., 2010; Gray et al., 2011).  
 
Having broad neutralizing antibodies may not mean a better clinical outcome (Doria-Rose, 2010) as 
shown by two studies (Euler et al., 2010; Piantadosi et al., 2009). In one study (Piantadosi et al., 
2009), neutralization breadth was assessed by measuring the neutralizing antibody levels in 70 ARV-
naïve women from a Kenyan cohort. Breadth of neutralization at that time point did not correlate 
with slower disease progression (delayed time for CD4 T-cell decline, initiation of ART and death by 
AIDS). Another study by Euler et al (Euler et al., 2010) demonstrated the lack of association 
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between neutralization breadth at three years’ post sero-conversion and time from sero-conversion to 
AIDS and AIDS related death in three groups of individuals (individuals with strong, moderate and 
weak neutralization breadth) with varying levels of neutralizing antibodies. To conclude, the breadth 
of neutralizing antibody response during an HIV-1 infection does not appear to be associated with 
protection from subsequent disease. . At the very least, this suggests that any fitness cost associated 
with escape from broader antibodies is not sufficient to slow progression to disease.  
 
1.5.5. Viral defence mechanisms to neutralizing antibodies: 
Viruses evade neutralizing antibodies by multiple pathways (Dorner and Radbruch, 2007; Pantophlet 
and Burton, 2006). Viral diversity is a major challenge to tackle HIV-1 by neutralizing antibodies 
(Mascola, 2009; Moore et al., 2009; Rong et al., 2009). The HIV-1 is highly diverse virus with 
>20% diversity in the envelope region within each subtype (Lynch et al., 2009). Nine subtypes and 
>35 circulating recombinant forms exist in group M: envelope sequences vary by >35% in their 
amino acid sequence (Hemelaar, 2012; Hemelaar, 2013; Hemelaar et al., 2006; Hemelaar et al., 
2011a; Lynch et al., 2009). A broadly neutralizing antibody would have to target conserved regions 
to neutralize multiple variants (Burton et al., 2012b). Another concern is the glycan shielding 
(Pantophlet and Burton, 2006). Approximately 50% of the gp120 is covered with carbohydrates 
which frequently shield the inner conserved domains from NAbs. Additionally by an “evolving 
glycan shield”, HIV-1 evades neutralizing antibodies (Moore et al., 2012). However, the immune 
system also co-evolves to recognize the glycan moieties and generates glycan-specific neutralizing 
antibodies as demonstrated by the mAbs 2G12 and PGT128 (Scanlan et al., 2002; Walker et al., 
2011). Mutation of target epitopes to escape neutralizing antibodies is another evasion strategy 
(Euler et al., 2012). In support of this, sera from infected individuals would neutralize viruses from 
earlier time points but not the contemporaneous virus variants (Frost et al., 2005; Mahalanabis et al., 
2009; Richman et al., 2003).  
 
1.6. Major target sites for broadly neutralizing monoclonal antibodies: 
1.6.1. Introduction: 
Though the viral envelope spike is highly secluded from NAbs, a handful of BNAbs have been 
isolated from HIV-1 infected individuals (Figure 1.8). These mAbs are useful reagents to understand 
the targets within HIV-1 envelope. Some mAbs are broad and neutralize viruses from different 
subtypes, implying they target conserved regions within gp160 (Mascola and Montefiori, 2010). 
However, autologous viruses within broad neutralizers from whom mAbs were isolated are generally 




Considerable advances have been made in the isolation of broadly neutralizing mAbs against the 
viral envelope in the recent years. Two key reason for this advances are; novel techniques to isolate 
mAbs (Huang et al., 2012; Scheid et al., 2011; Walker et al., 2009a; Wu et al., 2010) and 
standardized neutralization assays for high throughput screening of HIV-1 infected sera/plasma and 
mAbs by neutralization (Montefiori, 2005). There exist multiple mAb target sites within the gp120 
and one target site within the gp41 (Burton et al., 2012a) (Figure 1.8). mAbs targeting gp120 have 
been mapped to the CD4 binding site (Burton et al., 1994; Wu et al., 2010), V2 glycan (Bonsignori 
et al., 2011; Walker et al., 2011; Walker et al., 2009a) which recognize a quaternary virus envelope 
structure and glycan shield (primarily V3/V4) (Buchacher et al., 1994; Walker et al., 2011). 
However, within gp41, the MPER is the sole target of broadly neutralizing mAbs isolated to date 









1.6.2. CD4 binding site: 
The CD4 binding site (Figure 1.8) is an attractive mAb target (Burton, 1997; Burton et al., 2012a; 
Pantophlet and Burton, 2006; Wyatt et al., 1998; Wyatt and Sodroski, 1998). It is highly conserved 
and functionally essential to infect the target cell. The CD4 binds to a recessed region in the outer 
domain of HIV-1 gp120 (Wyatt and Sodroski, 1998) and this binding initiates infection (Pantophlet 
and Burton, 2006). Despite, being highly conserved, the CD4-binding site is protected from humoral 
recognition by glycan and conformational masking (Chen et al., 2009). 
 
Monoclonal antibody b12: 
The first broadly neutralizing CD4 binding site mAb b12 was isolated in 1994 by a phage display 
strategy (Burton et al., 1991; Burton et al., 1994). The mAb b12 neutralized approximately half of 
the virus panel tested by Binley et al (Binley et al., 2004) and is moderately broad. The epitope of 
b12 overlaps with the CD4 binding site of gp120 and mediates neutralization by occluding CD4 from 
binding to gp120 (Pantophlet and Burton, 2006). An early crystal structure of b12 (Saphire et al., 
2001) revealed that the heavy chain CDR of b12 penetrates into the CD4 binding site of gp120. A 
later crystal structure (Zhou et al., 2007) of b12 with the gp120 stabilized in the CD4 bound state 
showed that the mAb binds to a conformationally invariant surface of gp120, and is thus a site of 
high vulnerability. However HIV-1 envelope diversity at even the b12 contact site is likely, 
explaining why b12 is not very broadly neutralizing (Chen et al., 2009; Wu et al., 2009). 
 
VRC-series monoclonal antibodies:  
Years after the isolation of b12, a novel technique was used to isolate several mAbs (VRC-series) of 
much greater breadth and potency compared to the previously isolated mAbs directed at the CD4 
binding site (Wu et al., 2010). VRC01, for example, is a very broad and potent mAb. It neutralized 
over 90% of the isolates tested (Wu et al., 2010) and have extremely low geometric mean IC50 (0.25 
ug/ml) titer (Huang et al., 2012). VRC01 antibodies are highly somatically hypermutated (Wu et al., 
2010; Zhou et al., 2010). The CD4 binding site specific mAbs were isolated using a “bait method”, 
in which a resurfaced gp120 probe specific for the CD4 binding site was used to isolate and clone 
CD4 binding site specific memory B cells (Wu et al., 2010). Though the CD4 binding surface was 
retained in the probe, parts of the variable gp120 domains were not included to avoid isolating non-
neutralizing antibodies. Around 90% of the binding surface of VRC01 was focused on the outer 




Monoclonal antibodies NIH45-46: 
Another group of unusually broad and potent CD4 binding site antibodies were generated using a 
slightly different probe (Scheid et al., 2009). The probe (2CC) was a gp120 core stabilized in the 
CD4 bound conformation, but unlike the RSC3 probe (used to capture VRC-series antibodies) could 
also capture the co-receptor binding site antibodies in addition to the CD4 binding site antibodies 
(Scheid et al., 2011). NIH45-46 and 3BNC117 isolated with this method were very potent and 
neutralized 96% of the 118 viruses tested (Scheid et al., 2011). These antibodies are clonally related 
to VRC01 and mimic CD4 binding to gp120.  
 
Conclusion: 
In conclusion, all the CD4 agonist antibodies may act by destabilizing the envelope trimer. Such 
antibodies are not very rare, but are indeed made in some HIV-1 infected individuals (Scheid et al., 
2011; Wu et al., 2010; Wu et al., 2011). However, some of the recently isolated mAbs are unusually 
potent and broad. 
 
1.6.3. Quaternary sites: 
Monoclonal antibody PG9/PG16: 
The PG9/PG16 mAbs target another vulnerable site in the HIV-1 gp120 (Walker and Burton, 2010). 
They were isolated from a subtype A infected African donor (Walker et al., 2009a) by screening IgG 
culture supernatants from stimulated memory B cells distributed at clonal density. PG9/PG16 exhibit 
broad neutralization activity. 70-80% of the isolates tested were neutralized by PG9/PG16, which are 
somatically related variants. PG9 and PG16 tend to recognize the quaternary structure of the 
envelope in the context of the trimeric viral spike conformation, rather than binding to the monomer 
(Moore et al., 2011; Walker et al., 2009a). PG9/PG16 recognizes a glycosylated motif in the V2 
domain. Additional residues in the apex of V1/V2, and V3 are also necessary (Walker et al., 2009a). 
However, PG16 shows a greater interaction with V3 domain than PG9 (Moore et al., 2011; Walker 
et al., 2009a). The V1/V2 regions in HIV-1 are thought to have evolved as a viral evasion strategy; 
however, PG9/PG16 mAbs show extensive neutralization breadth target the variable regions in 
gp120 via glycan recognition. Alanine scanning mutants revealed that Phe159, Asn160, Lys169, 
Lys171and Lle181 within the V2 domain being the major amino acid residues recognized by 
PG9/PG16 (Moore et al., 2011; Walker et al., 2009a).  
 
Crystal structure of the CDRH3 region of PG16 mAb revealed a hammerhead like conformation 
being critical for its neutralization property (Pejchal et al., 2010). Furthermore, the extended CDRH3 
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regions (28 amino acid residues long) were tyrosine sulphated and this sulfation was functionally 
important in mediating neutralization. The crystal structure of PG9 (McLellan et al., 2011) with a 
V1/V2 scaffold also revealed how PG9 interacts with the variable domains and also gave insight into 
the V1/V2 domain structure. The CDRH3 loop of PG9 penetrates the glycan located at Asn160 
Asn156. The CDR3 loops interact further with the V1/V2 region strand C. Besides, multiple 
hydrogen bonds between the antibody and the glycans, supports and strengthens these interactions.   
 
Monoclonal antibody PGT141-145 series: 
Another clonally related set of mAbs also target a quaternary epitope (Walker et al., 2011). PGT141-
145 has specificities similar to PG9/PG16 antibodies. PGT145, the most potent in this series, 
neutralized 78/162 viruses tested at IC50<50 ug/ml. PGT145 was extremely potent with a median 
IC50 of 0.29ug/ml. Structural analysis indicated that PGT141-145 series mAbs penetrate the variable 
loop glycans by extended anionic loops (McLellan et al., 2011). and the CDRH3 loop like 
PG9/PG16 were tyrosine sulphated.  
 
Conclusion: 
PG9/PG16 and PGT-like antibodies with broad neutralization capacity are often inducible in natural 
infections (Moore et al., 2011; Walker et al., 2011; Walker et al., 2009a). In a subtype C 
superinfected individual (CAP256), antibodies targeted a quaternary V1V2 domain which 
overlapped with the PG9/PG16 epitope (Moore et al., 2011). Thus regions within V2/V3 domain are 
immunologic and conserved enough to induce broadly neutralizing antibodies. The quaternary 
structure recognizing mAbs described above neutralize diverse strains of HIV-1 at low 
concentrations which plausibly could be achieved by vaccination (Walker and Burton, 2010). 
However, generating immunogens that mimic this surface and induce such potent antibodies are 
likely to be challenging.    
 
1.6.3. Glycan dependent monoclonal antibodies:  
Monoclonal antibody 2G12: 
The prototype glycan dependent mAb, 2G12 was isolated in 1994 by an EBV-electrofusion 
technique (Buchacher et al., 1994). Having a neutralization breadth of 25-30% this mAb recognizes 
a cluster of conserved high-mannose glycans (Figure 1.8) on gp120 (Scanlan et al., 2002). Alanine 
scan mutants of the Asparagine residues at position 295, 332 and 392 resulted in a significant 
reduction in binding to gp120. However, 2G12 has an unusual dimer conformation (Calarese et al., 
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2003). The mAb 2G12 is said to recognize the “silent face” of gp120, because the 2G12 epitope is 
highly shielded by other oligosaccharide molecules, thus protecting the conserved gp120 region.  
 
Monoclonal antibodies PGT 121-137 series: 
Recently, a series of mAbs have been isolated from a set of elite neutralizers (Simek et al., 2009). 
The epitopes of these mAbs (PGT121–PGT123, PGT125–PGT128, PGT130, PGT131 and PGT135–
PGT137) are dependent upon the same glycan as 2G12 mAb (Walker et al., 2011). The PGT 121-
137 series mAbs competed with 2G12, confirming that he epitopes overlap. However, the PGT series 
mAbs were much broader and potent than 2G12, with a median IC50 of 0.02 ug/ml for PGT128 
(Walker et al., 2011). Most mAbs also failed to bind to a V3 deleted gp120, suggesting their epitope 
overlaps V3 region. Mapping specific amino acid residues by alanine scanning suggested that N-
glycans at position 301 and 302 to be critical for their neutralization. Crystal structures of PGT 128 
revealed a glycan specific (mannose) binding site (Pejchal et al., 2011). Neutralization was 
attributable to its ability cross-link the envelope trimers by penetrating the glycan shield to reach the 
V3 loop of HIV-1 gp120 (Julien et al., 2013a; Pejchal et al., 2011).   
Conclusions:  
The PGT antibodies exhibit a multivalent targeting approach and recognize a combination of glycans 
and proteins on HIV-1 gp120 (Pejchal et al., 2011).  Unlike the prototype glycan recognizing mAb 
2G12, PGT 121 and 128 are broader and more potent (Walker et al., 2011).  
 
1.6.4. MPER: 
The MPER as a target site for existing monoclonal antibodies is detailed in section 1.7 
 
1.7. Membrane Proximal External Region (MPER) as a vaccine target: 
1.7.1. Introduction: 
The membrane proximal external region of HIV-1 is also an important vaccine target. The MPER is 
a linear stretch of 24 amino acids (660-683 HXB2 numbering) and is located at the C terminus of the 
gp41 ectodomain. The MPER is considered an attractive vaccine target due to the following reasons 








Table 1.1: Membrane Proximal External Region as a vaccine target 
Why MPER is an attractive vaccine target? Implication for vaccine design 
1. MPER plays critical role in virus envelope fusion to 
the host cell membrane (Blumenthal et al., 2012; 
Wyatt and Sodroski, 1998) 
Neutralizing antibodies targeting MPER before 
virus fusion may prevent virus entry into the 
host. 
2. MPER is relatively less variable in comparison to 
other regions of HIV-1 gp160 (Sun et al., 2008; 
Zwick, 2005).  
Antibodies targeting highly conserved HIV-1 
epitopes may have greater neutralization 
breadth. But, steric occlussion of MPER 
epitopes in the native envelope spike seems to 
reduce accessibility to neutralizing antibodies 
(detailed in section 1.7.4)  
3. Three human monoclonal antibodies (10E8, 2F5 and 
4E10) target MPER and have exceptional 
neutralization breadth (Binley et al., 2004; Huang et 
al., 2012). 
Proof-of-concept that broad anti-MPER 
neutralizing antibodies can be induced. 
However, most MPER directed broadly 
neutralizing mAbs tend to be polyreactive 
(detailed in section 1.7.3.3) 
4. Many MPER epitopes are linear epitopes rather than 
complex tertiary structures (Gray et al., 2009a; Sun et 
al., 2008) 
Short linear peptides may recapitulate MPER 
epitopes thus making vaccine design simpler. 
However inducing anti-MPER antibodies with 
MPER mimcs has been largely unsuccessful 
(Dennison et al., 2011a; Guenaga et al., 2011; 
Wahome et al., 2012). 
 
 
1.7.2. Structure and function of MPER: 
The MPER comprises the last 24 amino acids of the gp41 ectodomain. At least three broadly 
neutralizing mAbs target different overlapping regions of the MPER (Huang et al., 2012; Zwick, 
2005). The MPER region is highly conserved (Montero et al., 2008a), plausibly due to the functional 
constraints as the MPER is critical in viral fusion (Buzon et al., 2010). The amino acid sequence of 
MPER (HXB2, numbering 660-683) is “LLELDKWASLWNWFNITNWLWYIK” (Montero et al., 
2008a). Fifteen of the twenty four amino acids within the MPER are hydrophobic in nature. The 
hydrophobic amino acids within the MPER tend to be the most conserved in comparison to the polar 
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amino acid residues (Sun et al., 2008) and many amino acid residues in the MPER are invariant 
across subtypes (see also Figure 2.8).     
 
An early NMR study (Schibli et al., 2001) using a 19-residue peptide in the MPER solubilized using 
dodecylphosphocholine micelles revealed a helical structure for the MPER. The recent crystal 
structures of the MPER peptide with mAbs (Brunel et al., 2006; Buzon et al., 2010; Huang et al., 
2012; Ofek et al., 2004) have given more clarity on the MPER structure. The 2F5 and 4E10 epitopes 
are partially embedded within the viral membrane (Cardoso et al., 2005; Sun et al., 2008). Crystal 
structure of 4E10 (Cardoso et al., 2005) with a 13-mer peptide containing the 4E10 epitope 
confirmed the helical nature of the MPER when bound to an anti-MPER antibody. Amino acid 
residues essential for 4E10 faced towards the same side of the helix. In another (Sun et al., 2008) 
NMR study carried on solubilized MPER peptide (HXB2), the MPER adopted a meta-stable L 
shaped structure. The N terminus (664-672) had a tilted alpha-helix and was joined to an almost 
horizontal C terminal helix (675-683) via a hinge (673-674). Parts of the C terminus were immersed 
into the membrane. The 10E8 mAb crystal structure with an MPER peptide (656-683) gave more 
insight into the structure of the MPER (Huang et al., 2012). Corroborating the previous studies 
(Cardoso et al., 2005; Liu et al., 2009; Sun et al., 2008), the MPER had an N-terminal helix 
(extending Asn 657-Ala 667) and a C terminal helix (Trp672-Arg683) separated by a 310-helix (Ser 
668 and Leu 669). In sharp contrast to the above studies, a crystal structure of Z13e1 mAb with a 12 
residue peptide (670-677), adopted a S-shaped structure (Pejchal et al., 2009) and differed from the 
alpha-helical structure adopted by 4E10 or 10E8 bound peptide (Cardoso et al., 2005; Huang et al., 
2012; Sun et al., 2008).  
 
The MPER plays an essential role in the fusion of viral membrane to the host cell membrane 
(Dimitrov et al., 2003; Munoz-Barroso et al., 1999; Salzwedel et al., 1999). Deletion of a 
hydrophobic amino acid stretch in the MPER (666-682) abrogated fusion. The Tryptophan residues 
were the most crucial, as alanine mutants of tryptophan residues in this region reduced fusion 
(Salzwedel et al., 1999). The role of the MPER in fusion was again confirmed by Dimitrov et al; 
deletion of amino anid residues (665-682), resulted in the loss of virus’s fusogenicity (Dimitrov et 







1.7.3. Antibody response to the MPER: 
1.7.3.1. Introduction: 
Exposure of gp41 to neurtralizing antibodies is limited compared to gp120, because some regions of 
gp41 are occluded between gp120 trimer in the envelope spike (Pietzsch et al., 2010). The gp41 
domain is only transiently exposed during fusion process and during the shedding of gp120. Due to 
the above reason, gp41-directed neutralizing antibodies tend to be rare (an exception is the 
monoclonal antibody D5 targeting the HR1 region of gp41 (Miller et al., 2005). However, gp41-
targeting non-neutralizing antibodies are generated in HIV-1 infection and this may be due to 
stimulation of the immune system by free or poorly folded gp41that may be released after shedding 
by dead HIV-1 viruses. Thus, gp41 may appear immunodominant with respect to total antibody 
production, but not with respect to neutralizing antibody production. 
 
 The MPER is the major neutralizing antibody target of HIV-1 gp41 and is well studied (Montero et 
al., 2008a; Zwick, 2005). MPER specific antibodies have been characterized in natural infections 
and MPER monoclonal antibodies have been isolated from broad neutralizers. Four mAbs exist 
against this region of which three are broadly neutralizing (Huang et al., 2012; Zwick, 2005) (see 
below). Binding to the MPER presumably blocks the viral entry to the host cell membrane by 
interfering with membrane fusion (Binley et al., 2003). Several studies on broad neutralizers have 
demonstrated the presence of MPER antibodies (Binley et al., 2008; Gray et al., 2011; Gray et al., 
2009a; Tomaras et al., 2011). The most important studies are summarized below.  
 
1.7.3.2. Natural immune response to the MPER: 
Approximately a quarter of HIV-1 infected individuals develop anti-MPER antibodies (Gray et al., 
2007; Huang et al., 2012) in the course of infection. In a cohort within USA, the prevalence of 
MPER antibodies was 27% (21/78) (Huang et al., 2012) with 18% having high titer anti 
(ID50>1:1000) MPER antibodies. In a South African cohort, MPER antibodies were detectable in 15 
of the 50 participants (30%), while only two (4%) individuals had high titer anti MPER antibodies 
(Gray et al., 2009b). As detailed in chapter two of this thesis, we find anti-MPER antibodies in 19% 
of the South African cohort (Figure 2.2).   
 
Several studies have shown the existence of MPER antibodies within broad neutralizers in plasma 
samples (Gray et al., 2009a; Gray et al., 2009b; Li et al., 2009; Tomaras et al., 2011) and their direct 
contribution towards neutralization breadth has been explored (Gray et al., 2009a; Tomaras et al., 
2011). One study (Tomaras et al., 2011) of nine broad neutralizers (Plot C, Figure 1.9) revealed anti-
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MPER antibodies in four individuals, of which three directly mediated neutralization breadth via 
anti-MPER antibodies. This was shown by anti-MPER antibody depletion in these samples, which 
resulted in a drop of neutralization activity (2 fold or higher) of at least four viruses tested. Another 
confirmation of MPER mediated heterologous neutralization in three broad neutralizers was 
demonstrated by Gray et al (Gray et al., 2009a). In yet another study by the same group (Gray et al., 
2011), a broad neutralizer (CAP206) was shown to mediate heterologous neutralization activity by 
the MPER antibodies (Plot B, Figure 1.9). The anti-MPER antibodies from the above studies 
primarily targeted the C-terminus of the MPER, but were distinct from the targets of existing mAbs. 





Figure 1.9: Contribution of anti-MPER antibodies to neutralization breadth in broad 
neutralizers (Overbaugh and Morris, 2012): 
 
Antibody targets in broad neutralizers were comprehensively mapped to understand the targets. 
Broad neutralizers (n=19) from Walker et al study (A) lacked MPER activity (Walker et al., 2010). 
Broad neutralizers (n=7 and 9 respectively) from the other two cohorts (Tomaras et al., 2011) had 
anti-MPER NAbs (B and C).   
 
 
1.7.3.3. Monoclonal antibodies targeting the MPER: 
Four broadly neutralizing mAbs targeting MPER have been isolated until now, of which three are 
broadly neutralizing. Their epitopes and neutralization mechanisms are different. Mutation of 
residues within the epitope resulted in the loss of neutralization activity (Brunel et al., 2006; Huang 





Monoclonal antibody 10E8:  
10E8 (Huang et al., 2012) is one among the most broad and potent MPER mAb and has a 6-9 fold 
lower geometric mean IC50 titre in comparison to 4E10 and 2F5. At an IC50<50ug/ml, 10E8 
neutralized 98% of the 180 viruses isolates tested. Additionally, the geometric mean IC50 of 10E8 
for neutralizing a panel of 181 viruses was low (0.22ug/ml) and was comparable to the broad 
neutralizing antibodies like VRC01 and PG9/PG16. Anti-MPER mAbs have been shown to be 
associated with lipid binding and auto-reactivity (Haynes et al., 2005), but, 10E8 does not bind to 
phospholipids and is not auto-reactive in a manner similar to 4E10 and 2F5 (Haynes et al., 2005) 
however, a recent report suggests that its activity may depend upon association with membranes 
(Chen et al., 2013). 10E8 is highly somatically hypermutated indicating its extensive affinity 
maturation and possess long CDRH3 loops. In contrast to 4E10 and 2F5-like antibodies, 10E8-like 
antibodies are also more frequently induced (approximately 8%), although most 10E8-like antibodies 
appear not to be broad (Huang et al., 2012).  
  
The minimal linear 10E8 epitope was recognized between residues 671-683 of the MPER. Though 
the 10E8 epitope had a considerable overlap with the 4E10 epitope; it differed from 4E10 epitope in 
the following aspects.  
1. Both 10E8 and 4E10 require Trp672, Phe673 and Trp680 for neutralization. But additional residues 
like Asn671 and Trp683 are crucial for 10E8 recognition (which 4E10 doesn’t require). 
2. 10E8 recognizes approximately 1/3rd of the C terminal helical face of the MPER, while 4E10 
recognizes more than 50%.  
 
Designing an immunogen which can induce 10E8-like broadly neutralizing antibodies would be 
presumably protective and is of high priority.   
 
Monoclonal antibody: 4E10:  
The mAb 4E10 was generated using EBV-electro-fusion (Buchacher et al., 1994). 4E10 has 
exceptional breadth and neutralized 98% of the 181 HIV-1 isolates at <50ug/ml (Huang et al., 2012). 
In a previous study, 4E10 neutralized all viruses tested (Binley et al., 2004). The epitope for 4E10 is 
located towards the C terminus of the MPER, with “NWFDIT” being considered as its core epitope 
(Zwick, 2005). Alanine scanning mutagenesis on HIV-1JR-FL confirmed that Trp672, Phe673 and Trp 
680 as the three most critical residues critical for 4E10 neutralization (Zwick et al., 2005) and this 
was confirmed by surface plasmon resonance (Brunel et al., 2006). Cardoso et al (Cardoso et al., 
2005) identified the crystal structure of the 4E10 core epitope (NWFDIT) in a synthetic peptide 
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bound with the mAb 4E10. 4E10 recognized a helical confirmation of 4E10 epitope with the key 
binding residues facing towards one side of the helix. 4E10 epitope has a L-shaped structure, with an 
alpha-helix at the N-terminus of the epitope followed by a helical C-terminal region (Sun et al., 
2008) which is partially buried within the viral membrane. Both helices are connected by a hinge 
region. The mAb has the ability to extract the partially buried epitope after its initial binding to the 
surface protruding region of the epitope (Sun et al., 2008). This property of 4E10 mAb is unique and 
may explain its broad neutralization capacity.  
 
Though broadly neutralizing, 4E10 has some undesired characteristics. 4E10 is an auto-reactive 
antibody (Haynes et al., 2005). 4E10 reacts with cardiolipin and systemic lupus erythematosus (SLE) 
auto-antigens. In addition, 4E10 reacts with some components of bio-membranes (eg: Phosphatidyl 
serine and related members). This can readily explain why 4E10-like antibodies appear rarer during 
natural infections, as self reactive B cells may become anergic or get clonally depleted during B cell 
development. Although one report suggests that its autoreactivity is a minor part of its binding 
activity (Singh et al., 2011), B cells in mice expressing a transgenic 4E10 antibody are deleted 
(Doyle-Cooper et al., 2013).  
 
Monoclonal antibody: 2F5: 
The mAb 2F5 is less broad, but more potent than 4E10 (Binley et al., 2004). Also generated by 
electro-fusion, the 2F5 epitope is proximal to the 4E10 epitope. The linear epitope is designated as 
“ELDKWA”. In a comprehensive study by Binley et al, 2F5 neutralized 67% of the virus isolates 
tested; however all subtype C viruses tested remained resistant due to a substitution (DSW instead of 
DKW) in the 2F5 epitope (Binley et al., 2004). Alanine scanning mutagenesis of 2F5 epitope 
revealed Asp664, Lys665 and Trp666 as the critical target residues in the 2F5 epitope important for 
neutralization (Zwick et al., 2005). A crystal structure (Zwick et al., 2004) of 2F5 mAb with the 
linear 2F5 epitope (662-667) indicated that 2F5 binds at the base of the linear epitope using the 
extraordinarily long CDRH3 loops. 2F5 tends to bind to the charged face of the 2F5 epitope, while 
the hydrophobic unbound face of the peptide was occluded (Ofek et al., 2004). Like 4E10 mAb, 2F5 
cross reacts with self antigens (Haynes et al., 2005) and is thus polyreactive. Possibly due to this 






1.7.4. Changes in accessibility of the MPER to neutralizing antibodies during target cell 
binding: 
The MPER accessibility to neutralizing antibodies depends on the stage of virus fusion. The 
envelope trimer exist in three conformational states; the prefusion state when epitopes are less 
accessible (gp41 surrounded by the quaternary envelope spike), the metastable pre-hairpin 
intermediate state and the post-fusion state (Blumenthal et al., 2012; Garg et al., 2011; Montero et 
al., 2008a; Zwick, 2005). The MPER is most accessible at the pre-hairpin intermediate state as 
shown with 4E10 mAb (Frey et al., 2010; Frey et al., 2008). Additionally, parts of the MPER may 
get inserted into the viral membrane, reducing its accessibility to neutralizing antibodies (Montero et 
al., 2012; Sun et al., 2008). Dennison et al (Dennison et al., 2009) suggested that the 4E10 epitope 
may be inserted into the membrane of synthesized liposome immunization constructs, reducing 4E10 
binding. The MPER accessibility also varies at the time of viral invasion (Chakrabarti et al., 2011; 
Dimitrov et al., 2007). It is known that fusion is associated with a conformational change in gp41 
following CD4 binding (Eckert and Kim, 2001; Gallo et al., 2003). Dimitrov et al (Dimitrov et al., 
2007) suggests that anti-MPER neutralizing antibodies target the fusion intermediate. Chakrabarti et 
al (Chakrabarti et al., 2011) present evidence that MPER is differentially exposed on the pre-
attachment envelope spike. Those viruses that do not expose their MPER in the pre-attachment spike 
were more resistant to 4E10 and 2F5 antibodies overall. Thus MPER is partially accessible in the 
envelope spike of some viruses before the virus attaches to a cell, and viruses with an accessible 
MPER in the envelope spike are more sensitive to neutralization by MPER antibodies (Chakrabarti et 
al., 2011). Changes in the lentivirus lytic peptide-2 (LLP-2) domain of the cytoplasmic tail of gp41 
also affect sensitivity to 4E10 (Gray et al., 2008).  
 
1.8. Study objectives: 
This thesis evaluated the MPER of HIV-1 envelope as a possible antibody based vaccine target. 
Additionally, this thesis aimed to identify highly neutralization resistant viruses and use them as a 
tool to characterize recognition of vulnerable epitopes (Jacob et al., 2012).   
 
Rationale of the study: 
The work in this thesis is an effort to gather the basic information needed to evaluate and potentially 
use the HIV-1 gp41 MPER as a neutralizing antibody based vaccine target. An approach to induce 
neutralizing antibodies against HIV-1 envelope might be fruitful for vaccine development (Mascola 
and Montefiori, 2010; Sattentau, 2008; Wyatt and Sodroski, 1998). The epitopes of broadly 
neutralizing monoclonal antibodies which target the HIV-1 gp120 and HIV-1 gp41 are candidates for 
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vaccine design (Burton et al., 2012a; Burton et al., 2012b; Walker and Burton, 2010). The MPER 
region of HIV-1 gp41is an attractive vaccine target as it is highly conserved in nature (Montero et 
al., 2008a; Sun et al., 2008; Zwick, 2005). The MPER is also constrained by functions due to its 
involvement in viral fusion (Montero et al., 2008a; Sun et al., 2008; Zwick, 2005). Anti-MPER 
neutralizing antibodies in some broad neutralizers have been shown to mediate neutralization of 
viruses (Gray et al., 2011; Gray et al., 2009a; Tomaras et al., 2011) and three MPER monoclonal 
antibodies are broadly neutralizing (Binley et al., 2004; Huang et al., 2012). However, inducing 
neutralizing anti-MPER antibodies using an immunogen has proven largely unsuccessful (Dennison 
et al., 2011b; Guenaga et al., 2011; Kamdem Toukam et al., 2012; Wahome et al., 2012) although 
there have been some recent modest successes. Though conserved, epitopes within the MPER are 
reported to be only transiently available (Frey et al., 2010; Frey et al., 2008), difficult to access 
(Chakrabarti et al., 2011) and sometimes immersed in the viral membrane (Sun et al., 2008) in HIV-
1 isolates. In this thesis, we investigated the ability of MPER epitopes to induce broadly neutralizing 
antibodies in natural HIV-1 infections. Additionally, we establish that although the MPER is a 
vulnerable target in highly neutralization resistant CRF02_AG viruses, it is inaccessible to most anti-
MPER antibodies.   
 
The specific objectives of my thesis are outlined below 
1. Specific objective 1 (Chapter 2): 
The Thai vaccine trial in Thailand showed modest efficacy (31%) (Rerks-Ngarm et al., 2009); with 
vaccinees showing a weak neutralization activity against highly sensitive (tier 1 (Seaman et al., 
2010a)) viruses (Montefiori et al., 2012). Binding antibodies directed against the variable region 2 
(V2) region of the envelope was a correlate for protection (Haynes et al., 2012). Yet, the antiviral 
mechanism behind V2 specific protection remains unclear. In the second chapter of this thesis, we 
asked the question: How likely does the MPER epitopes induce broadly neutralizing antibodies 
compared to the PG9/16 (a notable epitope within the V2) target site. Neutralization breadth was 
observed to be associated with the presence of anti-MPER antibodies. However, PG9/16-site specific 
antibodies were less likely to be broadly neutralizing in comparison to sera that lacked dominant 
anti-PG9/16-site neutralization activity suggesting that the MPER might be more amenable for 






2. Specific objective 2 (Chapter 3): 
The neutralization activity of CRF02_AG subtype infected plasma samples was examined and highly 
neutralization resistant CRF02_AG viruses were identified (Jacob et al., 2012). The thesis further 
explored how such highly resistant viruses could be neutralized. Even highly resistant CRF02_AG 
viruses were sensitive to MPER specific monoclonal antibodies, suggesting that even the resistant 
viruses can be targeted by anti-MPER neutralizing antibodies (Jacob et al., 2012).   
 
3. Specific objective 3 (Chapter 4): 
Finally, this thesis describes an HIV-1 isolate (253-11, CRF02_AG subtype) which is resistant to 
neutralization by most anti-MPER antibodies. This isolate remained resistant to anti-MPER 
antibodies in both the pre- and post-attachment conformation of gp41. The research provides 
evidence that MPER inaccessibility is a common but not universal phenomenon among HIV-
1isolates. The possible explanations for the MPER resistance against anti-MPER neutralizing 











Chapter Two:  
HIV-1 neutralization breadth is associated with the presence of anti-
Membrane Proximal External Region (MPER) antibodies and not of 
anti-PG9/16-site antibodies 
 
2.1. Summary:  
Background: 
Broadly neutralizing antibodies in HIV-1 infected individuals target conserved regions in the viral 
envelope, and two of their targets include the Membrane Proximal External Region (MPER) and the 
PG9/16-site. In this report we measured the neutralization activity directed at the MPER and at 
epitopes overlapping the PG9/16-site in 177 serum samples from ARV-naïve chronically HIV-1 
infected individuals, and correlated this with neutralization breadth.   
Results: 
Sera were screened for neutralization breadth on a diverse, neutralization-resistant HIV-1 
pseudovirus panel (n=24). An ID50 value for all serum/virus combinations was either directly 
measured or inferred from the percentage neutralization at 1/100 serum dilution using a statistical 
prediction model. Thirty-five sera (20%) were identified as broad neutralizers (geometric mean 
ID50>200 against the panel viruses). Furthermore, antibodies directed to the MPER (measured using 
HIV-2/HIV-1 MPER chimeric viruses) and PG9/16-site (measured using N160A and K169E 
mutants) was measured. Anti-MPER activity (19%, 33/177) and anti-PG9/16-site antibodies (34%; 
37/108) were frequent. The neutralization breadth of the MPER recognizing sera was significantly 
higher than that of the non-MPER recognizing samples (median 102 vs 53, p<0.0001); in contrast, 
samples with dominant anti-PG9/16 site antibodies did not elicit higher neutralization breadth than 
samples without dominant anti-PG9/16-site antibodies (median 114 vs 105, p=0.64), and were less 
likely to be broadly neutralizing. In accord with this, the epitope variability of MPER was 
substantially lower than that of the PG9/16-site and other antibody targets, measured from analyzing 
3829 envelope sequences. 
Conclusions: 
This is the first study to systematically assess the correlation between neutralization breadth and anti-
MPER and anti-PG9/16-site antibodies. Anti-MPER containing sera were more broadly neutralizing 
than non-anti-MPER-containing sera, and an equivalent association for sera containing anti-PG9/16 
site antibodies was lacking. Although successes at inducing anti-MPER antibodies by vaccination 
have been limited to date, our data suggest that this may be more approachable, even if PG9/16-site 
immunogen models can be engineered.  
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2.2. Introduction:  
A relatively small number of epitopes have been identified on the HIV-1 envelope glycoproteins, 
gp120 and gp41 that are targets of broadly cross-neutralizing antibodies (Kwong and Mascola, 
2012). These targets are models for candidate vaccine antigens (Burton et al., 2012a). The membrane 
proximal external region (MPER), a linear stretch of 24 amino acids in the gp41 and the PG9/16 site, 
which is a quaternary epitope comprised of the gp120 V2 and V3 domains are two important vaccine 
targets; with different structural and antigenic properties. The MPER is the target of three (10E8, 
4E10 and 2F5) broadly neutralizing monoclonal antibodies (mAb) (Binley et al., 2004; Huang et al., 
2012), while the V2/V3 site is the target of the broadly neutralizing mAb PG9 and PG16 (Walker et 
al., 2009b) and the type specific mAb 2909 (Gorny et al., 2005). MPER appears to be a relatively 
simple antigen derived from a linear amino acid sequence (Zwick, 2005), but harbours substantial 
complexity (Liu et al., 2009; Montero et al., 2012; Montero et al., 2008b; Shen et al., 2010; Sun et 
al., 2008). Linear peptides can partially mimic MPER epitopes by binding to and hence depleting 
anti-MPER antibodies (Gray et al., 2009a; Li et al., 2009; Morris et al., 2011; Tomaras et al., 2011) 
and can be used to model the binding of antibodies to MPER (Huang et al., 2012; Ofek et al., 2004; 
Sun et al., 2008). However, inducing neutralizing anti-MPER antibodies with MPER mimics has 
proven largely unsuccessful (Dennison et al., 2011b; Guenaga et al., 2011; Kamdem Toukam et al., 
2012; Wahome et al., 2012), although there have been some recent modest successes (Lutje Hulsik et 
al., 2013; Ye et al., 2011; Zhang et al., 2013; Zhou et al., 2012). On the other hand, the quaternary 
epitopes such as the PG9/16-site are presumably only formed in trimeric envelope structures, 
including the envelope spike. It is presumed that this will make immunogen design more difficult 
(McLellan et al., 2011).    
 
Among broadly neutralizing sera, antibodies targeting the MPER (Gray et al., 2009a; Gray et al., 
2009b; Li et al., 2009; Tomaras et al., 2011) and epitopes overlapping the PG9/16-site (Gray et al., 
2011; Tomaras et al., 2011; Walker and Burton, 2010) are found. However, the prevalence of anti-
MPER and anti-PG9/16 site antibodies and how frequently they are associated with neutralization 
breadth has not been systematically studied. In this chapter, the neutralization breadth, MPER-
specific neutralization activity and the PG9/16-site-specific neutralization in a cohort of ART-naïve 
HIV-1 individuals (infected >1 year) was measured. Further, we investigated if these epitopes induce 
antibodies with broad neutralization activity. We noticed that the neutralization breadth of the MPER 
recognizing sera was significantly higher than that of the non-MPER recognizing samples; however 





2.3.1. Study participants and neutralization samples: 
Serum samples were collected upon recruitment for neutralization studies. Study participants were 
>18 years old, HIV-1 infected for >1 year and ART naïve recruited from two clinics in Cape Town, 
South Africa. The median age was 33 (IQR 28, 37) with 17 (10%) males and 160 females (90%). 
The median CD4 count was 407 (IQR 286, 533). For 85 participants from Groote Schuur Hospital, 
the median reported time since infection was 3 years (IQR 1, 7). For 92 participants from 
Khayelitsha Site B clinic, median time since the earliest HIV positive test or the earliest recorded 
CD4 count was 2.37 years (IQR 1.40, 4.60). Written informed consent was taken from study 
participants. This study was approved by the Human Ethics Committee, Faculty of Health Sciences 
at the University of Cape Town.  
 
2.3.2. Pseudoviruses and neutralization assay: 
Cloned envelope constructs (obtained from the NIH AIDS Research and Reference Reagent Program 
(ARRRP, Germantown, USA and were co-transfected into 293T cells with a SG3∆env HIV-1 
genome plasmid (Montefiori, 2009). The envelope constructs were obtained through the ARRRP 
from Drs. D. Montefiori, F. Gao, C. Williamson, S. Abdool Karim, J. Overbaugh, B. Hahn, Y. Li, J 
Salazar-Gonzalez, D. Ellenberger, B. Li, M. Callahan S. Butera, R. Paranjape, S. Kulkarni,  L. 
Morris,  K. Mlisana, D. Montefiori, L. Stamatatos and C. Cheng-Mayer, except the constructs for 
Du151.2 (Li et al., 2006) and murine leukemia virus (MLV), which were provided by Dr. L. Morris, 
NICD, Johannesburg, South Africa. The HIV-2/HIV-1 MPER chimeras (C1, C1C, C6 and C7) were 
a kind gift from Dr George Shaw, while the HIV-2/253-11 MPER chimera was generated by site 
directed mutagenesis.  
Supernatants were harvested at 48 and 72 hours post-transfection and filtered (0.45µm). Single-use 
aliquots of pseudoviruses were stored at -80°C. Each virus preparation was later titrated in TZM-bl 
cells to determine a standard dilution that resulted in approximately 50,000 Relative Light Units 
(RLU). 
 
TZM-bl-based neutralization assays were preformed (Montefiori, 2009) by measuring the reduction 
in luciferase expression after pseudovirus infection. Briefly, dilutions of serum samples were pre-
incubated with the pseudovirus for one hour and then added to 1x10
4
 TZM-bl cells (obtained through 
the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH from Drs. John 
C. Kappes and Xiaoyun Wu) in flat bottom 96 well plates. DEAE-Dextran (Sigma Chemical 
Company, Schnelldorf, Germany) was used at 7.5ug/ml final concentration to enhance infection. The 
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serum ID50 values were generated by serial dilution of serum and the lowest dilution of serum used 
was 1:50. The percentage neutralization at single dilutions was analyzed using samples at 1:100 
serum dilutions (performed in triplicate). After 48-72 hours of incubation at 37°C and 5% CO2, cells 
were lysed with a detergent-containing buffer with Bright-Glo™ luciferase substrate (Promega, 
Madison, USA). Lysates were transferred to black 96 well plates and luciferase levels were measured 
on a VERITAS MicroPlate Luminometer (Turner BioSystems). Samples were tested against MLV as 
a negative control.  ID50 titers were calculated using curve fit functions in Prism version 5 
(GraphPad, La Jolla, USA). MLV was used as a negative control; detectable neutralization was 
rarely observed (<20% neutralization for all samples except for two with 20-30% neutralization at 
1/100 serum dilution). 
 
Percentage neutralizations were determined by the following calculation 
 
Difference in average RLU between virus control and sample             X 100%. 
Difference in average RLU between virus control and cell control 
 
2.3.3. Prediction of ID50 values from percentage neutralization at a single dilution: 
A predicted ID50 value was generated for every sample/virus combination for which an ID50 value 
was not measured. This predicted ID50 value was derived from the % neutralization value at 1/100 
serum dilution based upon a linear regression comparing the known ID50 values (n=240) to the % 
neutralization at 1/100. Sample/virus pairs measured as resistant were assigned an arbitrary value of 
ID50=10 for the regression model and combinations with a predicted ID50<10 were also assigned an 
ID50 value of 10.  The prediction model was validated using a test set (n=234). There was no overlap 
in samples between the training and the test set.  
 
2.3.4. Detection of anti-MPER and anti-PG9/16-site antibodies: 
Chimeric HIV-2 virus (7312A) engrafted either with a consensus subtype C MPER (C1C; (Gray et 
al., 2007)) or a Yu2 MPER (C1; (Binley et al., 2008; Gray et al., 2007)) or the MPER sequence of a 
CRF02_AG virus (253-11; refer to chapter 4) was used to detect anti-MPER antibodies. Sera that 
neutralized any of these three chimeric viruses at ID50>1000 were scored as containing anti-MPER 
neutralizing activity. Anti-PG9/16-site antibodies were detected using CAP45.2.00.G3 virus mutants 
(N160A and K169E) critical for PG9/16 recognition (Gray et al., 2011; Moore et al., 2011; Tomaras 
et al., 2011; Walker et al., 2009a). PG9/16-site specific neutralization activity was confirmed by a ≥3 
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fold drop in ID50 for either one of the two PG9/16-site mutants compared to the parent virus. ID50 
values for this purpose were derived from titration curves and not from ID50 predictions. 
 
2.3.5. Variability analysis: 
HIV-1 gp160 variability (Shannon’s entropy) in amino acid residue was assessed using the entropy 
one tool from the Los Alamos website (http://www.hiv.lanl.gov/content/indexml). 
 
2.4. Results: 
2.4.1. Estimation of ID50 for each serum/virus pair and its validation: 
A pseudovirus panel representative of the global HIV-1 pandemic was assembled to evaluate the 
neutralization breadth of the South Africa sera. The panel was selected based upon neutralization 
resistance, subtype and geographic diversity (Blish et al., 2009; Jacob et al., 2012; Seaman et al., 
2010b). TZM-bl based neutralization assay (Montefiori, 2009) was used to assess the neutralization 
of each of the panel viruses (n=24) by each of the serum sample (n=177) screened at 1/100 dilution.  
 
Of the 4248 serum/virus combinations, ID50 values were measured from titration curves for 7.3% 
(312/4248) of serum/virus pairs. For the rest, an ID50 was estimated from percentage neutralization 
(measured at 1/100 serum dilution) based on a linear regression analysis performed on a 
subpopulation (n=240; “training set”) of the sample/virus combinations with known percentage 
neutralization of serum (at 1:100 dilution) and measured ID50 values. The effect of percentage 




we measured the goodness 
of fit of the corresponding models and chose a linear model (Figure 2.1a). The equation was used to 
estimate the ID50  from % neutralization at 1/100 serum dilution (Figure 2.1a) (Jacob et al., 2012). 
The serum/virus pairs in the training set included some from this study (168/240) and the rest from a 










































Figure 2.1: Estimation model to predict ID50 value from percentage neutralization at 1/100 
dilution and validation of the model. (a) Regression line comparing percentage neutralization at 
1/100 dilution and ID50 titers (n=240). The prediction equation, R
2
 value, the corresponding p value 
and a line fit with 95% confidence interval are shown. (b) Regression line comparing estimated ID50 
values derived from the percentage neutralization at 1/100 serum dilution and the measured ID50 
values (n=234) for the test set. The R
2
 value, the corresponding p value and a line fit with 95% 
confidence interval are shown. 







ln(ID50)=1.303 + 0.060962 x % neutralization
R2=0.834; p<0.0001
(n=240)









































The model was validated on a separate subset of sample/virus combinations (“test set”) with known 
percentage neutralization of serum (at 1:100 dilution) and measured ID50 values (n=234). 122/234 
serum/virus pairs used in the test set were from this study. The estimated ID50 values derived from 
the percentage neutralization for the “test set” correlated well with the corresponding measured ID50 
values (linear regression R
2
=0.6700, p < 0.0001, Figure 2.1b).  
 
2.4.2.  Measuring the breadth of neutralization and its association with contemporaneous CD4 
T cell counts 
Sera were evaluated for neutralization breadth by two definitions; either by measuring the serum 
geometric mean ID50 titer or by considering the number of viruses neutralized (Figure 2.2). Twenty 
percent (35/177) of the cohort had a serum geometric mean ID50 titer>200 against the 24 panel 
viruses and 18% (32/177) of the cohort neutralized ≥3/4
th 
of the virus panel at ID50>100 and were 
considered broad neutralizers. Geometric mean ID50 titers correlated well with the number of viruses 
neutralized (Spearman’s correlation coefficient, ρ=0.97, p < 0.0001; data not shown). Whenever 
available measured ID50 values determined by titration (n=312) were used; otherwise, ID50 values 
predicted from % neutralization at 1/100 dilution (n=3936) was used for measuring neutralization 
breadth.   
 
A previous study have found an association between neutralization breadth and contemporaneous 
CD4 T cell counts (Sather et al., 2009). We also noted a negative association (Spearman’s ρ=-0.21, 
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252-7 269-12 255-34 278-50 253-11 33-7 251-18 928-28
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BNAB0001 15 36 20 14 56 27 132 83 12 10 287 1407 33 515 10 12 31 124 84 34 10 400 23 14 45 6 10 125 25 0.69 2.28 0
BNAB0002 848 46 40 44 57 1269 49 165 35 42 1165 499 36 321 370 118 44 37 495 42 10 303 50 39 105 10 10 125 25 0.60 3.08 1
BNAB0003 139 1071 10 58 70 1503 1566 752 225 33 591 803 10 4749 268 793 10 49 237 69 14 596 10 105 153 14 10 125 25 6.29 9.70 1
BNAB0004 414 510 206 10 429 912 803 10 56 587 1257 1567 1301 108 143 567 448 1331 1480 113 2998 154 1091 935 371 21 3749
BNAB0005 86 88 15 13 208 54 330 52 68 108 249 917 136 13 10 382 47 382 823 138 24 62 92 342 95 11 2797 1051
BNAB0006 165 388 20 10 321 28 379 30 54 11 36 18 74 10 10 620 871 76 95 40 33 19 20 41 53 6 10 125 25
BNAB0007 319 115 96 373 1424 1416 361 667 477 537 10 1514 245 292 10 1481 1422 422 533 34 27 1224 10 54 231 17 10 125 25
BNAB0008 80 297 10 10 53 10 20 10 25 18 25 1188 38 10 35 10 582 134 92 33 10 22 19 21 35 4 10 125 25
BNAB0009 11 10 10 10 28 20 43 14 10 17 10 1405 98 14 11 108 50 209 29 35 10 11 20 18 26 3 10 125 25
BNAB0010 114 57 90 44 102 160 58 58 62 10 394 304 44 10 10 10 50 404 146 39 30 20 12 46 52 7 1131 125 25 2.00 2.14 0
BNAB0011 10 17 10 10 10 10 12 11 10 10 10 46 41 10 10 10 10 28 89 33 10 10 10 17 14 0 10 125 25
BNAB0012 11 22 34 10 383 338 1263 21 10 30 125 1365 223 1399 10 10 1525 413 64 27 10 48 18 27 68 9 454 366 558 2.15 7.62 1
BNAB0014 14 64 10 10 13 124 32 18 15 19 37 334 20 27 40 16 16 15 69 34 10 16 14 13 24 2 10 125 25
BNAB0015 21 115 10 10 85 48 75 76 36 26 28 469 84 21 47 80 69 53 418 64 16 25 36 44 48 3 853 546 25
BNAB0016 59 141 26 10 67 103 177 43 27 56 57 1530 123 52 28 147 66 75 918 85 10 48 32 72 70 7 10 125 25
BNAB0017 10 41 10 10 59 42 42 51 23 32 65 961 90 44 15 857 35 61 242 80 10 31 30 58 47 3 10 125 25
BNAB0018 524 692 151 700 1067 1607 288 160 292 53 1221 541 10 1042 142 1534 890 72 120 25 3670 746 10 169 282 19 10 125 25 1.40 2.66 0
BNAB0020 18 57 18 34 33 19 17 25 18 43 154 895 24 45 91 25 56 32 140 49 10 39 22 65 40 3 10 125 25 3.52 3.70 1
BNAB0021 10 36 14 23 38 57 158 48 40 86 75 290 220 61 18 84 156 10 362 59 10 40 16 111 50 6 10 125 25
BNAB0022 16 10 16 20 10 11 20 32 14 10 36 10 45 10 17 13 10 10 143 29 10 10 10 12 16 1 10 125 25
BNAB0023 2993 1374 229 201 1361 216 1008 544 301 1004 610 751 329 232 1882 211 180 167 1304 107 47 842 66 892 425 22 10 25
BNAB0024 87 1177 18 21 291 24 73 144 30 29 61 110 277 321 15 140 88 19 163 38 10 30 10 52 60 8 10 125 25
BNAB0025 23 112 20 20 255 16 251 442 21 120 86 645 658 712 75 113 70 127 337 81 49 38 13 227 96 12 624 1144 5314
BNAB0026 257 1405 387 10 114 73 144 120 10 166 1057 1436 256 417 352 97 583 608 786 103 10 683 10 468 182 18 1523 903 1896 2.80 23.06 1
BNAB0027 36 80 47 10 501 97 10 224 10 295 372 1095 460 223 227 501 125 90 698 72 17 63 344 917 128 13 549 427 119 0.12 1.34 0
BNAB0028 10 24 22 17 28 22 54 92 14 75 97 313 64 27 39 24 10 14 259 57 10 17 13 60 33 2 10 125 258
BNAB0029 258 17 104 16 598 187 11 84 19 113 1267 663 76 1113 12 19 100 68 181 46 70 13 14 73 76 9 10 125 25 1.64 2.80 0
BNAB0030 11 20 14 10 33 10 25 58 10 426 1366 69 77 751 10 1271 666 22 188 46 10 10 28 153 53 7 919 647 599 0.99 2.15 0
BNAB0031 938 1038 11 10 15 10 54 28 18 115 891 10 96 101 10 10 10 16 362 34 10 18 22 108 41 7 10 125 25 0.00 11.04 1
BNAB0032 697 1540 55 10 281 354 235 10 242 789 1459 452 783 923 276 1131 92 228 1452 244 12 320 72 10 213 17 10 125 25 1.13 5.19 1
BNAB0033 15 30 34 10 612 10 104 88 15 155 455 87 77 53 45 107 12 25 165 75 17 33 26 109 51 7 10 125 25 1.30 1.77 0
BNAB0034 21 174 34 18 114 682 100 48 32 270 175 882 312 1185 470 874 44 20 247 47 10 76 26 102 105 13 10 125 25 0.02 6.28 1
BNAB0036 41 97 128 21 247 1460 529 237 38 264 552 684 225 261 49 36 40 215 243 62 473 72 22 171 140 14 10 125 616 0.80 1.44 0
BNAB0037 1671 720 152 97 138 135 132 52 10 228 15832 1503 51 664 1319 316 10 35 644 118 45 1285 70 275 209 16 774 633 558 0.19 30.07 1
BNAB0038 39 1060 701 62 447 685 221 801 327 191 3447 1412 426 497 189 18 387 146 281 117 519 99 10 85 242 18 10 125 25 0.88 2.46 0
BNAB0039 1003 1247 287 246 143 1487 713 1340 132 795 1392 1359 373 5268 689 1337 125 242 753 129 233 1452 70 504 528 23 10 125 25 1.15 1.97 0
BNAB0041 10 143 26 12 36 600 156 29 45 174 942 280 30 677 10 85 17 43 430 85 22 46 35 156 71 9 1052 350 25 2.78 2.86 0
BNAB0042 14 58 62 10 33 41 74 25 26 299 98 519 74 342 26 52 146 205 268 76 66 48 78 85 70 6 10 125 25
BNAB0043 10 10 10 10 10 10 10 10 10 109 11 10 15 44 48 10 10 10 50 33 10 10 10 75 16 1 10 125 25
BNAB0044 205 113 46 10 105 54 76 11 23 487 241 203 325 720 62 300 729 399 348 36 10 10 18 82 89 12 10 125 25 2.19 2.31 0
BNAB0045 10 27 10 10 10 10 10 10 20 31 10 10 16 14 12 10 10 15 34 46 10 16 10 27 14 0 10 125 25
BNAB0046 10 24 10 10 10 10 10 10 10 12 10 10 59 10 10 10 10 28 68 62 10 18 10 10 14 0 10 125 25
BNAB0047 10 51 11 10 168 10 10 10 10 10 254 15 20 132 136 10 18 11 99 51 10 534 44 73 30 5 10 125 25 14.49 14.49 1
BNAB0048 10 192 10 10 10 19 13 15 10 10 21 98 11 10 102 10 10 10 52 34 10 26 20 24 19 2 10 125 25
BNAB0049 10 15 10 10 10 10 10 12 10 10 17 10 11 10 10 10 18 17 31 37 10 12 16 17 13 0 10 125 25
BNAB0051 10 31 16 10 10 43 63 15 15 13 79 221 99 31 23 109 10 186 512 65 10 36 82 235 40 5 10 103 25
BNAB0052 498 17 24 26 330 1357 60 130 45 121 975 1481 66 69 220 96 10 82 338 36 11 449 105 46 105 11 10 125 25 0.82 2.23 0
BNAB0053 16 38 16 10 73 17 227 56 15 20 93 39 80 180 30 682 301 130 150 72 69 25 34 116 57 7 10 125 989
BNAB0054 13 531 15 17 16 13 28 87 23 12 321 181 1294 611 36 19 45 40 141 76 30 42 44 39 54 6 10 125 25 0.16 1.75 0
BNAB0055 16 35 11 11 10 10 10 14 11 10 10 536 52 686 34 21 25 46 97 75 13 20 74 52 29 2 10 125 25
BNAB0056 10 27 31 11 54 39 10 10 10 17 17 10 33 403 28 48 108 157 149 77 72 34 116 35 36 5 10 125 25
BNAB0057 10 76 15 11 22 35 22 88 22 10 10 10 41 10 10 215 17 12 40 47 14 15 19 22 22 1 10 125 25
BNAB0058 101 175 54 52 1142 1453 79 284 273 146 781 1503 595 1761 362 656 1073 340 358 86 38 606 59 159 280 18 10 125 25 1.70 1.11 0
BNAB0060 11 128 15 12 36 59 253 43 19 23 1825 1063 60 115 21 48 15 89 395 89 10 67 89 327 65 7 1781 1367 2389 1.55 17.93 1
BNAB0062 40 33 17 17 369 18 226 30 25 25 31 53 111 72 25 22 62 18 397 74 15 40 24 143 45 5 786 712 726
BNAB0063 283 287 17 26 640 10 329 81 10 47 41 76 10 10 25 20 58 203 350 69 10 50 29 1009 58 7 21028 >1000 27438
BNAB0066 29 242 89 24 550 72 170 67 21 94 197 1168 205 75 37 58 216 213 468 212 61 143 94 333 122 12 1770 2054 4159 0.40 0.94 0
BNAB0068 10 39 10 10 31 307 22 53 18 27 177 685 33 10 10 77 10 10 273 85 15 25 11 40 33 4 10 125 25 1.64 3.60 1
BNAB0069 10 26 10 10 24 11 35 26 16 38 79 531 52 34 18 12 10 25 178 71 18 32 13 44 28 2 10 125 25
BNAB0070 10 54 12 13 73 42 25 40 51 57 293 1420 1372 22 13 36 81 48 448 108 21 64 27 55 57 5 10 125 25 1.91 2.20 0
BNAB0071 58 148 728 23 35 233 35 29 18 154 89 519 38 93 13 242 46 36 528 90 1071 42 42 73 85 8 1577 847 25
BNAB0072 10 33 11 15 29 12 10 28 10 10 10 10 25 10 13 10 10 11 146 68 15 44 34 30 18 1 10 240 25
BNAB0073 14 55 17 18 18 16 15 27 21 32 23 10 39 10 102 10 10 14 28 15 11 129 21 40 22 2 10 62 33
BNAB0074 10 35 10 10 17 10 18 16 10 50 30 120 25 43 14 54 10 15 35 34 10 212 16 43 23 2 10 125 25
BNAB0075 14 94 17 13 119 237 57 93 17 93 48 860 88 80 26 469 26 462 51 35 10 380 73 201 71 7 7664 >1000 12966
BNAB0076 50 77 20 10 103 65 21 35 11 54 1212 1100 145 349 36 405 55 68 157 25 33 478 36 68 76 8 10 25
BNAB0077 21 85 121 11 219 217 123 59 21 200 53 722 90 28 22 110 159 153 54 53 60 525 74 272 87 11 494 1006 1096
BNAB0078 1054 59 11 10 199 77 49 473 11 103 176 383 204 87 85 20 105 109 194 23 29 395 20 196 83 12 1105 1683 3535 1.38 5.83 1
BNAB0079 108 1064 399 10 10 10 10 61 10 10 1172 1634 671 683 20 88 45 62 421 27 10 86 11 17 64 8 10 125 25 4.26 8.23 1
BNAB0080 654 931 142 10 776 1346 308 621 10 455 1457 1634 821 1433 163 622 1156 933 893 72 10 51 73 47 272 17 1073 282 371 0.81 1.68 0
BNAB0081 18 128 25 10 81 15 16 32 10 22 249 1634 792 272 155 22 10 10 315 183 10 31 75 27 51 8 717 125 86 0.54 0.67 0
BNAB0082 10 54 77 12 10 20 294 10 10 61 381 1634 263 530 40 274 10 10 1017 10 10 12 124 54 52 8 58 125 87 1.50 2.27 0
BNAB0083 86 85 132 17 10 22 20 54 27 830 1024 10 209 589 34 84 414 803 296 79 26 20 40 26 76 8 53 125 1300 3.44 5.86 1
BNAB0084 369 614 255 59 396 623 1081 270 426 1212 1243 1634 922 1621 604 1000 1479 1409 1172 411 228 372 785 714 621 23 134 125 84 1.33 2.04 0
BNAB0085 50 980 107 20 20 11 113 33 10 10 42 1634 520 1592 11 1626 722 10 592 49 10 55 55 30 76 9 10 125 25
BNAB0086 635 1605 31 728 105 1497 956 616 29 13 1346 1634 325 1629 1511 754 13 459 1244 34 63 1045 229 1196 338 18 10 125 34 1.15 1.77 0
BNAB0087 10 10 10 10 11 10 158 26 10 295 315 1634 1146 143 11 31 17 92 139 15 10 25 108 462 47 9 10 125 25 0.60 1.81 0
BNAB0088 118 130 13 18 1271 20 523 105 10 190 400 1634 44 210 77 265 123 10 579 12 65 45 48 1022 102 13 7968 2480 8780 1.08 0.77 0
BNAB0090 1573 471 18 10 1445 933 215 244 489 613 194 1634 816 1556 1152 1670 1432 1640 1634 116 10 118 333 991 406 21 57 136 25 1.00 1.00 0
BNAB0092 44 204 38 10 71 538 58 87 33 184 304 1634 186 468 1527 159 21 10 345 33 10 22 46 47 88 10 76 125 25 2.12 4.71 1
BNAB0098 1524 1180 10 10 24 78 1333 27 36 21 1452 1634 1021 1638 456 411 22 30 506 174 18 144 142 346 157 14 10 125 25 44.72 4.61 1
BNAB0101 10 29 10 15 12 10 10 10 16 10 10 18 47 22 10 16 48 10 96 10 10 15 30 19 16 0 97 125 25
BNAB0102 10 191 10 60 10 10 10 10 10 10 10 1634 443 15 10 11 10 10 64 10 10 495 10 10 23 4 96 52 25
BNAB0103 69 704 10 88 93 12 49 21 10 10 518 1634 176 607 57 279 83 10 594 130 50 417 427 177 98 11 1094 281 238 8.42 1.91 1
BNAB0104 27 965 10 36 206 1074 163 67 31 58 1370 1634 36 1349 285 289 25 10 578 30 12 55 132 211 115 12 2160 609 25 0.83 1.80 0
BNAB0143 43 464 22 23 163 12 182 55 11 48 904 1634 10 240 21 20 19 10 484 16 12 43 52 182 56 8 4204 3682 725 0.34 0.28 0
BNAB0144 10 24 19 13 18 10 30 11 10 20 144 10 12 15 10 14 10 10 45 10 12 19 24 25 17 1 10 25 25 1.00 1.00 0
BNAB0145 323 43 71 10 28 377 36 64 366 200 409 1634 116 1011 160 1009 23 10 1520 29 10 357 93 38 115 12 57 25 25 1.62 1.55 0
BNAB0146 1137 1462 155 27 216 1452 879 533 1164 1305 1477 1634 514 1633 467 1655 871 527 1634 411 241 1455 74 86 574 21 139 25 25 1.75 2.59 0
BNAB0147 10 31 32 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 15 10 10 16 10 10 11 0 10 25 25
BNAB0148 71 166 53 26 547 108 402 90 18 10 261 1634 103 205 24 1304 86 529 1014 120 20 102 227 666 140 15 6815 9113 8587 0.45 1.13 0
BNAB0149 166 869 240 1280 281 45 263 89 64 1032 2257 1634 72 1147 553 1163 1475 698 1032 48 10 722 141 675 341 18 4232 4457 1046 2.26 7.66 1
BNAB0150 10 10 10 10 10 10 41 10 10 10 20 1015 10 11 10 10 10 14 155 10 10 12 10 64 16 2 130 25 25
BNAB0151 16 73 48 16 143 919 11 133 278 359 953 1634 255 1174 113 557 21 30 249 11 10 203 29 34 102 13 10 25 25 0.75 1.77 0
BNAB0153 10 29 103 10 22 117 25 14 10 14 201 1634 11 1076 10 31 1372 129 111 10 10 44 26 17 43 8 188 25 25 0.03 1.21 0
BNAB0154 222 32 10 10 91 10 298 10 10 10 52 913 91 95 52 10 35 10 464 10 10 10 38 26 34 4 10 25 25
BNAB0155 38 106 110 10 10 21 10 10 10 18 343 1634 161 390 549 116 248 194 583 10 51 1203 25 33 73 12 269 141 25 0.80 2.00 0
BNAB0156 88 1557 40 12 50 70 80 163 15 18 1155 1634 10 1658 109 136 46 21 838 27 16 52 157 133 92 10 1050 820 25 0.74 1.76 0
BNAB0157 364 612 29 18 1025 102 57 16 68 30 56 1634 78 164 110 350 66 256 1041 17 54 76 120 143 114 12 10 25 25
BNAB0158 40 169 16 10 10 10 226 10 10 10 1362 901 14 524 10 10 10 10 183 33 10 23 138 15 34 7 10 25 25 38.20 2.95 1
BNAB0159 23 10 14 10 10 10 10 10 10 18 184 207 12 14 19 10 10 10 160 10 10 10 35 19 18 3 10 25 25 1.00 1.00 0
BNAB0160 20 12 12 10 10 10 10 10 10 10 10 117 13 55 23 26 10 10 188 688 10 10 30 10 19 3 10 52 25
BNAB0161 202 1568 30 56 370 169 15 10 10 10 44 20 12 17 45 15 11 10 118 10 10 26 32 30 32 5 90 25 25
BNAB0162 69 21 15 10 20 870 18 10 10 10 130 454 10 286 67 128 13 10 355 11 10 31 64 86 38 6 10 25 25 1.48 4.50 1
BNAB0163 15 10 10 10 10 10 11 10 10 10 26 128 20 14 17 10 133 11 148 10 31 11 31 19 18 3 10 25 25
BNAB0164 75 20 28 10 51 57 36 10 10 20 302 154 10 43 19 479 52 10 104 10 10 16 58 63 34 4 282 139 148 0.16 1.00 0
BNAB0165 42 13 112 10 908 18 1433 422 140 766 99 1634 169 1676 1452 1319 1688 10 1634 14 10 182 90 33 163 14 126 25 25
BNAB0166 15 82 14 10 12 34 15 10 10 13 383 369 12 21 45 30 755 44 70 12 10 14 49 22 30 3 10 25 25 5.20 1.85 1
BNAB0167 604 593 219 90 1071 1431 324 139 625 1030 1211 1634 177 1627 944 1247 1046 1231 1671 1570 14 277 222 149 509 22 3031 3746 340 0.83 1.35 0
BNAB0168 62 32 113 25 121 10 10 10 10 10 10 10 10 10 10 10 10 10 37 453 10 10 15 10 18 3 10 25 25
BNAB0169 76 66 25 28 1275 77 91 19 10 15 20 946 58 42 22 148 1293 342 168 10 10 35 43 167 64 7 840 814 374
BNAB0170 1269 396 17 55 10 11 286 10 10 10 88 1634 89 98 12 389 46 10 654 10 10 51 46 40 53 6 10 25 25
BNAB0171 127 1647 200 67 121 1461 299 83 11 145 1442 1634 43 1491 1278 992 289 30 279 355 10 56 88 188 205 16 10 25 25 0.46 1.36 0
BNAB0172 100 28 37 56 44 74 106 28 21 34 572 1634 13 36 129 216 210 56 282 26 10 24 64 47 65 7 153 25 25 2.30 4.44 1
BNAB0173 24 31 126 10 102 31 34 10 10 280 1015 1634 25 628 89 406 1685 472 145 10 10 10 34 30 71 10 95 25 25 1.71 7.44 1
BNAB0175 1345 1077 131 310 1534 883 661 835 381 272 1198 1634 159 1607 259 1170 1616 262 1634 351 24 1652 585 384 572 23 10 25 812 0.93 2.33 0
BNAB0176 1420 101 1005 642 1547 1385 142 474 718 10 365 1634 149 870 11 574 445 1562 242 768 2135 390 32 236 368 21 242 414 80 14.68 5.70 1
BNAB0180 1145 1264 10 47 1484 1376 723 40 270 767 1158 1634 143 1256 408 400 1652 1476 660 105 19 908 312 165 378 20 10 25 277 1.65 2.55 0
BNAB0181 187 87 38 57 721 24 644 32 46 32 202 1634 10 687 83 281 146 10 551 20 16 29 28 327 89 10 2480 25 530 5.45 5.45 1
BNAB0182 307 260 362 13 233 207 222 184 22 112 1457 1634 113 1682 419 631 278 494 988 70 235 1675 59 331 266 20 258 25 855 0.58 1.86 0
BNAB0184 769 88 20 185 855 567 22 406 252 11 1253 1634 354 1680 1053 1539 563 108 260 10 235 1416 145 112 255 19 10 25 25 1.50 2.11 0
BNAB0185 1470 1518 21 687 1138 1466 1265 1442 1270 312 80 1634 164 1630 1020 1351 483 210 254 16 13 1634 750 1071 469 20 10 62 79
BNAB0186 40 10 10 12 16 13 10 12 19 10 103 1031 10 24 42 11 11 16 75 10 10 10 33 40 21 2 142 25 25 1.00 1.00 0
BNAB0187 111 20 17 12 353 965 729 49 87 305 1404 1634 114 1039 611 144 961 312 1393 140 10 106 144 132 189 18 214 25 25 1.01 3.06 1
BNAB0188 60 19 38 12 42 47 32 52 47 28 103 25 10 27 18 15 13 65 277 14 12 67 64 42 33 2 71 25 223 1.00 1.00 0
BNAB0189 41 15 26 20 48 833 17 17 37 22 1112 1634 10 193 72 51 14 57 354 13 10 29 81 64 53 5 10 25 25 1.04 2.56 0
BNAB0190 24 12 12 14 10 142 10 10 10 10 10 1634 50 11 10 17 24 10 412 997 10 10 32 16 25 4 10 25 25
BNAB0191 90 83 16 16 111 91 272 126 17 108 833 1634 50 776 84 293 47 149 383 363 14 106 82 215 116 13 117 25 132 0.43 2.95 0
BNAB0192 115 349 47 17 37 317 14 39 31 13 62 110 10 834 26 30 20 24 145 10 10 248 41 46 47 7 10 25 25
BNAB0193 213 183 133 55 344 198 235 85 91 184 1087 1634 56 190 147 1273 134 291 1073 105 13 115 118 373 192 19 2329 3439 2080 1.56 3.34 1
BNAB0195 78 34 208 16 65 229 86 65 174 509 809 1634 63 1492 126 1370 1455 239 187 12 10 18 59 32 128 12 10 25 25 0.79 2.05 0
BNAB0196 50 37 27 18 15 33 57 33 27 22 792 1634 10 46 1585 41 16 108 134 15 29 18 65 20 49 5 10 25 25 1.39 0.89 0
BNAB0198 266 166 41 60 814 508 299 124 146 75 1454 1634 151 178 592 918 331 274 764 48 59 25 155 443 222 18 911 3046 402 0.28 2.28 0
BNAB0199 588 221 299 62 1240 496 959 412 209 746 1299 1634 190 1661 1251 1529 1264 1322 1464 1463 10 1158 264 145 524 22 75 25 25 0.96 1.66 0
BNAB0200 109 104 40 344 194 43 771 10 10 10 1338 1634 101 1154 183 23 758 219 63 567 10 182 119 24 116 15 393 319 25 2.68 3.94 1
BNAB0201 86 77 10 22 26 85 218 12 10 10 302 475 26 61 21 23 23 57 297 20 10 28 42 210 43 5 117 25 25 0.65 1.68 0
BNAB0202 183 37 10 30 144 37 46 21 10 72 43 10 52 635 159 40 33 21 76 10 10 10 32 105 38 5 166 25 25
BNAB0203 50 46 12 20 168 24 165 18 10 27 754 1634 28 53 44 23 1322 156 467 61 33 38 80 73 69 7 10 25 121 1.05 1.30 0
BNAB0204 27 13 10 15 10 20 10 10 14 10 26 10 17 16 11 10 14 25 21 10 10 10 22 15 14 0 10 25 25
BNAB0205 298 357 10 17 111 91 45 62 61 200 1041 1634 10 74 39 564 66 63 1181 12 201 71 104 55 99 10 10 25 25 1.28 2.55 0
BNAB0206 68 25 16 27 118 264 89 32 53 20 163 1634 11 90 17 96 77 77 592 16 47 10 66 33 57 5 10 25 25 1.00 1.00 0
BNAB0207 1272 1386 122 109 337 885 866 328 567 251 145 354 18 1670 241 1448 78 223 1627 1473 69 532 68 33 308 19 538 1260 25 1.52 4.08 1
BNAB0208 83 36 10 19 38 13 33 29 10 10 51 964 10 17 12 27 15 10 121 10 10 10 15 20 23 2 10 25 25
BNAB0209 536 327 45 39 860 323 590 112 108 1389 951 1634 446 1532 1578 1164 609 489 747 33 231 47 191 536 353 20 86 155 843 2.46 0.09 0
BNAB0210 82 33 37 55 34 40 62 51 33 37 233 941 49 99 74 59 32 14 181 10 11 10 19 24 45 3 10 25 25 1.00 1.00 0
BNAB0211 235 787 119 36 828 276 134 95 201 37 127 1634 10 382 99 71 943 779 301 29 32 69 50 326 152 14 10 25 1026 3.19 3.19 1
BNAB0213 617 458 67 514 619 103 285 502 282 253 895 851 10 242 172 293 353 278 873 276 297 467 374 124 286 22 10 25 25
BNAB0214 418 21 26 26 260 660 66 85 162 137 365 826 10 729 625 1321 60 206 1116 288 16 1517 48 31 154 14 10 25 25 4.11 5.60 1
BNAB0215 67 10 10 19 39 16 10 40 17 10 179 47 70 11 11 10 16 29 61 10 12 26 36 24 23 1 129 25 75 1.00 1.00 0
BNAB0216 315 1020 87 63 707 148 169 571 250 678 1481 1634 10 1626 639 138 1116 971 841 286 63 381 78 462 328 19 2269 4734 6154 5.78 11.11 1
BNAB0217 124 47 17 31 1567 205 42 1052 391 41 86 1634 108 1492 44 1435 689 48 132 20 23 90 86 65 134 11 10 70 25
BNAB0218 40 16 17 24 291 690 93 98 66 333 70 1634 86 428 191 638 1581 1267 197 32 10 149 123 105 135 13 316 313 47
BNAB0219 39 30 101 30 57 46 34 90 84 1042 887 755 87 116 43 116 46 112 185 53 15 167 150 58 91 10 10 25 25 0.40 0.54 0
BNAB0220 258 326 203 48 967 663 232 378 10 450 238 1634 159 1383 290 820 46 608 683 993 10 116 37 40 218 18 10 25 25 0.87 1.27 0
BNAB0221 68 24 22 27 141 141 95 203 59 125 729 1634 153 372 455 1009 72 80 802 47 14 329 74 110 131 13 511 144 231 0.95 0.85 0
BNAB0222 122 1450 30 33 336 269 115 176 46 69 242 1132 47 794 44 305 679 67 313 33 45 137 76 110 140 14 56 25 25 4.03 5.61 1
BNAB0223 30 10 30 17 16 24 10 44 18 13 26 10 10 17 11 14 23 25 36 13 10 61 24 30 19 0 10 25 25
BNAB0224 457 11 49 34 49 1468 94 190 236 161 1424 1634 10 1369 1373 85 141 39 1283 421 10 1671 144 193 183 15 10 25 25 0.32 1.01 0
BNAB0225 46 17 10 20 48 29 81 71 46 48 92 1634 28 22 25 41 35 34 420 36 19 364 90 67 53 3 59 25 25
BNAB0226 50 16 19 28 110 50 27 60 55 43 45 102 42 62 96 110 1457 142 170 24 10 74 50 35 57 6 55 52 25
BNAB0227 213 459 19 44 1198 466 249 549 112 147 1477 1634 53 1631 427 1311 1488 1459 317 855 13 118 77 63 279 18 2373 4498 2930 0.72 2.15 0
BNAB0228 1613 1544 50 111 348 147 143 101 10 10 1280 1634 53 1229 1559 1425 56 118 153 39 65 891 38 186 190 16 10 25 25 2.10 62.59 1
BNAB0229 34 10 10 32 10 10 37 10 10 10 51 27 67 64 28 60 18 33 677 18 10 46 37 115 28 2 10 25 25
BNAB0230 132 98 118 85 512 74 168 111 37 17 254 1634 30 69 178 205 109 51 639 48 17 176 84 289 114 13 3913 2951 310 0.64 0.87 0
BNAB0231 831 777 1830 59 74 285 173 380 116 381 1216 1634 72 1454 91 364 1063 564 735 526 249 191 83 202 339 19 143 25 25 2.62 2.51 0
BNAB0232 557 823 16 46 657 376 268 163 138 696 1561 1634 52 1025 43 1602 1313 80 442 25 13 76 79 60 200 14 10 25 25 0.83 2.37 0
BNAB0233 38 12 10 28 17 21 10 14 26 15 16 10 14 28 19 27 45 32 15 13 10 42 29 25 19 0 10 25 25
BNAB0234 45 33 10 79 46 55 50 31 54 45 59 10 30 66 32 215 48 65 205 28 10 48 62 65 44 2 10 25 25
BNAB0235 154 582 11 26 1531 29 262 23 28 19 183 1634 136 1594 16 1467 1237 423 1324 1393 10 153 88 48 155 14 275 131 240 2.35 5.85 1
BNAB0236 116 73 47 53 263 64 141 41 10 10 1462 1634 518 1198 47 36 59 72 237 23 14 53 10 130 83 9 115 75 1269 1.29 1.56 0
BNAB0237 997 1379 70 75 79 63 94 359 46 41 256 528 46 1491 254 711 178 119 308 21 10 100 23 69 132 12 197 25 25 4.19 3.33 1
BNAB0238 1654 1519 308 252 788 1496 1342 561 338 725 1520 1634 51 1575 1322 1400 979 1146 1448 287 35 1634 105 1242 664 22 2189 659 25 1.08 2.68 0
BNAB0239 38 20 383 62 61 1627 466 121 75 584 284 202 34 252 32 98 1697 166 154 20 11 131 68 68 117 12 10 25 25 1.09 0.85 0
BNAB0240 45 28 22 24 281 15 57 64 81 67 530 1634 10 1381 56 941 1571 157 260 34 10 41 44 35 88 8 10 29 25 0.63 1.51 0
BNAB0241 10 10 10 33 55 129 10 10 16 258 10 199 22 24 494 164 1001 10 25 10 65 17 29 34 36 6 10 25 25
BNAB0242 10 10 11 22 10 10 10 10 10 73 71 148 32 10 10 10 10 10 11 10 10 10 10 10 14 1 10 25 25
BNAB0243 1464 1381 18 466 1289 103 1327 1167 329 163 200 1634 114 1363 60 1002 358 16 128 15 10 424 21 147 213 18 10 88 397 1.00 1.00 0
Tier 2 Tier 2 Tier 3
South Africa sera
24 Virus panel
Subtype A Kenya Subtype B, various locations Subtype C southern Africa Subtype C India CRF02_AG









Figure 2.2: Heterologous neutralization capacity of 177 HIV-1 infected (>1yr.) South Africa 
serum samples to a 24 pseudovirus panel. (a) ID50 titers of the indicated pseudovirus for each of 
the serum samples are shown. The serum geometric mean titer and the number of viruses neutralized 
are shown. The MPER activity in the cohort was measured using three different (C1C, C1 and 253 
MPER) HIV-2/HIV-1 chimeric constructs. The PG9/16-site directed antibodies were detected using 
CAP45.2.00.G3 N160A and K169E mutants. ≥3 fold drop in ID50 in either the N160 or K169E 
mutants were considered a PG9/16-site specific hit. Colour codes: Red shading: ID50>1000; Orange 
shading: ID50 300-1000; Yellow shading: ID50 100-300; Green shading: ID50 50-100. (b) the 




Figure 2.3: Correlation of geometric mean ID50 titer to contemporaneous CD4 T cell counts 
for South Africa donors: The corresponding p value and spearman’s correlation coefficient are 
shown. 
  





Spearman's r = -0.21
p = 0.0090











2.4.3. Sensitivity of viruses to South Africa sera:  
The neutralization sensitivity of viruses was evaluated by ranking viruses using the geometric mean 
of the ID50 values for all 177 serum samples neutralizing each virus (Figure 2.4). Within-subtype 
neutralization, i.e. better neutralization of viruses matched to the sera by subtype (Binley et al., 2004; 
Brown et al., 2008; Bures et al., 2002; Rademeyer et al., 2007; Seaman et al., 2010b; van Gils et al., 
2010b) was notably observed with subtype C. Four subtype C pseudoviruses were among the six 
most sensitive viruses to the South Africa sera (~98% subtype C (Wilkinson and Engelbrecht, 2009); 




Figure 2.4: Relative sensitivity ranking of viruses to the South Africa serum samples and their 
sensitivity to monoclonal antibodies: Viruses are ranked by the geometric mean of the ID50 values 
of all sera neutralizing that virus; four highly resistant viruses are shaded green. The largest 
percentage distance between any two viruses among the resistant viruses was taken as the clearest 
cutoff between the most resistant viruses and other viruses. The sensititivity of the 24 virus panel to 





2.4.4.  Clustering analysis of neutralization:  
We generated heat maps to study the clustering patterns of neutralization by serum samples (Figure 
2.5). Serum samples clustered into three distinct groups. Cluster S1 (n=95) contained the most 
broadly neutralizing sera and cluster S2 (n=20) the least. Sera in clusters S1 and S3 (n=62) were 
generally similar, except that S1 were more potent and broadly neutralizing. S1 tended to neutralize 
the highly resistant viruses in comparison to S3. Viruses generally clustered by their overall 
neutralization sensitivities. Four most resistant viruses (253-11, Q461.e2 and QH343.21M.ENV.A10 
and PVO.4) clustered together. Separately, the most sensitive viruses (Du151.2, 001428-2.42, 
CAP45.2.00.G3 and 255-34) clustered together. No obvious clustering by virus subtype was 











Figure 2.5: Clustering map of serum samples and viruses. Serum samples and viruses clustered to four 
major groups based on their neutralization capacity and neutralization susceptibility respectively. Higher 
neutralization values are shown in darker colours while the lower values are shown in light shades. Log10 of 
neutralization score was used to plot the dendogram. 
 
2.4.5.  Detection of antibodies overlapping the PG9/16 site within the cohort:  
Next we investigated the prevalence of PG9/16-site specific antibodies in the cohort. Although 
previous studies have noted that some broadly neutralizing monoclonal antibodies (Walker et al., 
2011; Walker et al., 2009a) or sera (Gray et al., 2011; Moore et al., 2011; Tomaras et al., 2011; 
Walker et al., 2010) target this site, their prevalence among chronically-HIV-1-infected individuals 
has not been reported. The V2 loop glycan at position 160 and the lysine residue at position 169 are 
two crucial residues essential for PG9/16 mAb recognition (Moore et al., 2011; Walker et al., 
2009b); single amino acid substitutions in this region abolish PG9 and PG16 mAb recognition and 
neutralization (Moore et al., 2011; Walker et al., 2009b) and have been used to identify PG9/16-like 
antibodies from blood samples in various reports (Gray et al., 2011; Mikell et al., 2011; Moore et al., 
2011; Walker et al., 2010).  
 
Sera (n=108) which neutralized the HIV-1 subtype C virus CAP45.2.00.G3 (with an ID50 titer >100) 
were further screened on the CAP45.2.00.G3 V2 region mutants N160A and K169E which disrupt 
the PG9/16 epitope (Figure2.2a). Anti-PG9/16-site activity was captured from all available sera 
which neutralized the parent virus at an ID50>100. Thirty four percent (37/108) of the 
CAP45.2.00.G3 neutralizers exhibited a diminished (≥3 fold drop) neutralization activity against 
either one of the two V2 region mutants in comparison to the parent virus, confirming anti-PG9/16-
site specific neutralization activity in a substantial fraction of the cohort.   
 
2.4.6.  Lack of a positive association between presence of anti-PG9/16-site antibodies and 
neutralization breadth in sera: 
Anti-PG9/16-site antibodies have been shown to mediate breadth in some broad neutralizers (Gray et 
al., 2011; Gray et al., 2009a; Tomaras et al., 2011; Walker et al., 2010). The association between the 
presence of anti-PG9/16-site specific antibodies and neutralization breadth was evaluated in this 
cohort. Anti-PG9/16-site neutralizing antibodies were present in approximately 1/5
th
 of the broad 
neutralizers. 17% (6/35) of the broad neutralizers with serum geometric mean ID50 titer >200 and 
seven of the thirty two (22%) serum samples which neutralized ≥3/4
th
 of the panel viruses had 
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PG9/16-site specific antibodies. Surprisingly, the sample set (n=37) with anti-PG9/16-site 
neutralization activity did not elicit a higher neutralization breadth compared to the sample set 
(n=71) without any detectable anti-PG9/16-site activity. The median geometric mean ID50 titer (114 
vs 105; p =0.64, Wilcoxon rank sum test) and the number of viruses neutralized (12 vs 12; p = 0.84) 
by samples with PG9/16-site specific neutralization activity was not significantly different from their 
negative counterparts (Figure 2.6). In fact, PG9/16 site neutralizers were less likely (p=0.04) than 
non-PG9/16 site neutralizers to be able to neutralize >18/24 panel viruses; tested by a two-sample 




Figure 2.6: Box-plot depicting the neutralization breadth of samples with and without PG9/16-
site specific neutralization activity: A Wilcoxon-rank sum test was used to compare and calculate 
the median difference between the samples set with and without PG9/16-site activity.  
Neutralization breadth was defined either by the serum geometric mean ID50 titer (left) or the 
number of viruses neutralized (right). Corresponding p values and the number of samples analyzed 








Table 2.1: The proportions of broad neutralizers in the sample set with and without PG9/16-
site specific activity: Breadth is defined either by the geometric mean ID50 titer (top) or the number 
of viruses neutralized (bottom). The p values are derived from 2-sample test for equality of 






2.4.7.  Anti-MPER antibodies within the cohort:   
To detect anti-MPER antibodies in the cohort, three different HIV-2 chimeric viruses with the native 
HIV-2 MPER replaced by an HIV-1 MPER was used (Gray et al., 2007). The HIV-2 MPER was 
replaced either with a consensus subtype C MPER (C1C; (Gray et al., 2007)) or Yu2 MPER (C1; 
(Binley et al., 2008; Gray et al., 2007)) or the MPER from a CRF02_AG virus (253-11 MPER 
chimera, refer to thesis chapter four). The parent HIV-2 virus (7312A) was screened alongside to 
detect cross-neutralization activity directed against the HIV-2 envelope. In order to be scored as 
containing anti-MPER antibodies, the serum had to exhibit high titers (ID50>1000) of neutralization 
against at least one of the three chimeric constructs. 19% (33/177) of the cohort had anti-MPER 
antibodies by this definition (Figure 2.2a). Only one sample had high titer 4E10-like antibody 
(ID50>1000) while none had detectable 2F5-like antibodies measured by using HIV-2/HIV-1 MPER 
chimera containing the minimal 2F5 (C7) and 4E10 (C6) epitope. Antibodies directed against the 
chimeras in these samples were directed against the HIV-1 MPER: as none of these sera detectably 








<3 fold (neg) 50 21 21/71 (29.5%)







<3 fold (neg) 47 24 24/71 (33.8%)
>3 fold (pos) 31 6 6/37 (16%)
Neutralization category: (Num. of viruses 
neutralized with ID50>100)
0.04







2.4.8. Thresholds for distinguishing sera with significant anti-MPER activity: 
A previous study established that high titers (C1C ID50>1000) of anti-MPER antibodies are required 
to neutralize HIV-1 isolates via MPER (Gray et al., 2009a). The probability that samples with anti-
MPER titers<300 mediate HIV-1 neutralization via MPER has been reported to be negligible or low, 
as five samples tested with anti-MPER antibody titers <300 failed to neutralize via MPER (Gray et 
al., 2011; Gray et al., 2009a).  
  
Based on the above observations, the cohort was categorized into two groups; MPER Pos (n=33) with 
high titer MPER activity (ID50>1:1000 for at least one of the three MPER chimeras) and MPER Neg 
(n=126) with anti-MPER titers<300 for all the three HIV-2/HIV-1 MPER chimeric constructs. 
Eighteen serum samples with which the highest tier among the three HIV-2/HIV-1MPER chimera 
constructs was between 300 and 1000 were dropped from the analysis as we were unable to score 
them as anti-MPER positive or anti-MPER negative with sufficient certainty (Gray et al., 2011; Gray 
et al., 2009a). 
 
 
2.4.9. Presence of anti-MPER antibodies is associated with neutralization breadth: 
Two previous reports concluded that MPER is the predominant neutralization target in samples with 
anti-MPER antibody titers>1000 (against C1C/C1) (Gray et al., 2009a; Tomaras et al., 2011). Gray 
et al first reported that anti-MPER antibodies were the primary neutralizing antibody in 3/3 samples 
tested with a C1C ID50>1000. This association was further confirmed on three broad neutralizers 
from the CHAVI study (Tomaras et al., 2011). Efficient depletion of anti-MPER antibodies resulted 
in a significant (≥3 fold) drop in neutralization of at least three viruses in six of the eight serum 
samples tested in our lab (Figure 4.5 in chapter 4 and data not shown). This suggests that the 
majority of the neutralization activity in samples with high titer anti-MPER antibodies (ID50>1000) 
is attributable to this particular specificity. 
 
We noticed a significant positive correlation between log anti-MPER antibody titer and 
neutralization breadth by number of viruses neutralized (data not shown). A similar association was 
observed in a previous report, in a set of 52 plasma samples (Gray et al., 2009b), although only 2/52 
samples had an anti-C1C titer>1000, a threshold subsequently found by the same group to be 
associated with dominant anti-MPER neutralization activity (Gray et al., 2011; Gray et al., 2009a) 
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(discussed above). Next we compared the neutralization breadth of samples with and without anti-
MPER activity. MPER positive samples neutralized a significantly higher (p<0.0001) number of 
viruses (median=12) and were more potent (p<0.0001, serum geometric mean ID50 titer=102) than 
the sample set which lacked MPER activity (median number of viruses neutralized=6; serum 
geometric mean ID50=53; Figure 2.7).  
 
We wished to compare this effect directly to the same comparison made for anti-PG9/PG16 site 
antibodies. Thus, this analysis was restricted to the 108 serum samples for which we measured 
PG9/16-site specific data. The association remained significant in this smaller sample set (p=0.04 
and 0.028; Figure 2.7). Furthermore, the MPER Pos samples were 2.25 (95% CI: 1.14-4.44, p=0.02) 




Figure 2.7: Box-plot depicting the neutralization breadth of samples with and without anti-
MPER activity: Neutralization breadth was defined either by the serum geometric mean ID50 titer 
(left) or the number of viruses neutralized (right). A Wilcoxon-rank sum test was used to compare 
and calculate the median difference between the samples set with and without anti-MPER activity.  
Neutralization breadth was defined either by the serum geometric mean ID50 titer (left) or the 
number of viruses neutralized (right). Corresponding p values and the number of samples analyzed 











Table 2.2: The proportions of broad neutralizers in the MPER positive and MPER negative 
category: Breadth is defined either by the geometric mean ID50 titer (top) or the number of viruses 
neutralized (bottom). The relative risk ratios with the 95% confidence intervals (95% CI) and 






2.4.10. Variability analysis of neutralizing antibody epitopes within gp160:  
We analyzed the epitope variability of neutralizing antibody target sites by calculating Shannon’s 
entropy score for all identified target sites for broadly neutralizing antibodies using 3829 HIV-1 
envelope sequences chosen to represent the range of worldwide sequences (Figure 2.8b) 
 








Anti-MPER activity (ID50<300) 106 20
Anti-MPER activity (ID50>1000) 24 9








Anti-MPER activity (ID50<300) 109 17
Anti-MPER activity (ID50>1000) 23 10
2.25 (1.14 - 4.44) 0.02
Neutralization category: (serum geometric 
mean titer)
1.72 (0.86 - 3.42) 0.12








Figure 2.8: (a) Shannon’s entropy plot for HIV-1 gp160 from HIV-1 sequences downloaded 
from the Los Alamos database (n=3829): The curated HIV-1 gp160 alignment used to plot 
variability represented nine major subtypes, 51 circular recombinant forms and unique recombinant 
form. Of the 3960 sequences, 115 sequences with stop codons and 16 sequences whose amino acid 
residues were uncertain were removed from the alignment (b) Mean variability across the core 
epitopes of the existing monoclonal antibodies are depicted. For each mAb, the one letter amino acid 
residue and the corresponding position in HXB2 is indicated. Gray shading: Entropy <0.5; Yellow 
shading: Entropy 0.5-1.0; Light orange shading: Entropy 1.0-1.5; Dark orange shading: Entropy 
>1.5.  
 
The gp120 had a higher average variability score (H=0.68) than that of gp41 (H = 0.41). The lower 
variability of gp41 compared to gp120 is possibly due to its occlusion from host neutralizing 
antibody pressure as the gp41 stalk is concealed within the quaternary envelope spikes (Dimitrov et 
al., 2003; Wyatt and Sodroski, 1998). Within the MPER, amino acid sequence variability was highly 
restricted (H=0.39). Interestingly, 13/24 amino acids in the MPER were highly conserved (H<0.1), in 
particular the hydrophobic residues.  Importantly, the neutralizing antibody epitopes of the four 
mAbs within the MPER (2F5, 4E10 and 10E8; calculated singly or in aggregate) had a lower 
variability than the PG9/PG16 (H=0.65), glycan recognizing mAb epitopes (2G12, PGT128; 0.73) 




HIV-1 is an antigenically diverse virus and good coverage by a neutralizing antibody-based vaccine 
is likely to entail targeting epitopes recognized by broadly neutralizing antibodies (Burton et al., 




PG9/16 N156 S158 F159 N160 S162 K169 K171 Y173 F176 I181 P299 K305 I307 I309 F317 V318
0.072 0.297 0.276 0.39 0.178 1.686 1.201 1.172 0 0.865 0.072 1.053 0.975 0.977 0.755 0.483
D185 N276 S364 S365 P369 T373 N386
b12 1.85 0.072 0.984 0.864 1.075 0.816 0.296
2G12/PGT 128 N295 N301 N332 N339 N386 N392
1.11 0.242 0.999 1.117 0.296 0.621
2F5 662A 663L 664D 665K 666W 667A
0.851 0.149 0.142 0.779 0 0.994
Z13 666W 667A 668S 669L W670 671N 672W 673F 674D 675I 676T
0 0.994 0.757 0 0.845 0 0.046 1.101 0.026 0.738
4E10 671N 672W 673F 674D 675I 676T 680W
0.845 0 0.046 1.101 0.026 0.738 0.046
10E8 671N 672W 673F 674D 675I 676T 677N 678W 679L 680W 681Y 682I 683K











this study, we measured the neutralization breadth of sera from a South Africa cohort and detected 
antibodies directed at the PG9/16-site and the MPER. In this chapter, the ability of PG9/16-site and 
the MPER epitopes to induce broadly neutralizing antibodies in natural infections was assessed by 
comparing samples with and without the above antibody specificities. 
 
A predominantly neutralization resistant (Seaman et al., 2010b) and diverse virus panel (comprising 
five different subtypes) similar to our previously published panel (Jacob et al., 2012) was assembled 
to measure neutralization breadth. Approximately one in five samples of the cohort was broadly 
neutralizing depending on the definition of breadth: having a geometric mean ID50 titer>200 (20%, 
35/177) or the ability to neutralize ≥18 viruses (18%, 32/177) (Figure 2.2). This frequency of broad 
neutralizers appears similar to previously observed frequencies (Binley et al., 2008; Doria-Rose et 
al., 2010a; Doria-Rose et al., 2009; Euler et al., 2010; Gray et al., 2011; Sather et al., 2009; Simek et 
al., 2009; Tomaras et al., 2011) although differences in criteria for neutralization breadth, differences 
in panel viruses and cohort characteristics make precise comparisons difficult. We observed a 
significant inverse correlation between neutralization breadth and contemporaneous CD4 T cell 
counts (Figure 2.3). 
 
A regression line was used to estimate the ID50 values from percentage neutralization at 1/100 serum 
dilution (Figure 2.1). Our estimation model enabled us to analyze a large number of individual serum 
samples as against using pooled sera for determining neutralization breadth (Figure 2.2). This model 
was necessary especially as we had limited serum samples and other reagents necessary for 
conducting neutralization studies. The degree of error inherent in the model is likely very low the 
model was validated on a test set and the estimated ID50 values correlated well with the 
corresponding measured ID50 values (linear regression R
2
=0.6700, p < 0.0001, Figure 2.1b).  
 
 
In this study, 19% (33/177) of the cohort had high-titers (ID50>1000) of anti-MPER antibodies 
(Figure 2.2 a), comparable to a North American HIV-1 subtype B cohort (18%; 14/78; C1 ID50 titer 
>1000) (Huang et al., 2012). This prevalence is much higher than a blood bank cohort from South 
Africa (4%; 2/50; C1C ID50 titer >1000, (Gray et al., 2009b)) perhaps because the blood bank cohort 
participants may have been infected for shorter time periods on average than our study participants, 
and thus their sera would contain lower levels of neutralizing antibodies (Gray et al., 2011; Mikell et 




Previous reports and our own data suggest that the ability to recognize an HIV-2/HIV-1 MPER 
chimeric virus is associated with the dominant neutralizing antibodies being MPER-specific:  
Combining data from previous reports (Gray et al., 2009a; Tomaras et al., 2011) and our data (not 
shown), of 14 samples with high (ID50>1000) titers against one or more MPER chimeric viruses, the 
anti-MPER antibody was the dominant neutralizing antibody for at least three HIV-1 isolates in 12 
(86%) sera, as determined by anti-MPER depletion experiments.  In contrast, five samples with low 
anti-C1C activity (ID50<300) did not neutralize any tested HIV-1 viruses primarily via MPER (Gray 
et al., 2011; Gray et al., 2009a). Thus, neutralization of the HIV-2/HIV-1 MPER chimeras (at 
titers>1000) is associated with the dominant neutralizing antibody activity being directed against 
MPER. 
 
Three mAbs targeting the MPER are broadly neutralizing (Binley et al., 2004; Huang et al., 2012). 
We ascertained an association between the presence of anti-MPER antibodies and the ability to 
neutralize potently a wider range of HIV-1 isolates (Figure 2.7, Table 2.2). The highly conserved 
MPER (Figure 2.8) is presumably constrained by function because it plays a critical role in viral 
fusion and incorporation of envelope proteins into newly synthesized virions (Montero et al., 2008a; 
Sun et al., 2008; Zwick, 2005); this might explain why targeting MPER confers neutralization 
breadth.  
 
This is the first study to document the prevalence of PG9/16-site specific neutralizing antibodies in a 
chronic HIV-1 infection cohort. Approximately 1/3
rd
 (37/108) of the tested samples in our cohort 
targeted this site. Anti-PG9/16-site antibodies have previously been found to be frequent in broadly 
neutralizing sera (Gray et al., 2011; Tomaras et al., 2011; Walker et al., 2010); our study revealed 
that around 1/5
th
 of the broad neutralizers in our cohort targeted this site, a frequency similar to that 
observed in broad neutralizers from other cohorts (Gray et al., 2011; Tomaras et al., 2011; Walker et 
al., 2010). However, we provide evidence that many antibodies directed to this site do not exhibit the 
broad neutralization activity of PG9/16 (Figure 2.6) even after considering >5 fold differences 
between the CAP45.2.00.G3 wild type virus and the corresponding PG9/16 mutant (Appendix 2). In 
fact, the opposite was true: samples with PG9/16-site specific activity were less likely to be broadly 
neutralizing (neutralize >18/24 panel viruses) compared to the set which lacked detectable antibodies 
against this site (p=0.04).  
 
Different mAbs targeting the PG9/16-site elicits a range of neutralization activities. The mAb 2909’s 
neutralization is limited to a very few viruses such as SF162 (Gorny et al., 2005). The CH01-CH04 
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mAb (Bonsignori et al., 2011) series recognize PG9/16-like site but neutralize only 36-47% of tier 2 
isolates while the PG9 and PG16 mAbs neutralize around 80% of the isolates (Walker et al., 2009a). 
We speculated that the lack of association between neutralization breadth and the presence of 
PG9/16-site specific activity was due to a higher variability at this site. The PG9/16 site indeed was 
more variable (H=0.66) than the MPER (H=0.39) which in turn remained more conserved than the 
CD4 binding site and the glycan epitopes (2G12, PGT128 (Figure 2.8).  
 
In this study, we observed neutralization breadth to be associated with the presence of anti-MPER 
antibodies and not with the presence of PG9/16-site directed antibodies. However the study has some 
limitations. Some samples with anti-MPER antibody titer>1000 (detected using the HIV-2/HIV-1 
chimeras) might be miscategorized for their neutralization breadth. Specificity studies on some broad 
neutralizers have revealed antibodies targeting multiple epitopes, each contributing towards 
neutralization breadth (Gray et al., 2011; Tomaras et al., 2011). But, as argued above, the 
neutralization of HIV-2 / HIV-1 MPER chimeric virus at high-titers is strongly associated with anti-
MPER antibody being the dominant antibody, suggesting that such miscategorizations are few. A 
second limitation of this study is that screening for PG9/16-site antibodies are detected only when 
they contribute at least two-thirds of the neutralization activity against CAP45.2.00.G3. Therefore, 
we also did not test for the presence of PG9/16-site specific antibodies in the sera which did not 
neutralize the parent CAP45.2.00.G3 virus. However, the association between neutralization breadth 
and MPER neutralization remained significant (p=0.04) even for those samples that neutralized 
CAP45.2.00.G3 alone (Figure 2.7 b).   
   
For effective protection from a vaccine, antibodies induced by an immunogen targeting the HIV-1 
surface envelope should be broadly neutralizing. Designing immunogens which mimic the surface of 
the native, functional envelope complex which could induce broadly neutralizing antibodies is an 
important approach for vaccine development. Our results in natural HIV-1 infections suggest that 
raise the possibility that inducing broadly neutralizing antibodies against the PG9/16 epitope will be 
more challenging than against the MPER epitopes, suggesting that the MPER might be more 









Identification and characterization of neutralization-resistant 
CRF02_AG subtype HIV-1 isolates 
 
3.1. Summary: 
Background: The first antibody-inducing HIV-1 vaccines are unlikely to protect against all HIV-1 
isolates. There is thus a danger that a vaccine will select for HIV-1 viruses that are highly resistant to 
antibody-mediated neutralization. CRF02_AG viruses have been previously reported to be highly 
neutralization resistant.  
Results: We sought to identify and characterize such neutralization resistant CRF02_AG viruses 
using plasma samples infected with the same subtype and monoclonal antibodies. In contrast to 
previous reports, CRF02_AG plasma samples neutralized CRF02_AG viruses better than other 
viruses. This included six of eight CRF02_AG viruses previously designated as resistant (tier 2/3 or 
3). Only 253-11 and 278-50 remained highly resistant. All CRF02_AG viruses were sensitive to 
membrane proximal external region (MPER)-specific monoclonal antibodies.  
Conclusions: MPER is a vulnerable neutralization target for even the resistant CRF02_AG viruses. 
We also propose using high-neutralizing-within-subtype samples for evaluation of neutralization 
resistance of viruses. 
 
3.2. Introduction 
Human Immunodeficiency virus-1 (HIV-1) is an inefficiently transmitted virus (Royce et al., 1997), 
and thus depends upon survival within the host for extended periods of time. To persist, it must 
survive in the face of intense and sustained immune responses (Mascola and Montefiori, 2010; 
McMichael, 2006).  In part, this persistence is accomplished by its error-prone replication process 
and high recombination rate (Taylor et al., 2008) which generate substantial diversity early in 
infection (Keele, 2010; McMichael et al., 2010). This diversity, in turn, likely assures that viruses 
resistant to particular antibody responses are almost always present, even if at very low frequency 
(Loh et al., 2008), and that neutralizing antibody selects them (Bunnik et al., 2008; Burton et al., 
2005; Frost et al., 2005; Gray et al., 2007; Li et al., 2006; Mahalanabis et al., 2008; Moore et al., 
2009; Richman et al., 2003; Rong et al., 2009; Wei et al., 2003). 
 
There is evidence that inducing neutralizing antibodies to HIV-1 may be a fruitful approach for 
vaccine development. Passive immunization with neutralizing antibodies can prevent infection in 
primate models (Johnson et al., 2009; Mascola et al., 1999; Shibata et al., 1999; Xu et al., 2002) and 
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also protects neonatal primates (Ruprecht et al., 2003), even at low doses of antibody (Hessell et al., 
2009), all in cases in which the antibodies can neutralize the challenge virus. It thus appears likely 
that vaccine-induced antibodies will be able to protect a vaccinee from infection by viruses that they 
neutralize. The vaccine-induced  prophylactic antibodies would have to be broadly neutralizing 
because of the great diversity of the pool of HIV against which vaccinees would have to be protected 
(Woodman and Williamson, 2009). Nonetheless, even a vaccine that gives rise to neutralizing 
antibodies with highly broad but less than 100% coverage of HIV-1 isolates may be able to prevent 
many infections. About three-quarters of heterosexual HIV-1 infections (Abrahams et al., 2009; 
Keele et al., 2008; Salazar-Gonzalez et al., 2008) can be traced back to a single virus. Neutralization 
by vaccine-induced antibody of one or a few infecting virus(es) will presumably be a protective 
event.  
 
In the case of less than 100% strain coverage of a vaccine, a worrisome prospect is the possibility 
that such a vaccine might select for difficult-to-neutralize HIV-1 viruses. Viruses differ substantially 
in their neutralization resistance. A recent large study classified 107 viruses into 4 ordered 
categories, or tiers: tier 1A and 1B viruses were most sensitive and tier 3 viruses the most resistant 
(Seaman et al., 2010a). The relatively high neutralization resistance of CRF02_AG viruses was 
reported in the same study, with several fitting into tier 3 or tier 2/3 categories. CRF02_AG viruses 
were more likely to fit into the resistant category than other viruses. In addition, a CRF02_AG-
infected plasma pool was unable to preferentially neutralize within-subtype viruses, including the 
viruses used in this study (Brown et al., 2008; Seaman et al., 2010a; Seaman et al., 2010b).  
 
CRF02_AG viruses circulate primarily in West Africa and their neutralization sensitivity to 
antibodies is not well characterized. In this part of my thesis, we demonstrate that CRF02_AG 
viruses are not exceptional but are indeed vulnerable to within-subtype neutralization (ie. 
neutralization of viruses by serum/plasma samples infected with the same subtype). We also 
identified two highly resistant CRF02_AG viruses (even resistant to subtype specific neutralization). 
Last, we identified monoclonal antibodies (against the MPER region of gp41) that neutralize these 
highly resistant viruses, which will help understand how these viruses can be neutralized. This 







3.3.  Materials and methods 
3.3.1. Study participants and reagents 
Anonymous blood samples found to be HIV-1-infected were obtained from Yaoundé Central 
Hospital Blood Service, Yaoundé, Cameroon (n=64). Twenty-two samples confirmed to be 
CRF02_AG subtype infected (using information from gag and nef sequences) by Tongo et al (Tongo 
et al., 2013) were screened and selected for longer duration of HIV-infection, as they tend to have a 
higher neutralization capacity. Twelve samples estimated to be HIV-infected for >5.5 months using 
the BED
TM
 HIV-1 incidence test kit (Parekh et al., 2011) (CALYPTE Biomedical, Portland, Oregon, 
USA) were used for neutralization studies. This study was approved by the Human Research Ethics 
Committee of the Faculty of Health Sciences of the University of Cape Town and the National Ethics 
Committee of Cameroon.  
 
Recombinant soluble human CD4 (sCD4) was obtained from Progenics, IgG1 b12 (Burton et al., 
1994) from Dr. D. Burton, 2G12 (Trkola et al., 1996) 2F5 (Muster et al., 1993) and 4E10 (Buchacher 
et al., 1994) from Dr H. Katinger, all via the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH (ARRRP).  
 
3.3.2. Virus panel and pseudovirus preparation 
A 27 virus panel comprising subtypes A, B, C, G and CRF02_AG were assembled to represent the 
global HIV-1 epidemic. Pseudoviruses were chosen based upon subtype diversity, neutralization 
resistance (Blish et al., 2009; Jacob et al., 2012; Seaman et al., 2010b) and geographic diversity of 
origin. All references to tier designations are according to (Seaman et al., 2010b). Viruses are 
described as “tier 2/3” if they were between the clusters of tiers 2 and 3. Molecularly cloned gp160 
genes were co-transfected into 293T cells  (obtained through the AIDS Research and Reference 
Reagent Program (ARRRP), Division of AIDS, NIAID, NIH from Dr. Andrew Rice) with a 
Division of AIDS, NIAID, NIH from Drs. John 
C. Kappes and Xiaoyun Wu) using Fugene 6 transfection reagent (Roche, Basel, Switzerland) by 
standard protocols for HIV-1 pseudovirus production (Montefiori, 2009). Supernatants were 
harvested at 48 and 72 hours post-transfection and filtered (0.45µm). Single-use aliquots were stored 
at -80°C. Each virus preparation was later titrated in TZM-bl cells to determine a standard dilution 
that resulted in approximately 50,000 Relative Light Units (RLU).  
 
The envelope constructs were obtained through the ARRRP from Drs. D. Montefiori, F. Gao, C. 
Williamson, S. Abdool Karim, J. Overbaugh, B. Hahn, Y. Li, J Salazar-Gonzalez, D. Ellenberger, B. 
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Li, M. Callahan S. Butera, R. Paranjape, S. Kulkarni,  L. Morris,  K. Mlisana, D. Montefiori, L. 
Stamatatos and C. Cheng-Mayer, except the constructs for Du151.2 (Li et al., 2006) and murine 
leukemia virus (MLV), which were provided by Dr. L. Morris, NICD, Johannesburg, South Africa.   
 
3.3.3. Neutralization assay 
TZM-bl-based neutralization assays were preformed as described (Montefiori, 2009). Briefly, 
dilutions of serum/plasma samples were pre-incubated with the pseudovirus for one hour and then 
added to 1x10
4
 TZM-bl cells (obtained through the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH from Drs. John C. Kappes and Xiaoyun Wu) in flat bottom 96 well 
plates. DEAE-Dextran (Sigma Chemical Company, Schnelldorf, Germany) was used at 7.5ug/ml 
final concentration to enhance infection. The serum/plasma ID50 values were generated by serial 
dilution of serum/plasma and the lowest dilution of serum/plasma used was 1:50. The percentage 
neutralization at single dilutions was analyzed using samples at 1:100 serum/plasma dilutions 
(performed in triplicate). After 48 hours of incubation at 37°C and 5% CO2, cells were lysed with a 
detergent-containing buffer with Bright-Glo™ luciferase substrate (Promega, Madison, USA). 
Lysates were transferred to black 96 well plates and luciferase levels were measured on a VERITAS 
MicroPlate Luminometer (Turner BioSystems). Samples were tested against MLV as a negative 
control and against the highly neutralization-sensitive subtype B SF162.2 as a positive control.  
 
Percentage neutralizations were determined by the following calculation 
 
Difference in average RLU between virus control and sample             X 100%. 
Difference in average RLU between virus control and cell control 
 
3.3.4. Identification of highly resistant viruses 
To determine a cutoff for the highly resistant viruses, the percentage difference in neutralization 
score between any two adjacent viruses was calculated. The largest percentage distance between any 
two viruses among the more resistant 50% of viruses was taken as the clearest cutoff between the 
most resistant viruses and other viruses. 
 
3.3.5. Calculations and statistical analysis 
Twelve CRF02_AG plasma samples were screened at 1/100 serum dilution on the 27 virus panel. A 
predicted ID50 value was generated for every plasma/virus pairing for which an ID50 value was not 
measured from the percentage neutralization at 1/100 plasma dilution (refer figure 2.1 of chapter 2 
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for prediction model). The prediction model and its validation are described in detail in chapter 2. 
Geometric mean ID50 titers for the CRF02_AG plasma was measured by taking the geometric mean 
of all of the ID50 values for that plasma sample (measured where available; predicted where not). 
Separately, for each virus, a neutralization score, which was the geometric mean of all of the ID50 for 
all the plasma samples, was calculated. To measure the impact of each virus on sensitivities to 
neutralization we fitted a linear mixed model with ln(ID50) as the outcome and virus as co-variable. 
Serum/plasma samples were used to construct a random intercept and account for the correlation of 
within-plasma measurements, meaning that the model accounts for the fact that a serum/plasma 
sample that neutralizes one virus is therefore more likely to neutralize another virus. This model was 
used to calculate the 95% marginal prediction interval for each virus neutralization score.   
 
To explore subtype-specific neutralization we fitted a linear mixed regression model with ln(ID50) as 
the outcome and subtypes as co-variable. Serum/plasma sample were again used to construct a 
random intercept. Subtype comparisons were then made using Wald tests. Comparisons among tier 3 
CRF02_AG viruses are also based on a similar linear mixed model, but with virus as co-variable 
(except that 278-50 and 253-11 were treated as one virus). 
 
3.4. Results 
3.4.1. Plasma samples and study participants 
Anonymous blood samples found to be HIV-1-infected were obtained from Yaoundé Central 
Hospital Blood Service, Yaoundé, Cameroon (n=64) between December 2006 and August 2007. 
Twenty-two samples CRF02_AG plasma samples confirmed to be infected with CRF02_AG subtype 
based on sequence information from gag and nef genes (Tongo et al., 2013) were screened for longer 
duration of HIV-1 infection. Of the 22, 12 samples likely to be HIV-infected for >5.5 months were 
selected, using the BED
TM
 HIV-1 incidence test kit (Parekh et al., 2011) (CALYPTE Biomedical, 
Portland, Oregon, USA, data not shown) because broad neutralizers are more frequent among 
individuals infected for longer time (Binley, 2009; Gray et al., 2011; Mikell et al., 2011; Sather et 
al., 2009).  
 
Median age of the donors of the 12 samples was 29 (27, 32); 33% (4/12) of donors were female; 
median viral load was 94200 copies/ml (53000, 231000), and median CD4 count was 464 cell/ul 





3.4.2. Evaluation of neutralization breadth 
3.4.2.1. Pseudovirus panel 
A pseudovirus panel (n=27) representative of the global HIV-1 pandemic was assembled, 
CRF02_AG viruses were well represented in the panel (n=10). The panel viruses were screened for 
sensitivity to the CRF02_AG plasma samples at 1/100 serum dilution (Figure 3.1a). Pseudoviruses 
were chosen based upon subtype diversity, neutralization resistance ((Blish et al., 2009; Seaman et 
al., 2010b) and other unpublished data), within-subtype sequence diversity, and geographic diversity 
of origin. All references to tier designations are according to Seaman et al (Seaman et al., 2010b). 
Viruses are described as “tier 2/3” if they were between the clusters of tiers 2 and 3.  
 
We estimated the relative sensitivity of each virus (n=27) to neutralization by our CRF02_AG 
plasma samples (n=12). ID50 values were measured for a subset of plasma/virus combinations 
(n=72). For the rest, an ID50 value was predicted from the % neutralization at 1/100 plasma dilution 
using the prediction equation detailed in the chapter 2 of the thesis (Fig 2.1). Viruses were evaluated 
by a “virus neutralization score” that was the geometric mean of the ID50 values for all samples 
neutralizing that virus. Sera were evaluated by a “serum neutralization score” that was the geometric 
mean of all of the ID50 values for that serum against all panel viruses. Viruses and virus subtypes 
were ranked by sensitivity using this score (Figure 3.1b, c). The neutralization of CRF02_AG tier 3 
viruses by CRF02_AG samples was based upon measured ID50 values only (Figure 3.1d). 
 
3.4.3. Sensitivity of viruses to CRF02_AG plasma 
Neutralization of each of the panel viruses to CRF02_AG plasma (Figure 3.1a) was initially assessed 
using a single dilution (1/100) in the TZM-bl based neutralization assay (Montefiori, 2009). All 
plasma samples were screened for any non-HIV specific neutralization using the control Murine 
Leukemia Virus (MLV). SF162.2, a highly neutralization sensitive (tier 1a) virus was used as a 
positive control. The overall neutralization capacity was assessed by measuring the proportion of 
sample/virus combinations that neutralized at ≥50% at 1/100 dilution. The overall neutralization 
capacity of the CRF02_AG infected plasma samples was 43.2% (140/324), indicating the existence 
of good neutralizing antibodies within the group. Two samples (BS47 and BS06) neutralized ≥23 of 
the 27 pseudovirus panel at ID50>100 and were deemed to be broad neutralizers. On the other hand, 
two samples (BS55 and BS43) had extremely low levels of neutralizing antibodies and elicited no 





3.4.4. CRF02_AG viruses are sensitive to CRF02_AG plasma 
Collectively, the CRF02_AG viruses as a subtype were 2-3 fold more sensitive to the CRF02_AG-
infected plasma samples than the subtype A, B or C virus groups or the lone subtype G virus (Figure 
3.1a, Table 3.1). All of the six most sensitive viruses to the CRF02_AG-infected plasma samples 
were CRF02_AG viruses, and two others were moderately sensitive (Figure 3.1a, c). Strikingly, three 
tier 3 CRF02_AG viruses (251-18, 33-7, 257-31) were moderately or highly sensitive (Figure 3.1a, c, 
d). These three were significantly and substantially (overall 3.33-fold) more sensitive to 
neutralization by our CRF02_AG-infected plasma than the two resistant CRF02_AG viruses (253-11 
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Figure 3.1: Sensitivity of panel viruses to 12 plasma samples from CRF02_AG-infected study 
subjects: (a) The percent neutralization of the indicated pseudovirus by the indicated plasma at a 
screening dilution of 1/100 is shown. Plasma samples are ranked by number of viruses neutralized at 
>50%; ties were broken by ranking the number of viruses neutralized at 70% and then at 90%. 
Plasma samples that neutralized ≥16 of the 24 viruses (at ≥50% neutralization) are indicated in bold. 
Neutralization assays were performed as described previously (Montefiori, 2009) . Samples were 
tested against murine leukemia virus (MLV) as a negative control and against the highly 
neutralization-sensitive subtype B SF162.2 as a positive control. unk, tier unknown; virus not 
analyzed in Seaman et al (Seaman et al., 2010a). (b) Graphic depiction of the aggregate sensitivity 
of viruses grouped by subtype to the CRF02_AG plasma samples. The vertical axis represents the 
aggregate virus neutralization score for all viruses belonging to a particular subtype. Error bars 
represent the 95% confidence intervals from a linear mixed regression model. *, P <0.0005. The 
virus neutralization score is the marginal prediction of a linear mixed model and is equal to the 
geometric mean of the 50% inhibitory dilution (ID50) values of all plasma samples neutralizing that 
virus. The ID50 value was directly measured on the following viruses: 33-7, 251-18, 278-50, 253-
11, 257-31, and 928-28, or for other viruses a predicted ID50 was calculated based on the percent 
neutralization at 1/100 for other viruses. (c) Relative sensitivity rankings of individual viruses to the 
subtype CRF02_AG plasma samples. Viruses were ranked by the same virus neutralization scores 
used for panel b; 95% prediction intervals from the model are also shown. (d) Measured ID50 values 
for tier 3 CRF02_AG viruses neutralized by individual CRF02_AG plasma samples. 
 
 
3.4.5. Neutralization sensitivity of CRF02_AG viruses to monoclonal antibodies and sCD4 
Understanding the vulnerability of CRF02_AG viruses to characterized monoclonal antibodies 
(mAb) could provide information for vaccine design. Thus we assessed the neutralization of panel 
viruses to four commonly used mAbs and soluble CD4 (sCD4). Nine of ten CRF02_AG viruses were 
resistant to b12 (recognizes the CD4 binding site (Saphire et al., 2001)) and 2G12 (cluster of α1→2-
linked mannose residues on gp120 (Scanlan et al., 2002)). Only one virus (278-50) had an intact N-
glycosylation site (NxS/T) motif at positions N295, N301, N322, N386 and N397, which comprises 
the 2G12 epitope. However 278-50 was also resistant to 2G12. Five of the seven CRF02_AG viruses 
were also sensitive to sCD4. On the other hand, CRF02_AG viruses were sensitive to the anti-gp41 
membrane proximal external region (MPER)-recognizing mAbs (Zwick et al., 2001). All 
CRF02_AG viruses were sensitive to 4E10, and 8/10 were sensitive to 2F5 (Figure 3.2). Two (269-
12  and  255-34 ) of the ten CRF02_AG isolates resistant to 2F5 had substitutions in their epitope. 
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While 269-12 had a K665N substitution, 255-34 had a K667E substitution, rendering them resistant 





















Figure 3.2: Fifty percent inhibitory concentration (IC50) titers against the panel viruses for 
monoclonal antibodies and soluble CD4. The “REF” row refers to previously reported IC50 values, 
as follows (reference indicated in parentheses): A (Blish et al., 2007); B (Blish et al., 2009); C (Li et 
al., 2005); D (Li et al., 2006); E (Kulkarni et al., 2009); F (this study). (unk, tier unknown; virus not 






We studied neutralization responses of 12 CRF02_AG HIV-1infected plasma samples from 
Cameroon. The samples were selected for greater time since infection by BED assay, as 
neutralization capacity increases with time since infection (Euler et al., 2010; Gray et al., 2011; 
Mikell et al., 2011; Sather et al., 2009). Two of the twelve (sixteen percent) CRF02_AG infected 
plasma samples neutralized ≥23/27 viruses at an ID50>100 (Figure 1a) and were deemed broad 
neutralizers. The two broad plasma samples (BS06 and BS47) neutralized all the ten CRF02_AG 
viruses within the virus panel (Figure 3.1 a). 
 
The major objective of the study was to characterize neutralization resistant CRF02_AG viruses to 
subtype-specific plasma and monoclonal antibodies. The relatively high neutralization resistance of 
CRF02_AG viruses has been reported previously with several classified as tier 3 and several others 
fitting between tier 2 and tier 3 groupings (Seaman et al., 2010a). CRF02_AG viruses were more 
likely to fit into the tier 3 category (8/17 vs. 20/90, 2=4.565, p=0.033 ;) than other viruses (Seaman 
et al., 2010b). In addition, a CRF02_AG-infected plasma pool was unable to preferentially neutralize 
within-subtype viruses, including the viruses used in this study (Brown et al., 2008; Seaman et al., 
2010b). In contrast, we observed substantial within-subtype neutralization with our CRF02_AG-
infected samples (Figure 3.1). Not all tier 3 viruses were highly resistant to our CRF02_AG plasma 
samples: Four CRF02_AG viruses previously scored as highly resistant (tier 2/3 or tier 3) were 
highly sensitive to the CRF02_AG plasma samples (Figure 2.1c). Furthermore, four of the twelve 
CRF02_AG plasma samples neutralized all the five tier 3 viruses with an ID50>50 (Figure 3.1 c). 
Two of the above five tier 3 viruses (251-18 and 33-7) were ranked among the three most resistant 
viruses of all 107 that were previously tier ranked (Seaman et al., 2010a). The most parsimonious 
explanation for this discrepancy may be that the CRF02_AG pools used in the previous reports did 
not contain high levels of heterologous neutralizing antibody, even specific for within-subtype 
CRF02_AG viruses. We demonstrate that CRF02_AG viruses are indeed sensitive to subtype 
specific neutralizing antibodies. 
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Our studies highlight two tier 3 CRF02_AG viruses to be highly neutralization-resistant (253-11 and 
278-50), while the other three tier 3 CRF02_AG viruses were sensitive to CRF02_AG plasma (257-
31, 33-7 & 251-18). The two resistant tier 3 viruses were significantly different from the three 
sensitive tier 3 viruses (Figure 3.1a, c and Table 3.1). Differential sensitivity to CRF02_AG plasma 
samples was also evident within the three sensitive tier 3 CRF02_AG viruses (Figure 3.1a, c and 
Table 3.1); with 257-31 being more sensitive than 33-7 or 251-18. Thus, our study demonstrates the 
utility of using pools or panels of within-subtype samples selected for good neutralizers to identify 
such viruses selectively. It is also striking that neutralizing antibody specific for highly resistant 
viruses such as 253-11 and 278-50 occur rarely, even among CRF02_AG-infected donors.  
 
We further characterized the sensitivity of these CRF02_AG viruses to monoclonal antibodies and 
soluble CD4 (Figure 3.2). Sensitivity to sCD4 protein is thought to be associated with exposure of 
the CD4 binding site (Pugach et al., 2004), although the CRF02_AG viruses were mostly b12 
resistant and thus apparently lack the b12 epitope or is not accessible to neutralizing antibodies. All 
the ten CRF02_AG viruses were sensitive to 4E10 and 8/10 CRF02_AG viruses were neutralized by 
2F5. Although 253-11 and 278-50 were generally resistant to neutralization by plasma samples in 
our study, they were sensitive to anti-MPER mAbs (Figure 3.2).We conclude that it may be possible 
to neutralize even highly resistant CRF02_AG viruses such as 253-11 and 278-50 with antibodies 
directed at the MPER (eg: 4E10, 2F5) or the CD4 binding site (278-50 was sensitive to sCD4). This 
may be important for development of an HIV-1 vaccine effective for a wide variety of HIV-1 strains, 
including neutralization resistant strains such as 253-11.  
 
It is important that viruses with high neutralization resistance be defined as rigorously as possible. 
Based upon our study, we propose that procedures for selection of highly neutralization-resistant 
viruses include within-subtype neutralization using samples selected for good neutralizers. 
Identification and study of these viruses is important because: (i) epitopes from resistant viruses may 











Accessibility of the HIV-1 MPER to a set of polyclonal anti-MPER 




The Membrane Proximal External Region (MPER) within HIV-1 gp41 envelope is an attractive 
vaccine target.  The MPER is a highly conserved region of the viral spike and functionally 
constrained presumably because it mediates viral fusion to the target cell membrane and insertion of 
the envelope spike into the viral membrane. In this chapter, the anti-MPER neutralization activity is 
characterized in a highly neutralization resistant virus, 253-11 (CRF02_AG subtype). 
Results:  
We found that a neutralization-resistant virus, 253-11, is rarely neutralized by anti-MPER antibodies 
in a serum panel of individuals HIV-infected >1yr. Very few sera were able to neutralize 253-11 by 
recognizing its MPER; but, 19 of 217 sera (9%) tested recognized (as measured by neutralization) 
253-11’s MPER in an HIV-2 chimeric construct even though they were unable to recognize the same 
MPER in the original 253-11 virus. At least 13/19 of these sera neutralized other HIV-1isolates via 
MPER, indicating that these anti-MPER antibodies were not generally defective for neutralization of 
HIV-1. A similar resistant pattern was observed in a second virus (Du422.1, subtype C), suggesting 
that the resistant pattern is not uncommon. Alanine scan mapping revealed several overlapping but 
distinct epitopes; conformational differences of MPER between the native 253-11 virus and the HIV-
2/253-11 MPER chimera seems un likely to explain the inability of antibodies that recognize several 
distinct epitopes to neutralize 253-11.   
Conclusion:  
Our data suggests indicate that many sera are able to neutralize an HIV-2/HIV-1 MPER chimera 
displaying the 253-11 MPER, yet neutralize the native 253-11 isolate poorly or not at all. The anti-
MPER antibodies in these sera are able to neutralize other HIV-1 isolates, indicating that they are not 
globally defective for neutralization of HIV-1 isolates. Strikingly, the only antibodies (sera or 
monoclonal antibodies) that are capable of neutralizing 253-11 virus via recognition of MPER are all 
highly broadly neutralizing. We considered conformational differences between the MPER displayed 
by the HIV-2 chimeric virus and the same MPER displayed by the 253-11 virus for the neutralization 
resistance to anti-MPER antibodies. However, for this to explain our results, the series of epitopes 
recognized by the different sera would all have to be present in the HIV-2/253-11 MPER chimera but 
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not in the native 253-11 virus. We thus consider this explanation unlikely. Several other possible 
explanations for our observations are discussed; but, we propose that the most parsimonious 
explanation for the rare anti-MPER-neutralization of 253-11 is obstruction of access of antibody to 
the MPER. If our proposed explanation is true, it would imply that the ability of rare antibodies to 
penetrate this shielding may be an important factor in determining their neutralization breadth and 
potency. In this case, only the limited proportion of anti-MPER antibodies that can penetrate this 
obstruction would be able to provide the protection against the large number of HIV-1 variants that 




The membrane-proximal external region (MPER) of the gp41 subunit of HIV-1 envelope 
glycoprotein is one of very few attractive targets for vaccine-induced antibodies. It is relatively 
conserved, presumably because it plays critical roles in viral fusion with target cell membranes and 
in incorporation of envelope into new virions (Montero et al., 2008b). In addition, anti-MPER 
antibodies often bind to MPER peptides (Gray et al., 2009a), suggesting that peptides can 
recapitulate many MPER epitopes/surfaces. This raises the possibility that a vaccine that induces 
neutralizing antibodies directed at the MPER may be more feasible than for more complex targets of 
broadly neutralizing antibodies, such as the PG9/PG16 binding site, which is a relatively complex 
quaternary epitope (McLellan et al., 2011; Walker et al., 2009b). However, inducing neutralizing 
anti-MPER antibodies with MPER mimics has proven largely unsuccessful (Dennison et al., 2011b; 
Guenaga et al., 2011; Kamdem Toukam et al., 2012; Wahome et al., 2012), although there have been 
some recent modest successes (Lutje Hulsik et al., 2013; Ye et al., 2011; Zhang et al., 2013; Zhou et 
al., 2012). 
 
There is substantial evidence that neutralization by anti-MPER monoclonal antibodies is affected by 
changes in sequences outside the MPER (Binley et al., 2004; Gray et al., 2008; Montero et al., 
2012). There is speculation in these reports that differences in neutralization could be due to 
differences in the extent of MPER exposure. However, to our knowledge, there are few data 
confirming this hypothesis, particularly with respect to binding the MPER at the post-CD4 
conformation, which is the primary target for anti-MPER antibodies (Frey et al., 2008; Liu et al., 
2008). Most prior findings could also be explained by changes in the conformation of that 




Here we describe an HIV-1 isolate that is resistant to neutralization by most but not all antibodies 
that recognize the MPER, despite the fact that its MPER is readily recognized by a substantial 
proportion (19/217) of sera in our cohort. This discrepancy (i.e. the ability to recognize 253-11’s 
MPER in an HIV-2/HIV-1 MPER chimera but not in the context of the native 253-11 virus), is very 
difficult to explain for such a large number of sera by changes in conformation that result in the loss 
of epitopes. Our data suggests that the resistance of MPER to anti-MPER neutralizing antibodies 
might be a common but not universal phenomenon among HIV-1isolates, i.e. some viruses are easily 
neutralized through recognition of the MPER. Several explanations for the lack of neutralization of 
253-11 through the MPER are considered in this chapter of the thesis. 
 
4.3. Methods: 
4.3.1.   Study participants and neutralization samples: 
Study participants attended the HIV wellness clinic at Khayelitsha Site B Clinic (n=125) or were 
caregivers of children attending the Paediatric HIV Clinic of Groote Schuur Hospital, n=92), in Cape 
Town, South Africa. All participants were >18 years old, known to be infected with HIV-1 for >1 
year, and were ART naive, except for drugs to prevent mother to child transmission (PMTCT) >3 
months prior. Median participant age was 33.0 years (IQR 27.6, 37.0), with 24 males (11%) and 193 
females (89%), which largely reflected the sex ratio among the recruiting populations. Median CD4 
count was 416 (IQR 308, 549). For 117 participants, including all from Groote Schuur Hospital, the 
median reported time since infection was 3 years (IQR 2, 7). For 99 participants, all at Khayelitsha 
Site B clinic, median time since the earliest CD4 count or positive HIV test recorded in the clinic 
folder was 2.37 years (IQR 1.40, 4.60). HIV-1 infection time data for 1 participant was not properly 
collected. Serum samples were collected upon recruitment for neutralization studies. Written 
informed consent was taken from participants involved in this study. This study was approved by the 
Human Research Ethics Committee of the University of Cape Town, Faculty of Health Sciences.  
 
4.3.2. Reagents, envelope clones, pseudoviruses and chimeric viruses: 
Monoclonal antibodies 2F5, 4E10 and 10E8 were obtained from the NIH AIDS Research and 
Reference Reagent Program (ARRRP, Germantown, USA) from Drs. H. Katinger and M. Connors. 
Cloned HIV-1 envelope constructs were obtained through ARRRP from Drs. D. Montefiori, F. Gao, 
C. Williamson, S. Abdool Karim, J. Overbaugh, B. Hahn, Y. Li, J Salazar-Gonzalez, D. Ellenberger, 
B. Li, M. Callahan S. Butera, R. Paranjape, S. Kulkarni, L. Morris, K. Mlisana, D. Montefiori, L. 
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Stamatatos and C. Cheng-Mayer. Du151.2, COT6.15, murine leukemia virus (MLV) and the alanine 
scan mutants of COT6.15 were provided by Dr. L. Morris, NICD, Johannesburg, South Africa.  
 
The 7312A parent HIV-2 construct and all HIV-2/HIV-1 chimeric constructs containing HIV-1 
MPER sequences (C1, C1C, C6 and C7) (Gray et al., 2007) (except the HIV-2/253-11 MPER) were 
provided by Dr. George Shaw, University of Pennsylvania, Philadelphia, USA. The HIV-2/253-11 
MPER construct was produced by mutagenesis from HIV-2 C1 using the Stratagene QuikChange II 
XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, USA). Mutagenesis was confirmed by 
sequencing.  
 
The pseudoviruses were prepared from molecularly cloned gp160 genes by co-transfection with a 
SG3 Delta env backbone (obtained through the ARRRP, Division of AIDS, NIAID, NIH from Drs. 
John C. Kappes and Xiaoyun Wu) into 293T cells (obtained through the AIDS Research and 
Reference Reagent Program (ARRRP), Division of AIDS, NIAID, NIH from Dr. Andrew Rice) 
using Fugene 6 transfection reagent (Roche, Basel, Switzerland) by standard protocols for HIV-1 
pseudovirus production (Montefiori, 2009). Supernatants were harvested at 48 and 72 hours post-
transfection and filtered (0.45µm). Single-use aliquots were stored at -80°C. Each virus preparation 
was later titrated in TZM-bl cells to determine a standard dilution that resulted in approximately 
50,000 Relative Light Units (RLU).  
 
4.3.3.  Neutralization assay: 
TZM-bl-based neutralization assays were preformed as described (Montefiori, 2009). Briefly, 
dilutions of serum samples were pre-incubated with the pseudovirus for one hour and then added to 
1x10
4
 TZM-bl cells (obtained through the AIDS Research and Reference Reagent Program, Division 
of AIDS, NIAID, NIH from Drs. John C. Kappes and Xiaoyun Wu) in flat bottom 96 well plates. 
DEAE-Dextran (Sigma Chemical Company, Schnelldorf, Germany) was used at 7.5ug/ml final 
concentration to enhance infection. The serum ID50 values were generated by serial dilution of 
serum/plasma and the lowest dilution of serum used was 1:50. The percentage neutralization at 
single dilutions was analyzed using samples at 1:100 serum dilutions (performed in triplicate). After 
48 hours of incubation at 37°C and 5% CO2, cells were lysed with a detergent-containing buffer with 
Bright-Glo™ luciferase substrate (Promega, Madison, USA). Lysates were transferred to black 96 
well plates and luciferase levels were measured on a VERITAS MicroPlate Luminometer (Turner 
BioSystems). Samples were tested against MLV as a negative control and against the highly 




Percentage neutralizations were determined by the following calculation 
 
Difference in average RLU between virus control and sample             X 100%. 
Difference in average RLU between virus control and cell control 
 
4.3.4. Ranking of viruses for neutralization resistance and sera for neutralization breadth: 
The 24 virus panel were ranked for neutralization resistance based upon their sensitivity to a subset 
of the samples utilized in this study (n=177) tested at a screening dilution of 1/100. The 177 serum 
samples were also ranked for neutralization potency and breadth based upon this data. The 24 virus 
panel was comprised of 5 Tier 3 viruses, 4 tier 2/3 viruses, 13 tier 2 viruses and two viruses not 
analyzed for tier designation.  All tier designations are as per Seaman et al (Seaman et al., 2010b).  
Tier 3 viruses: PVO.4 (B); 278-50, 253-11,251-18 and 33-7 (all CRF02_AG), Tier 2/3 viruses: 
Q461.e2 (A); Du422.1 and 001428-2.42 (both C), and 928-28 (CRF02_AG); Tier 2 viruses: Q168.a2 
(A); TRO11, RHPA4259.7, REJO 4541.67, SC422661.8 (all B); ZM249M.PL1, CAP45.2.00.G3; 
Du151.2, 26191-2.48, 16936-2.21 (all C); 252-7 (G); 269-12 and 255-34 (both CRF02_AG); and 
viruses not analyzed for tier: QG984.21M.ENV.A3 and QH343.21M.ENV.A10.  
 
4.3.5.  Depletion of anti-MPER antibodies: 
A 10-virus panel was assembled to test sera for their capacity to neutralize HIV-1isolates by 
recognition of the MPER. Five of the 10 panel viruses were previously shown to be sensitive to 
neutralization by recognition of MPER (Gray, et al 2009): COT6.15 (C, South Africa), Du151.2 (C, 
South Africa), CAP45.2.00.G3 (C, South Africa), TRO.11 (B, Italy) and REJO4541.67 (B, USA). 
Five additional moderately resistant viruses from the 24-virus panel were added to expand the 
geographic and subtype diversity of the viruses: RHPA4259.7 (B, USA), Du422.1 (C, South Africa), 
001428-2.47 (C, India), 928-28 (CRF02_AG, Cote d’Ivoire) and 269-12 (CRF02_AG, Cameroon).  
 
Antibodies were depleted in two rounds of depletion as described (Gray et al., 2009a; Tomaras et al., 
2011) using a biotinylated MPER peptide (MPR.03 (Morris et al., 2011); 
KKKNEQELLELDKWASLWNWFDITNWLWYIRKKK-biotin-NH2; Peptide Synthetics, 
Hampshire, UK). Streptavidin-magnetic Dynabeads (Invitrogen, Darmstadt, Germany) Control 
depletions were performed as above using a biotinylated control peptide with a scrambled sequence 
(KKKNEKSNNDWERLWLEWLYIWLQDWAFTLIKKK-biotin-NH2). A threshold of a ≥3-fold 
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drop in ID50 compared to control peptide depletion was accepted as positive for MPER-mediated 
neutralization, unless there was a corroborating >3-fold drop in ID50 of any COT6.15 alanine scan 
MPER mutant, in which case a ≥2-fold drop was accepted.  
 
MPER negative sera (ID50 titer <50 for C1C, C1 and HIV-2/253 MPER) was used as an appropriate 
control. In no case, did we observed a >1.01 fold drop in neutralization of the MPER peptide 
depleted sera compared to the control peptide depletion (data not shown).   
 
4.4. Results  
4.4.1. A substantial proportion of cohort sera (19/217) recognize the 253-11 MPER but not in 
the context of the native 253-11 isolate: 
In an attempt to better understand how antibodies mediated neutralization of the highly resistant 
virus 253-11, we screened sera for neutralizers of 253-11 (Kulkarni et al., 2009), which we 
previously identified as highly neutralization-resistant, even to within-subtype neutralization (Jacob 
et al., 2012). This virus was also highly resistant to serum samples from a South Africa cohort, 
which is mostly subtype C: HIV-1 infections in the Cape Town area are ~98% subtype C (Wilkinson 
and Engelbrecht, 2009). Virus 253-11 was the most resistant virus in a panel of 24 moderately to 
highly resistant viruses when screened against 177 sera from a South African cohort of ART-naive 
HIV-infected (>1yr) individuals (Figure 2.4 of thesis chapter 2). 
 
We identified 19 sera (9%) that neutralized 253-11 at ID50>1:100 from among 217 sera from this 
same South African cohort (Figure 4.1a). Sera that neutralized 253-11 at ID50>1:100 were frequently 
weakly neutralizing, with a median ID50 of 297, i.e. half of the samples had ID50 values against 253-
11 between 100 and 297.  
 
Despite being highly neutralization resistant, the CRF02_AG isolate 253-11 was demonstrated to be 
sensitive to the anti-MPER monoclonal antibodies 2F5 and 4E10 (see Figure 3.2 of chapter 3). In 
order to understand how 253-11 is neutralized via MPER, anti-MPER neutralizing antibodies and 
PG9/16 site directed antibodies were measured in the South Africa cohort. Samples with 
ID50>1:1000 against a chimeric HIV-2 virus construct in which the native MPER was replaced with 
a subtype C consensus MPER sequence (C1C) (Binley et al., 2008; Gray et al., 2007) were scored 
positive (Figure 4.1a). We use this cut-off because only sera that neutralized this C1C chimeric 
construct at ID50>~1000 also neutralized HIV-1 isolates by recognizing the MPER (Gray et al., 
2011; Gray et al., 2009a). Anti-MPER activity was frequent in the cohort. Subtype C MPER 
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specificities at high titers (ID50>1:1000) were detectable in 15% (33/217) of the sera (Figure 4.1a). 
Neutralization against the control HIV-2 parent, 7312A, was very low, with only two samples (1%) 
exhibiting detectable (ID50>50) anti-7312A ID50 values; neither of these two sera neutralized the 
C1C construct (data not shown).  
 
To further understand the MPER-targeted neutralization of 253-11 we generated a chimeric HIV-2 
virus displaying the MPER sequence of 253-11: referred to as HIV-2/253-11 MPER (Figure 4.1b). 
Of the analyzed sera that neutralize 253-11 potently (ID50>100), only one recognized the HIV-2/253-
11 MPER construct at ID50>1000 (Figure 4.1b). In addition, one sample, BNAB0004, was no longer 
available to assess HIV-2/253-11 MPER neutralization but neutralized 253-11 by recognizing MPER 
(Figure 4.3, see below) and therefore would presumably have also recognized the 253-11 MPER 
chimeric construct. Of the remaining four sera that neutralized 253-11 potently and also neutralized 
the C1C consensus C MPER chimeric construct at ID50>1000 (Figure 4.1, red triangles), three 
neutralize the HIV-2/253-11 MPER construct poorly compared to the C1C MPER construct (>4 fold 
difference, Figure 4.1). This indicates an MPER sequence preference of their antibodies for 
sequences other than that of 253-11 (Figure 4.1b). There are 5 amino acid differences between the 
MPER sequences of 253-11 and C1C (Figure 4.1b). It is possible that these three sera neutralize 253-
11 with non-MPER antibodies, which is directly tested below (Figure 4.4). 
 
Figure 4.1: Correlation between MPER antibodies and 253-11 neutralization. 
The neutralizing activity of serum samples against 253-11 and anti-MPER activity against the HIV-
2 chimeric constructs (a) C1C, consensus subtype C MPER (n=217) or (b) 253-11 MPER (n=216), 
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were compared. A threshold titer of 1:1000 was used to define significant anti-MPER activity. A 
threshold titer of 1:100 was used to define substantial anti-253-11 activity. In all figures, resistant 
sera were displayed with an ID50 set to 25. Red triangles represent sera which neutralized 253-11 
(ID50>100) and C1C (ID50>1000), one of which was not analyzed in Figure 4.1b. 
4.4.2. Nineteen sera recognize the MPER in the HIV-2/253 MPER chimera, but not in the 253-
11 virus 
Good recognition of the 253-11 MPER construct was nonetheless observed in several sera that did 
not neutralize 253-11: Nineteen of 216 sera (8.8%) recognized the 253-11 MPER construct well 
(ID50>1000) yet neutralized the 253-11 virus poorly or not at all (ID50<100) (Figure 4.1b). It appears 
that these 19 sera recognize the 253-11 MPER in the context of the HIV-2 chimeric construct but 
poorly or not at all in the context of the original 253-11 virus.  
 
4.4.3. Several sera recognize Du422.1 MPER, but not in the Du422.1 virus: 
This pattern of recognition did not appear to be unique to 253-11: The MPER sequence of virus 
Du422.1 (subtype C) matches that of the C1 HIV-2 chimeric construct derived from Yu2 
MPER(Binley et al., 2008). We subjected Du422.1 to the same analysis as 253-11 (Figure 4.2). Of 
97 sera analysed, 12 sera recognized the Du422.1 MPER construct at ID50>1000; but, 8 of these 12 
recognized the same MPER within the Du422.1 virus poorly or not at all (ID50<100). Thus, the 
phenomenon of recognition of the MPER sequence of a virus by some sera but not in the context of 





Figure 4.2: Correlation between MPER antibodies and Du422.1 neutralization. Serum samples 
were screened for anti-MPER activity using HIV-2 chimeric constructs and compared for 
neutralization of Du422.1 vs Du422.1 MPER (n=97). Neutralization of Du422.1 was measured by 
neutralization of the HIV-2/Yu2 MPER construct called C1 in the literature. Yu2, C1 and Du422.1 
have matching amino acid sequences in the MPER region. A threshold titer of 1:1000 was used to 
define significant anti-MPER activity. An arbitrary threshold titer of 1:100 was used to define 
substantial anti-Du422.1 activity 
 
4.4.4. Anti-MPER monoclonal antibodies neutralize the HIV-2/HIV-1 MPER chimera more 
potently than the native virus:  
We compared the neutralization of 253-11, HIV-2/253-11 MPER chimera, Du422.1 and HIV-
2/Du422.1 MPER chimera (C1) by anti-MPER monoclonal antibodies 2F5, 4E10 and 10E8 (Table 
4.1). The MPER chimera virus was always neutralized substantially more potently than the native 
virus from which the MPER sequence came, with a ratio of greater than 15-fold in all cases except 
for 4E10.  
 
Table 4.1: IC50 values for anti-MPER monoclonal antibodies against 253-11, HIV-2/253-11 MPER 
chimera, Du422.1 and HIV-2/Du422.1 MPER chimera (C1) 
 
 
4.4.5. The nineteen sera recognize a series of overlapping but distinct epitopes: 
“Mapping of the epitopes by the 19 sera which recognize the HIV‐2/HIV‐1 253‐11 MPER construct 
but not the native 253-11 virus revealed a minimum of six distinct epitope patterns, reflected by six 
different patterns of neutralization of MPER alanine scan mutants of COT6.15 (Gray et al., 2009a) 
and the C6 HIV-2 /HIV-1 MPER chimera construct which contains the minimal 4E10 epitope (Gray 
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et al., 2007) (Figure 4.3). In order to err on the side of caution, samples with no alanine scan hits 
were not characterized into any group in case the anti-MPER antibody did not neutralize COT6.15 
mutants and/or was diluted by a non-MPER antibody. In addition, increases in neutralization were 
not catalogued as part of the mapping profile because it has been proposed that such mutants can 
reflect increased MPER epitope exposure (Nelson et al., 2007; Zwick et al., 2005).  
 
A seventh epitope pattern could be discerned when we noted that a few samples had strikingly high 
ratio’s between the ID50 for the 253-11 HIV-2/HIV-1 MPER chimera and the C1C (Consensus C) 


















The 19 sera that recognize the HIV‐2/HIV‐1 253‐11 MPER construct and one serum that neutralizes 
253‐11 by recognition of MPER were mapped by COT6.15 MPER mutants. Mutants for which there 
were no decreases ≥3‐fold are not shown. ID50 values of 19 sera neutralizing COT6.15 and alanine 
scan mutants of COT6.15 within the MPER are shown. All decreases in ID50 of more than 3‐fold are 
marked in red. A value of 25 was assigned when the ID50 was below the reliable detection threshold 
(<50) for the purpose of calculating ratios. 
COT6.15 wild type ID50 values are colour coded: Red, >1000; Orange, 300‐1000; Yellow 100‐300; 
Green, 50‐100; Gray, <50. The HIV‐2/HIV‐1 MPER chimera C6 contains the minimal 4E10 epitope 
and is also shown and used to distinguish epitope pattern groups 5 and 6. ID50 values against the 
HIV‐2/HIV‐1 MPER chimeras for 253‐11 and C1C are also shown, along with the ratio between 
them, which was used to distinguish epitope pattern groups 6 and 7. ND: not determined; R: 
resistant. 
 
Some of the sera that neutralize both 253-11 and the HIV-2/253-11 MPER chimera appear not 
to neutralize 253-11 via recognition of MPER:  
We directly tested the five C1C-MPER-recognizing sera that neutralize 253-11 well (Figure 4.1a, red 
triangles) for their ability to recognize 253-11 via the MPER. We focused upon the sera that 
neutralized 253-11 at ID50 titers above 1:300 because, at this level, it is feasible for us to determine 
whether the antibodies in the sera neutralize 253-11 via recognition of the MPER. To do so, we 
depleted sera of anti-MPER antibodies using a biotinylated MPER peptide (MPR.03) (Morris et al., 
2011), and compared to a control peptide with a scrambled MPER sequence. A highly sensitive virus 
(Seaman et al., 2010b), SF162.L.S was used as a negative control for depletion because anti-SF162 
antibodies against multiple epitopes are expected in most sera; thus, depletion of the anti-MPER 
antibodies would normally be expected to have little effect because it would not affect antibodies to 
other epitopes in the same sample. Control depletions was set on serum samples with no detectable 
(ID50<50) MPER activity. Of the five samples, only BNAB0004 showed evidence for neutralization 
of 253-11 by recognizing the MPER (Figure 4.4), while the others appeared to neutralize 253-11 by 
targeting regions other than the MPER. One explanation for this could be incomplete depletion of 
anti-MPER antibodies. Depletion of anti-MPER antibodies was confirmed for all samples (>20-fold 
reduction in neutralization, Figure 4.4) except BNAB0179 (~2.8-fold depletion); however, 
BNAB0179 neutralized the 253-11 MPER HIV-2 chimeric construct poorly (Figure 4.4), suggesting 
that it is unlikely that the residual undepleted anti-MPER antibodies were able to neutralize 253-11. 
Generally, we cannot exclude that neutralization comes from both anti-MPER antibodies and non-
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MPER neutralizing antibodies in the same sample (Gray et al., 2009a). Strikingly, BNAB0004 is 
very broad, neutralizing 22/24 panel viruses (>50% neutralization at 1/100 dilution) and is at the 90
th
 





Figure 4.4:  Effect of anti-MPER antibody adsorption on 253-11 neutralization.  
Five 253-11 neutralizing serum samples (ID50>300) with high C1C and/or 253 MPER activity were 
used for MPER antibody depletion using the MPR.03 peptide as compared to a scrambled sequence 
control peptide. A value of 25 was assigned when the ID50 was below the reliable detection 
threshold (<50) for the purpose of calculating ratios. *: indicates a reference to the notation below; 
VR: Indicates that the virus is resistant to the indicated serum; ND, not determined; shading: Red, 
>10-fold; Orange, 3-10-fold; Gray, <3 fold/not neutralized via MPER. 
 
 
4.4.6.  Anti-MPER antibodies that fail to neutralize 253-11 are nonetheless functional against 
other HIV-1 isolates: 
We considered the possibility that the anti-MPER antibodies in these 19 sera (Figure 4.1b, top left 
quadrant) recognized MPER epitopes/surfaces that appeared only in the HIV-2 chimeric constructs. 
To test this, we depleted anti-MPER antibodies from six of the 19 sera, and tested if this reduced 
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neutralization activity against HIV-1 isolates compared to a scrambled peptide depletion control 
(Figure 4.5). This would indicate that the MPER-specific antibodies in the particular serum were 
capable of neutralizing the MPER in the context of HIV-1 isolates. For each serum, anti-MPER 
antibodies were responsible for neutralization of at least three of the viruses tested (Figure 4.5); 
BNAB0149 neutralizing COT6.15 (2.1-fold) was scored as a positive despite exhibiting <3-fold drop 
because a D674A (inside the MPER) mutant of COT6.15 resulted in >3-fold lower neutralization 
(data not shown). An additional 7 sera also recognized COT6.15 by recognition of the MPER: these 
sera had reduced (>3-fold) neutralization against one or more COT6.15 MPER alanine scan mutants 
compared to the parental COT6.15 virus (Figure 4.5).  
 
In total, at least 13/19 sera neutralize HIV-1 isolate(s) by recognizing the MPER, indicating that the 
anti-MPER antibodies in these sera are not generally defective for neutralization of HIV-1 isolates. 
Notably, five of the ten HIV-1 isolates tested were neutralized by at least half of the six sera tested 
against them (Figure 4.5). They were TRO11, COT6.15, Du151.2, 928-28 and 269-12. Nonetheless, 














Figure 4.5:  Anti-MPER antibodies are functional against other HIV-1 pseudoviruses.  
Six serum samples which had high 253-11 MPER activity (ID50>1000), but minimal or no 253-11 
neutralization (ID50<100) were used for MPER antibody depletion using the MPR.03 peptide as 
compared to a scrambled sequence control peptide. Controls to ascertain the extent of anti-MPER 
BNAB0060 BNAB0063 BNAB0075 BNAB0088 BNAB0149 BNAB0197
<50 <50 <50 65 <50 52
Control depl 1604 * 15031 * * 1081
MPER depl 86 * 646 * * <50
Fold reduction 18.6 ND 23.3 ND ND 43.2
Control depl * 25493 6436 17354 5483 ND
MPER depl * 778 <50 864 <50 ND
Fold reduction ND 32.8 257.4 20.1 219.3 ND
Control depl 2672 12505 4197 9272 1766 3790
MPER depl <50 559 <50 <50 <50 <50
Fold reduction 106.9 22.4 167.9 370.9 70.6 151.6
Control depl * 804 99 683 140 338
MPER depl * <50 <50 <50 41 64
Fold reduction VR 32.2 4.0 27.3 3.4 5.3
Control depl 219 337 * 660 155 *
MPER depl 80 35 * <50 56 *
Fold reduction 2.8 9.7 VR 26.4 2.8 VR
Control depl * * * * * *
MPER depl * * * * * *
Fold reduction VR VR ND VR VR ND
Control depl 191 302 373 1671 1059 895
MPER depl <50 <50 45 182 504 294
Fold reduction 7.6 12.1 8.4 9.2 2.1 3.0
Control depl 339 * 1959 * * 12838
MPER depl 100 * 752 * * 216
Fold reduction 3.4 VR 2.6 ND ND 59.5
Control depl * * * * * *
MPER depl * * * * * *
Fold reduction VR ND VR VR VR VR
Control depl * * * * 1620 *
MPER depl * * * * 430 *
Fold reduction VR VR VR ND 3.8 VR
Control depl * * * 316 1177 *
MPER depl * * * 214 1140 *
Fold reduction VR VR VR 1.5 1.0 ND
Control depl 239 675 163 1410 * 402
MPER depl 37 <50 <50 <50 * 114
Fold reduction 6.5 27.0 6.5 56.4 ND 3.5
Control depl * 425 463 * * 730
MPER depl * <50 30 * * 158
Fold reduction VR 17.0 15.4 ND ND 4.6
Control depl * 26497 21219 9149 4897 2892
MPER depl * 27489 15046 6212 3099 2615

























depletion are shown on top. A value of 25 was assigned when the ID50 was below the 
reliable detection threshold (<50) for the purpose of calculating ratios. *: indicates a 
reference to the notation below; VR: Indicates that the virus is resistant to the indicated 
serum; ND, not determined; shading: Red, >10-fold; Orange, 3-10-fold; Green, 2-3-fold 
with independent evidence from reduced sensitivity of one or more alanine substitution 
mutants in MPER; Gray, <3 fold/not neutralized via MPER. A value of 25 was assigned 





Previously,  a highly neutralization-resistant (Seaman et al., 2010b) CRF02_AG virus, 253-11 was 
characterized (Jacob et al., 2012). In this chapter, we examine the MPER region of 253-11 and 
characterize the accessibility of its MPER both in the native virus and in the HIV-2/HIV-1 MPER 
chimeric virus. The thesis demonstrates that 253-11 is resistant to neutralization by most but not all 
antibodies that recognize its MPER. The inaccessibility of MPER to antibodies was also observed in 
other HIV-1 isolates. Of the 12 serum samples that recognized the MPER of Du422.1, eight 
recognized the same MPER in the native Du422.1 context poorly or not at all (Figure 4.2). In 
addition, viruses 001428-2.42 and RHPA 4259.7 are poorly recognized by the tested anti-MPER 
antibodies (Figure 4.5), although we are unable to exclude MPER sequence preference as an 
explanation for this neutralization resistance. Nonetheless, five of the ten HIV-1 isolates tested were 
neutralized through MPER by at least 3/6 sera tested that was unable to neutralize the 253-11 MPER 
(Figure 4.5) indicating this pattern of resistance not to be universal. 
 
2F5, 4E10 and 10E8 all neutralize 253-11 with substantial potency (Table 4.1), and thus apparently 
overcome the shielding of the MPER 253-11. We predicted that overcoming the MPER shielding 
would have a cost in potency. We measured the potency of each antibody against 253-11 and 
Du422.1 and the respective HIV-2/HIV-1 MPER chimeric viruses (Table 4.1). Each antibody 
neutralized the MPER chimera virus ≥15-fold more potently than the corresponding native virus, 
except in the case of 4E10. Although many other explanations are possible for this increased potency 
against the chimeric viruses, these data are in line with our prediction based upon shielding of the 
HIV-1 viruses but not the HIV-2/HIV-1 MPER viruses. 
 
Only one (eg: BNAB0004, Figure 4.4) among the 217 sera analyzed, neutralized 253-11 detectably 
by recognizing its MPER (Figure 4.4). Nonetheless, a substantial number (19/217) of sera recognize 
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the 253-11 MPER sequence in the context of an HIV-2/253-11 MPER chimeric virus (Figure 4.1b, 
upper left quadrant). Most or perhaps all of these sera neutralize HIV-1 isolates other than 253-11 by 
recognition of the MPER (Figures 4.3, 4.5). A large number (19) and proportion (9%) of polyclonal 
sera neutralize the 253-11 MPER within the alternative chimeric construct but not the original virus. 
Various explanations for the lack of neutralization via MPER are outlined below and described 





Figure 4.6: Possible explanations for the lack of anti-MPER neutralization: Unlikely 
explanations are in pink backgrounds while likely explanations are in green backgrounds. 
 
a) Sequence polymorphisms within and outside MPER determine neutralization in some 
HIV-1 isolates: 
It has been established that various viruses with the same amino acid sequence in the 4E10 epitope 
are neutralized differentially (Binley et al., 2004). Rare polymorphisms within the MPER in some 
HIV-1 isolates have been reported to result in either the exposure or inaccessibility of MPER to 
neutralizing antibodies (Blish et al., 2008; Ringe et al., 2010; Shen et al., 2010). Blish et al (Blish et 
al., 2008) discusses two amino acid polymorphisms between two variant envelope protein sequences 
from the same donor, one which was unusually neutralization-resistant and one unusually 
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neutralization-sensitive. These two changes, when introduced into resistant viruses, conferred large 
increases in neutralization sensitivity to 4E10 and 2F5. The polymorphisms are I675V in the MPER 
and T569A in the N-terminal heptad repeat. Two other rare polymorpishms within MPER, Y681H 
(Ringe and Bhattacharya, 2012) and L669S (Shen et al., 2010) have a similar effect. Both COT6.15 
(neutralized by anti-MPER antibodies) and 253-11 (rarely neutralized by anti-MPER antibodies) 
have the resistant polymorphism at all four positions. Thus, it is unlikely that the MPER sequence 
polymorphisms are controlling the inaccessibility of anti-MPER antibodies that we observe.  
 
b) Polymorphisms in the LLP2 domain (lentivirus lytic peptide-2 domain) affect MPER 
accessibility: 
Gray et al (Gray et al., 2008) show that changes in the LLP-2 domain of the cytoplasmic tail of gp41 
affects sensitivity to 4E10. This could be an effect upon the accessibility or formation of the 4E10 
epitope. The LLP-2 domain sequence of 253-11 (rarely neutralized by anti-MPER antibodies) and 
COT6.15 (easily neutralized by anti-MPER antibodies) are more similar to each other than they are 
to either the sensitive or resistant variants in Gray et al. Thus the polymorphisms in LLP2 domain 
observed by Gray et al are unlikely to be responsible for the inaccessibility of anti-MPER antibodies 
on 253-11, though we cannot rule out other residues in 253-11 virus.   
 
c) Immersion of MPER epitopes into the viral membrane: 
It has been reported that the MPER is partially inserted into the viral membrane of some viruses. Not 
only can viruses differ in the level of insertion, but antibodies can differ in their ability to extract the 
MPER from the membrane (Sun et al., 2008). Dennison et al (Dennison et al., 2009) suggest that the 
4E10 epitope may be inserted into the membrane of synthesized liposome immunization constructs, 
reducing 4E10 binding. Montero et al (Montero et al., 2012) specifically suggest that the C-terminus 
of the MPER may be differentially inserted into the membrane, mediated by polymorphisms in 
amino acid residues 678 and 682-684. It thus appears possible that the ability to pull the MPER out 
from within the membrane and immobilize it may differ among anti-MPER antibodies (Sun et al., 
2008). We note that 253-11 (resistant to anti- MPER antibodies) and COT6.15 (easily neutralized via 
MPER) have identical amino acid sequence in these potentially critical regions, residues 678-695. 
Thus, the potential of the MPER to sink into the membrane may not appear to play a role in the lack 






d) Conformational differences in MPER epitopes between 253-11 and HIV-2/253-11 MPER: 
Using COT6.15 MPER alanine scan mutants, we mapped the 19 sera targeting the 253-11 MPER in 
the HIV-2/253-11 MPER chimeric virus (Figure 4.1 b). Analysis of differential neutralization of the 
MPER alanine scan mutants of COT6.15 (Gray et al., 2009a)  and HIV-2/HIV-1 MPER chimeric 
viruses, including C6, which expresses the minimal 4E10 epitope (Gray et al., 2007) indicate that at 
least seven distinct MPER epitopes are recognized among the 19 sera (Figure 4.3). Although the 
epitopes are largely overlapping, they are distinct making it unlikely that so many epitopes could be 
present in the HIV-2/HIV-1 253-11 MPER chimera and yet not in the native 253-11 envelope 
glycoprotein. Thus conformational change is highly unlikely to explain the inability of so many 
independent antibodies (with distinct epitopes) to neutralize 253-11. 
 
e) Limited MPER-accessibility in the pre-attachment spike:  
There are reports that detail variability in MPER accessibility over time during viral invasion 
(Chakrabarti et al., 2011; Dimitrov et al., 2007). It is known that fusion is associated with a 
conformational change in gp41 following CD4 binding (Eckert and Kim, 2001; Gallo et al., 2003). 
Dimitrov et al (Dimitrov et al., 2007) show evidence suggesting that anti-MPER neutralizing 
antibodies target this fusion intermediate. Chakrabarti et al (Chakrabarti et al., 2011) suggested that 
(i) the MPER is partially accessible in the envelope spike of some viruses before the virus attaches to 
a cell, and (ii) viruses with an MPER accessible in the envelope spike are more sensitive to 
neutralization by anti-MPER antibodies. In contrast, the neutralization resistance of the MPER to 
anti-MPER antibodies which we observe in 253-11 will have to occur in both the pre-attachment 
phase (envelope spike) and in the post-attachment phase (Frey et al., 2008; Liu et al., 2008) in order 
to result in the resistance we observe in a standard neutralization assay.  
 
f) Antibody maturation levels: 
Broadly neutralizing anti-MPER (Huang et al., 2012; Zwick, 2005) and  other broadly neutralizing 
anti-HIV-1 (Scheid et al., 2011; Walker et al., 2011 ; Walker et al., 2009b; Zhou et al., 2010) 
antibodies have  high levels of somatic hypermutation (Breden et al., 2011) (particularly in the 
framework regions (Klein et al., 2013)). Antibody affinity maturation is associated with breadth of 
neutralization of 2F5-like anti-MPER antibodies (Zhu et al., 2011). It is possible to speculate that a 
relatively low level of antibody maturation may contribute to the inability of these 19 sera to 
neutralize 253-11. But, 13 of the 19 sera which recognize the MPER of 253-11 in the chimera and 
does not neutralize the native 253-11 virus however neutralized other HIV-1 isolates via MPER 




g) Viral entry dynamics and MPER exposure: 
Single amino acid substitutions in the gp41 can mechanistically contribute to prolonged exposure of 
the MPER epitopes in HIV-1 isolates (Shen et al., 2010). This results in an enhanced neutralization 
via MPER. Most antibodies directed to MPER mediate neutralization at the pre-hairpin intermediate 
state (Frey et al., 2010; Frey et al., 2008). If the pre-hairpin intermediate state is extremely short 
lived, a MPER neutralization resistant phenotype is likely to develop. Thus, viral entry dynamics 
might be an explanation for the observed neutralization resistance to anti-MPER antibodies.  
 
h) Steric  obstruction of MPER to antibodies in the pre- and post-attachment spike  
Another likely explanation for the lack of neutralization via MPER is steric obstruction of access to 
the MPER or shielding. The shielding phenomenon is in line with previous observations using 
engineered molecules each carrying one or two 4E10 (anti-MPER) binding site(s) and the 4E10 
antibody itself: for a given number of binding sites per molecule, the smaller molecules neutralized 
more potently, suggesting that  in order to bind to its epitope, 4E10 needed to fit into a sterically 
constrained space (Klein et al., 2009).  
 
Crystal structures of anti-MPER antibody/antigen utilize peptide antigens (Huang et al., 2012; Ofek 
et al., 2004) and therefore do not address shielding of MPER by other parts of gp41 or gp120.  A 
recently published cryo-electron microscopy analysis of an anti-MPER antibody complexed with an 
envelope trimer shows that the anti-MPER antibody inserts itself between gp120 and the viral 
membrane in order to bind to its target in the MPER (Harris et al., 2013). This gives ample 
opportunity for regions within gp120 to sterically hinder binding of most anti-MPER antibodies.  
 
4.6. Conclusion and vaccine implications: 
The high neutralization resistance of 253-11 to anti-MPER antibodies was studied in this chapter. 
We propose that the most parsimonious explanation for this observation is steric occlusion. Rare 
anti-MPER antibodies are capable of neutralizing 253-11 via MPER. In particular, monoclonal 
antibodies 4E10, 2F5 and 10E8 and serum BNAB0004 neutralize 253-11 by recognizing its MPER 
(Figure 4.4; (Huang et al., 2012; Jacob et al., 2012). Monoclonal antibodies 10E8 and 4E10 
neutralized 98% of a panel of 181 viruses at IC50<50ug/ml and 10E8 neutralized 72% at IC50<1ug/ml 
(Huang et al., 2012); these antibodies therefore bind to the MPER despite any shielding exhibited by 
this wide range of viruses. Monoclonal antibody 2F5 is also broadly neutralizing although less so 
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(Huang et al., 2012), as is serum BNAB0004 (neutralizes 22/24 panel viruses and is at the 90
th
 
percentile for neutralization breadth and potency among our 177 samples, Fig 2.2 of chapter two).  
 
Strategies to induce broadly neutralizing anti-HIV antibodies to any region of the envelope proteins 
with a vaccine are still in the very early stages of development. Analysis of the natural immune 
response to the MPER by virus such as 253-11 which is resistant to most anti-MPER antibodies will 
aid in the understanding needed to develop a vaccine that induces broadly neutralizing antibodies 






Chapter 5: Conclusion and Recommendation: 
 
Since HIV-1 was discovered three decades ago (Barre-Sinoussi et al., 1983), considerable efforts 
have been made to generate an effective vaccine (Barouch, 2008; Burton et al., 2012a; Walker and 
Burton, 2008). The targets of broadly neutralizing antibodies are models for candidate antibody 
based vaccines (Binley et al., 2008; Burton, 1997; Burton et al., 2012a; Corti and Lanzavecchia, 
2013; Kwong et al., 2012; Mascola and Haynes, 2013; Mascola and Montefiori, 2010; Overbaugh 
and Morris, 2012). As such, characterizing epitopes in the HIV-1 envelope targeted by broadly 
neutralizing monoclonal antibodies will inform vaccine design (Binley, 2009; Binley et al., 2008; 
Dhillon et al., 2007; Gray et al., 2011; Gray et al., 2007; Gray et al., 2009b; Li et al., 2009; Mikell et 
al., 2011; Sather and Stamatatos, 2010; Tomaras et al., 2011; Walker and Burton, 2010; Walker et 
al., 2010). The MPER within the gp41 is an attractive vaccine target (Gray et al., 2009a; Huang et 
al., 2012; Montero et al., 2008a; Zwick, 2005). This thesis evaluated 1) the association between the 
presence of anti-MPER and anti-PG9/16-site antibodies to neutralization breadth activity, 2) 
explored the neutralization sensitivity of CRF02_AG viruses to a set of plasma samples infected with 
the same subtype and to anti-MPER monoclonal antibodies (Jacob et al., 2012) and 3) observed that 
a highly neutralization resistant virus is rarely neutralized via MPER by a set of anti-MPER 
antibodies which targeted multiple distinct epitopes within the MPER.  
 
Through the first project in this thesis, the ability of PG9/16-site and the MPER epitopes to induce 
broadly neutralizing antibodies in chronic HIV-1 infections was assessed by comparing samples with 
and without the above antibody specificities. Our results indicate an association between the 
presence of anti-MPER antibodies and the ability to neutralize potently a wider range of HIV-1 
isolates (Figure 2.7, Table 2.2). In contrast, samples with dominant anti-PG9/16 site antibodies were 
less likely to be broadly neutralizing than samples without anti-PG9/16-site antibodies (Figure 2.6, 
Table 2.1). Our study confirms the observation made in a previous study that anti-MPER antibodies 
tend to be broadly neutralizing (Gray et al., 2009a; Gray et al., 2009b).   
 
We developed an estimation model to predict ID50 values from the percentage neutralization at 1/100 
serum/plasma dilution using a linear regression prediction equation (Figure 2.1). The estimation 
model is useful for predicting the approximate serum/plasma ID50 from a single dilution screening. 
The model was validated using a “test set”. The estimated ID50 values derived from the percentage 
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neutralization for the “test set” correlated well with the corresponding measured ID50 values (Figure 
2.1).     
 
In the third chapter (second project) of this thesis (Jacob et al., 2012), viruses with high 
neutralization resistance especially from the CRF02_AG subtype were defined rigorously. HIV-1 
CRF02_AG subtype isolates circulate primarily in West Africa and have been reported to be fitting 
predominantly into the neutralization resistant category (tier 3 and tier 2/3) (Seaman et al., 2010a). 
Using the principle of within-subtype neutralization (Brown et al., 2008) (Gray et al., 2007; Oballah 
et al., 2011; Seaman et al., 2010a) we refine the identification of highly resistant CRF02_AG viruses 
by using a panel of CRF02_AG infected plasma samples. Two highly neutralization resistant 
CRF02_AG viruses were identified: 253-11 and 278-50 were resistant to subtype-specific 
neutralization (Jacob et al., 2012). Despite being highly resistant to polyclonal sera, we provide 
evidence that most CRF02_AG viruses (even the resistant strains) are sensitive to anti-MPER mAbs. 
This study revealed vulnerable neutralization targets (MPER) even within highly resistant 
CRF02_AG viruses and would contribute to the design of vaccines targeting MPER.  
 
Further (chapter four), to understand the accessibility of MPER to anti-MPER neutralizing antibodies 
within highly neutralization resistant viruses, we used 253-11 (a CRF02_AG virus) as a model 
neutralization resistant virus.  253-11 was rarely neutralized by anti-MPER antibodies in a large 
serum panel of HIV-1 infected individuals. However, a substantial number of sera which hitherto 
were unable to neutralize 253-11 recognized the 253-11 MPER sequence in the context of an HIV-2 
chimeric virus. The panel of anti-MPER antibodies which failed to neutralize 253-11 via MPER in 
the native virus were functional as they neutralized other viruses through MPER. We consider 
several explanations for the inaccessibility of anti-MPER antibodies in this highly neutralization 
resistant virus, 253-11. We propose that the most parsimonious explanation for this observation is 
steric occlusion. We also observe that the inaccessibility of MPER is a common but not a universal 
phenomenon among HIV-1 isolates. 
 
Put together, the research in this thesis evaluates the neutralization breadth of anti-MPER antibodies 
and makes the observation that neutralization via MPER is a rare event in neutralization resistant 
isolates like 253-11. Based on the research recorded in this thesis, the following are recommended: 
 
1. Data from chapter two suggests anti-MPER and not anti-PG9/16-site antibodies to be 
associated with neutralization breadth. Similar studies mapping antibodies to the 2G12/PGT128 
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epitope or the CD4 binding site and understanding which epitopes induce broadly neutralizing 
antibodies in chronic HIV-1 infections will inform vaccine design.  
 
2. Based on data from chapter three, the thesis supports that procedures for studying and 
identifying highly neutralization-resistant viruses should preferentially include neutralization 
samples from the same subtype. Identification and characterization of these viruses is important 
because: (i) epitopes from resistant viruses may be desirable in a vaccine, and (ii) resistant viruses 
should be included in panels to evaluate candidate vaccines.  
 
3. Construction of chimeric viruses with the MPER domains swapped between “MPER 
resistant” (eg: 253-11, chapter four) and “MPER sensitive” viruses (eg: COT6.15, TRO11, 928-28, 
Figure 4.5) will be helpful to understand MPER accessibility better.   
 
4. Construction of appropriate gp120/gp41 envelope chimeric viruses will give insights into the 
mechanistic features behind the possibility of MPER occlussion. Chimeras generated with part of the 
envelope emanating from a virus with hidden MPER (eg: 253-11, chapter four) and another region 
originating from a virus with an exposed MPER (eg: COT6.15, TRO11 and 928-28, Figure 4.5) 
should shed light as to why anti-MPER antibodies are obstructed from MPER.   
 
5. Isolation of mAbs from rare sera like BNAB0004 which mediate MPER-targeted 
neutralization of 253-11 (Figure 4.4) and understanding how they target MPER by structural studies 
will inform vaccine design.  High levels of somatic hypermutations and long CDRH3 loops are 
hallmarks of broadly neutralizing anti-HIV-1 antibodies (Huang et al., 2012; Pejchal et al., 2011; 
Pejchal et al., 2010; Saphire et al., 2001; Sun et al., 2008). 
 
6. Finally, It will be interesting to generate envelope clones from participants with significant 
MPER activity (anti-MPER antibody titer >1000) to analyze if immune pressure drives MPER 
escape mutants. Since, MPER is highly conserved (Figure 2.8, (Montero et al., 2008a)) and involved 
in fusion (Blumenthal et al., 2012; Garg et al., 2011; Munoz-Barroso et al., 1999), assessing the 
fitness cost of MPER escape mutants should guide antibody-based vaccine design in the control of 









 Appendix 1: Amino acid level map of MPER and the broadly neutralizing monoclonal 







Appendix 2: Box-plot depicting the neutralization breadth of samples with and without 
PG9/16-site specific neutralization activity (using fivefold effect): A Wilcoxon-rank sum test was 
used to compare and calculate the median difference between the samples set with and without 
PG9/16-site activity.  Neutralization breadth was defined either by the serum geometric mean ID50 
titer (left) or the number of viruses neutralized (right). Corresponding p values and the number of 
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